Document:

EX-10.31

 Exhibit 10.31 
 EXECUTION COPY 
 CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 TERMINATION AND TRANSITION AGREEMENT 
 THIS TERMINATION AND TRANSITION
AGREEMENT (“Termination Agreement”) dated as of November 8, 2012 (“Termination Effective Date”), is entered into between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410
Central Expressway, Santa Clara, CA 95051 (“XenoPort”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex,
UB6 0NN, England (“GSK”). 
 BACKGROUND 

A. XenoPort has developed the Product (as hereinafter defined), which is a Transported ProdrugTM of gabapentin,
for the treatment of restless legs syndrome (“RLS”) and the management of neuropathic pain (which includes post-herpetic neuralgia (“PHN”) and diabetic peripheral neuropathy), and which is currently marketed in the
United States under the brand name “Horizant®” for the treatment of moderate-to-severe primary RLS in
adults and for the management of PHN in adults; 
 B. The Parties (as hereinafter defined) entered into that certain Development
and Commercialization Agreement dated as of February 7, 2007, as amended by that certain First Amendment to Development and Commercialization Agreement between XenoPort and GSK, dated as of May 4, 2007 (“First Amendment”),
and as further amended by that certain Second Amendment to Development and Commercialization Agreement between XenoPort and GSK, dated as of February 13, 2009 (“Second Amendment”) (together with the First Amendment and the
Second Amendment, the “Original Agreement”), pursuant to which XenoPort granted to GSK certain rights for the Product worldwide except for certain countries in Asia, and pursuant to which GSK and XenoPort were to co-develop and, in
certain cases, co-commercialize the Product in the United States, all in accordance with the Original Agreement; 
 C. The
Original Agreement was subsequently superseded and replaced by that certain Amended and Restated Development and Commercialization Agreement between XenoPort and GSK, dated as of November 7, 2010 (“Restated Agreement”),
pursuant to which the Parties amended and restated the Original Agreement in its entirety to provide, among other matters, the reversion to XenoPort of all rights for the development and commercialization of the Product in all countries other than
the United States and the right to conduct and control activities relating to the development of the Product for certain indications in the United States; 
 D. The Parties, and GlaxoSmithKline LLC and GlaxoSmithKline Holdings (Americas) Inc. are currently parties to a litigation pertaining to GSK’s performance of the Restated Agreement, filed in the
United States District Court for the Northern District of California (originally filed in Santa Clara County Superior Court, Case No. 1-12-CV-21937), and the Parties are currently parties to a declaratory judgment action pertaining to
GSK’s performance of the Restated Agreement 

 EXECUTION COPY 
  

 
in the United States District Court for the District of Delaware and styled XenoPort, Inc. v. Glaxo Group Limited, et al., Case No. CV 12-01544 EJD and Glaxo Group Limited v. XenoPort,
Inc. et al., Case No. 1:12-CV00225-GMS, respectively (collectively, the “Litigation”); and 
 E. The
Parties deem it to be in their best interests and to their mutual advantage to settle and dismiss the Litigation and terminate the Restated Agreement in its entirety, on the terms and conditions set forth in this Termination Agreement and the Stock
Purchase Agreement to be entered into between XenoPort and GSK dated as of the Termination Effective Date (the “SPA”), to provide, among other matters, the reversion to XenoPort of all rights with respect to the Product, and for GSK
to purchase certain shares of Common Stock of XenoPort pursuant to the SPA. 
 NOW, THEREFORE, in consideration of all of the
terms and conditions of this Termination Agreement, the Parties agree as follows: 
 ARTICLE I 

DEFINITIONS 
 The following capitalized terms will have the meanings set forth in this Article I when used in this Termination Agreement. 
 1.1 “Accounts Receivable” shall mean all trade accounts receivable and other similar rights to payment to GSK or its Affiliates from customers of GSK or its Affiliates, including all
trade accounts receivable representing amounts receivable by GSK or its Affiliates, in each case with respect to Product sold by or on behalf of GSK or its Affiliates on or prior to the Transition Period End Date. 

1.2 “ADAP” shall have the meaning set forth in Section 5.5(h) of this Termination Agreement. 

1.3 “Additional Transferred Asset” shall have the meaning set forth in Section 3.6(c) of this Termination
Agreement. 
 1.4 “Additional Licensed Asset” shall have the meaning set forth in Section 3.6(c) of this
Termination Agreement. 
 1.5 “Affiliate” of a Party shall mean any Person that, directly or indirectly through
one or more intermediaries, controls, is controlled by or is under common control with such Party, as the case may be, for as long as such control exists. As used in this Section 1.5, “control” shall mean: (a) to possess,
directly or indirectly, the power to direct the management and policies of such Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial
ownership of at least fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital in such Person. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 2 - 

 EXECUTION COPY 
  

 1.6 “AMP” shall have the meaning set forth in Section 5.5(a) of
this Termination Agreement. 
 1.7 “Ancillary Agreements” shall have the meaning set forth in
Section 3.5(c) of this Termination Agreement. 
 1.8 “API” shall mean the gabapentin enacarbil active
pharmaceutical ingredient used in the manufacture of Product. 
 1.9 “Applicable Laws” shall mean the
applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits
(including the NDA) of, from or agreed to with any court, arbitrator, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item. In addition, with respect to either Party, Applicable Laws shall
include the obligations of any corporate integrity agreement entered into by such Party with the Office of Inspector General of the Department of Health and Human Services, during the term of such obligations. 

1.10 “Artwork” shall have the meaning set forth in Section 4.5(e) of this Termination Agreement. 

1.11 “Assignment and Assumption Agreement” shall mean the assignment and assumption agreement, a form of which is
attached hereto as Exhibit 1.11. 
 1.12 “Assumed Liabilities” shall have the meaning set forth in
Section 3.7(b) of this Termination Agreement. 
 1.13 “Auditor” shall have the meaning set forth in
Section 5.11(c) of this Termination Agreement. 
 1.14 “Bill of Sale” shall mean the bill of sale, a form
of which is attached hereto as Exhibit 1.14. 
 1.15 “Bulk Manufacturer” shall have the meaning set
forth in Section 5.13 of this Termination Agreement. 
 1.16 “Bulk Product” shall mean tablets containing,
as and if applicable, 300mg or 600mg of gabapentin enacarbil, bulk packaged into large-scale intermediate containers (e.g., fiber drums) for use in the manufacture of commercial Product. 

1.17 “Business Day(s)” shall mean a day (other than a Saturday or Sunday) on which banks are open for business in the
State of Delaware but excluding each day in the period between December 24 and January 1 (inclusive) in any year. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 3 - 

 EXECUTION COPY 
  

 1.18 “cGMPs” shall mean the then-current requirements for current good
manufacturing practices set forth in the United States Code of Federal Regulations 21 CFR Parts 210 and 211, and all related rules, regulations, guidance and regulatory requirements, together with the ICH Guidelines applicable to the manufacture,
storage, transportation and testing of pharmaceutical drug products. 
 1.19 “Chargeback Contracts” shall have
the meaning set forth in Section 5.8(b) of this Termination Agreement. 
 1.20 “Chargeback Product Termination
Date” shall have the meaning set forth in Section 5.8(b) of this Termination Agreement. 
 1.21
“Claims” shall mean any and all claims, actions, causes of action, demands, costs, grievances, duties, obligations, rights, counterclaims, debts, damages, losses, liabilities, judgments, and charges of whatever nature, whether known
or unknown, including but not limited to, claims asserted in the Litigation or that could have been asserted in the Litigation. 

1.22 “CMS” shall have the meaning set forth in Section 5.5(b) of this Termination Agreement. 

1.23 “Commercialization Transition Plan” shall have the meaning set forth in Section 4.4(a) of this Termination
Agreement. 
 1.24 “Commercially Reasonable Efforts” shall mean that level of efforts and resources consistent
with the usual practice followed by a Party in the exercise of reasonable business discretion relating to other pharmaceutical products owned by it or to which it has exclusive rights, which is of similar market potential and at a similar stage in
development or product life, taking into account issues of patent coverage, safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the compound or product, the regulatory structure involved, the
profitability of the products (including, without limitation, pricing and reimbursement status achieved), and other relevant factors, including without limitation technical, legal, scientific, and/or medical factors. 

1.25 “Completion” shall mean, with respect to the Low Dose Study, GSK’s delivery of the second draft of the
clinical study report to XenoPort as set forth under Section 4.3(a)(i), and with respect to each Ongoing Study other than the Low Dose Study, GSK’s delivery to XenoPort of a copy of the manuscript with respect to such Ongoing Study.

 1.26 “Compound” shall mean that certain compound, referred to as gabapentin enacarbil, the structure of
which is set forth on Schedule 1.26, and all esters, hydrates, metabolites [... * ...]salts, solvates, isomers and/or mixtures of isomers thereof. 
 1.27 “Confidential Information” shall have the meaning set forth in Section 8.1 of this Termination Agreement. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 4 - 

 EXECUTION COPY 
  

 1.28 “Contracts” shall mean any contract, agreement or instrument,
including, without limitation, supply contracts, market research agreements, ad agency agreements, quality agreements, clinical trial agreements, licenses, sale orders, bids, understandings or commitments, customer agreements, managed care
agreements, distributor agreements, agreements with healthcare professionals, subcontracts or conditional sales agreements.  
 1.29 “Control” (including any variations such as “Controlled” and “Controlling”), in the context of the tangible and intangible assets of a Party
(including, without limitation, intellectual property rights), shall mean that such Party or its Affiliate owns or possesses rights sufficient to assign, or grant the applicable license under or to such tangible or intangible assets, as provided
herein without violating the terms of an agreement with a Third Party. 
 1.30 “Coverage Gap Program” shall
have the meaning set forth in Section 5.5(a) of this Termination Agreement. 
 1.31 “Data” shall mean any
and all research data, pharmacology data, preclinical data, clinical data and/or all regulatory documentation, manufacturing data, quality data, information and submissions pertaining to, or made in association with, a Regulatory Filing for, a
pharmaceutical product. 
 1.32 “DDR” shall have the meaning set forth in Section 5.5(b) of this
Termination Agreement. 
 1.33 “Development Plan” shall have the meaning set forth in Section 4.3(a)(i) of
this Termination Agreement. 
 1.34 “Dispute” shall have the meaning set forth in Section 10.1 of this
Termination Agreement. 
 1.35 “Direct Customer Contracts” shall have the meaning set forth in
Section 5.8(c) of this Termination Agreement. 
 1.36 “Distributor Invoice” shall have the meaning set
forth in Section 5.8(b) of this Termination Agreement. 
 1.37 “Domain Name(s)” shall mean any Internet
domain names, whether in the form of an address for use in electronic mail transfer, a Universal Resource Locator (URL), a file transfer protocol (FTP) location, or other form suitable for specifying the location of an electronic data file over a
distributed computer network, together with all translations, adaptations, derivations and combinations thereof. 
 1.38
“Domain Name Assignment Agreement” shall mean the domain name assignment agreement, a form of which is attached hereto as Exhibit 1.38. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 5 - 

 EXECUTION COPY 
  

 1.39 “Equipment” shall have the meaning set forth in Section 5.13
of this Termination Agreement. 
 1.40 “Excluded Assets” shall have the meaning set forth in
Section 3.4(c). 
 1.41 “Excluded GSK Contracts” shall mean, subject to Sections 3.6(b) and 4.2(a)
below, (i) any GSK Contracts between GSK and its Affiliates (i.e., inter-company agreements); (ii) any GSK Contracts between GSK or its Affiliate and a Third Party that relate (but not solely) to Compound or Product; (iii) any
GSK Contracts between GSK or its Affiliate and a Third Party that solely relate to the Compound or Product but cannot be assigned by GSK or its Affiliate without such Third Party’s prior consent; and (iv) any other GSK Contracts so
identified by GSK. The Excluded GSK Contracts referenced in (ii), (iii) and (iv) are identified on Schedule 1.41. 
 1.42 “Excluded GSK Inventory” shall mean the Inventory identified on Schedule 1.42, which specifies certain quantities of API that will be excluded from the Inventory
transferred to XenoPort under this Termination Agreement. 
 1.43 “Excluded GSK Know-How” shall mean
(i) any internal policies, processes and procedures used by GSK or its Affiliates from time to time prior to or after the Termination Effective Date that relate to the discovery, development, commercialization, promotion, marketing, sale,
pricing and/or distribution of a pharmaceutical product; (ii) any internal policies and procedures used by GSK or its Affiliates from time to time prior to or after the Termination Effective Date that relate to the manufacture of a
pharmaceutical product; and (iii) other GSK Know-How as identified on Schedule 1.43. 
 1.44 “Expired GSK
Contracts” shall mean all Contracts between GSK or its Affiliate and a Third Party, which are solely related to the development, manufacture, marketing or commercialization of Compound or Product in the Territory and which have expired or
been terminated prior to the Transition Period End Date, but under which GSK or its Affiliates have post-termination rights or obligations. 
 1.45 “FDA” shall mean the U.S. Food and Drug Administration, or any successor entity thereto performing similar functions. 

1.46 “Final Transferred GSK Inventory Quantities” shall have meaning set forth in Section 4.2(f)(i)(A). 

1.47 “Financial Information” shall mean all financial information solely relating to Compound or Product in the
Territory that is Controlled by GSK or its Affiliates during the Original and Restated Term and/or the Transition Period, as identified in Schedule 1.47. 
 1.48 “Finished Product” shall have the meaning set forth in Section 5.4(a) of this Termination Agreement. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 6 - 

 EXECUTION COPY 
  

 1.49 “Firm Order” shall have the meaning set forth in
Section 4.5(a) of this Termination Agreement. 
 1.50 “First Amendment” shall have the meaning set forth
in paragraph B in the preamble of this Termination Agreement. 
 1.51 “FSS” shall mean federal supply schedule.

 1.52 “Governmental Price Reports” shall have the meaning set forth in Section 5.5(a) of this
Termination Agreement. 
 1.53 “GSK” shall have the meaning set forth in the preamble of this Termination
Agreement. 
 1.54 “GSK Contracts” shall mean all Contracts in effect as of the Transition Period End Date to
which GSK or its Affiliate is a party and which are related to the development, manufacture, marketing or commercialization of Compound or Product in or for the Territory, including all supply arrangements (including all related quality contracts)
for Compound or Product (or any raw and pack materials, supplies and packaging materials therefor) and all clinical trial arrangements (including for the Ongoing Studies) for Compound or Product. 

1.55 “GSK Distribution Center” shall mean the distribution center owned by GSK and located in Richmond, Virginia.

 1.56 “GSK Indemnitees” shall have the meaning set forth in Section 9.1 of this Termination Agreement.

 1.57 “GSK Housemarks” shall have the meaning set forth in Section 4.2(i) of this Termination Agreement.

 1.58 “GSK Housemarks License” shall have the meaning set forth in Section 4.2(i) of this Termination
Agreement. 
 1.59 “GSK Know-How” shall mean all Know-How relating to Compound or Product (including Financial
Information) that are Controlled by GSK or its Affiliates and that prior to (i) the Transition Period End Date or (ii) the Completion of the Ongoing Studies (but only with respect to such Know-How arising out of the conduct of the Ongoing
Studies) or (iii) the Supply Term (but only with respect to such Know-How arising out of the conduct of the manufacture and supply of Product during the Supply Term), were used in the development, manufacture or commercialization of Compound or
Product in or for the Territory. 
 1.60 “GSK Patents” shall mean all Patents Controlled by GSK or its
Affiliates and that, prior to (i) the Transition Period End Date, or (ii) the Completion of the Ongoing Studies (but only with respect to such Patents arising out of the conduct of the Ongoing Studies) or (iii) the Supply Term (but
only with respect to such Patents arising out of the conduct of the manufacture and supply of Product during the Supply Term), are used in the development, manufacture or commercialization of Compound or Product. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 7 - 

 EXECUTION COPY 
  

 1.61 “GSK Safety Agreement” shall have the meaning set forth in
Section 4.9 of this Termination Agreement. 
 1.62 “GSK’s Applicable Policies and Procedures” shall
mean the then current applicable provisions of the policies or procedures of GSK in effect from time to time. 
 1.63
“HCERA” shall have the meaning set forth in Section 5.5(a) of this Termination Agreement. 
 1.64
“Know-How” shall mean all scientific, medical, technical, marketing, regulatory, manufacturing and other information, including Data and inventions for which no patent application has been filed. 

1.65 “Improvement(s)” shall mean any inventions made by or under authority of a Party during the Original and Restated
Term or Transition Period, and with respect to GSK, after the Transition Period with respect to the Ongoing Studies or manufacture and supply of Product during the Supply Term, in connection with manufacture, development and/or commercialization of
Product and that solely relates, or was invented in the course of activities primarily directed, to Compound or Product, or the manufacture, storage, transport, use or formulation thereof. 

1.66 “Indemnitee” shall have the meaning set forth in Section 9.3 of this Termination Agreement. 

1.67 “Indemnitor” shall have the meaning set forth in Section 9.3 of this Termination Agreement. 

1.68 “Interim Supply Notice” shall have the meaning set forth in Section 4.5 of this Termination Agreement.

 1.69 “Inventory” shall mean API and related starting/intermediate material (if any), in each case,
Controlled by GSK or its Affiliates directly relating to the manufacture and supply of Compound or Product, including, without limitation, clinical supplies (to the extent such clinical supplies are transferable under Applicable Laws). An initial
schedule of the Inventory as of the Termination Effective Date (excluding the Excluded Inventory) is attached hereto as Schedule 1.69; provided that a list of clinical supplies shall be included in the Schedule 1.69 within thirty
(30) Business Days. 
 1.70 “Inventory Transfer Date” shall have the meaning set forth in
Section 4.2(f)(ii) of this Termination Agreement. 
 1.71 “JAMS” shall have the meaning set forth in
Section 10.2 of this Termination Agreement. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 8 - 

 EXECUTION COPY 
  

 1.72 “Labels and/or Labeling” shall mean all labels and other written,
printed or graphic matter on the Product or any container, carton or wrapper or other packaging utilized with the Product, or any written material accompanying the Product, including, without limitation, packaging inserts or outserts or medical
information guides. 
 1.73 “Liabilities” shall have the meaning set forth in Section 9.1 of this
Termination Agreement. 
 1.74 “Licensed Assets” shall have the meaning set forth in Section 3.2(a) of
this Termination Agreement. 
 1.75 “Licensed GSK Know-How” shall mean all GSK Know-How other than the
Transferred GSK Know-How and the Excluded GSK Know-How. Licensed GSK Know-How shall include any Additional Transferred Asset that is identified as Transferred GSK Know-How after the Termination Effective Date pursuant to Section 3.6 below
before such Additional Transferred Asset is assigned and transferred from GSK to XenoPort pursuant to Section 3.6 below. 

1.76 “Licensed GSK Patents” shall mean all GSK Patents other than the Transferred GSK Patents that claim an Improvement.
The Licensed GSK Patents are identified on Schedule 1.76. 
 1.77 “Limited API” shall have the meaning
set forth in Section 4.2(f)(vii) of this Termination Agreement. 
 1.78 “Litigation” shall have the
meaning set forth in paragraph D in the preamble of this Termination Agreement. 
 1.79 “Low Dose Study” shall
have the meaning set forth in Section 4.3(a)(i) of this Termination Agreement. 
 1.80 “Manufacturing Technology
Transfer Plan” shall have the meaning set forth in Section 4.6 of this Termination Agreement. 
 1.81
“Material Adverse Effect” shall mean a [... * ...] materially adverse effect on [... * ...] but shall exclude any [... * ...] 

1.82 “MDRP” shall mean the Medicaid Drug Rebate Program. 

1.83 “NDA” shall mean a New Drug Application or supplemental New Drug Application as defined in Title 21 of the U.S.
Code of Federal Regulations, Section 314.50, et seq., which is filed with the FDA in order to gain the FDA’s approval to commercialize a pharmaceutical product in the United States for the indications set forth in the New Drug Application
or supplemental New Drug Application. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 9 - 

 EXECUTION COPY 
  

 1.84 “NDC” shall mean the National Drug Code, as such term is used in
the United States Federal Food, Drug and Cosmetic Act, as amended from time to time, including all regulations promulgated thereunder. 
 1.85 “New Safety Agreement” shall have the meaning set forth in Section 4.9 of this Termination Agreement. 
 1.86 “Non-Assignable Contract” shall have the meaning set forth in Section 4.2(a)(ii) of this Termination Agreement. 

1.87 “Non-Assigned Contract” shall have the meaning set forth in Section 4.2(a)(iii) of this Termination Agreement.

 1.88 “Non-Transferred GSK Know-How” shall have the meaning set forth in Section 4.2(c) of this
Termination Agreement. 
 1.89 “On-Going Stability Studies” shall have the meaning set forth in
Section 5.14(a) of this Termination Agreement. 
 1.90 “Ongoing Studies” shall mean those studies
identified on Schedule 1.90, which includes the Low Dose Study. 
 1.91 “Original Agreement” shall have
the meaning set forth in paragraph B in the preamble of this Termination Agreement. 
 1.92 “Party” shall mean
XenoPort or GSK individually, and “Parties” shall mean XenoPort and GSK collectively. 
 1.93
“Patent(s)” shall mean any patented and unpatented inventions (including, inventions in patent applications for which claims have been filed and inventions in patent applications for which no claims have been filed; whether
patentable or unpatentable and whether or not reduced to practice) and any patents and patent applications, together with all additions, divisions, continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions,
registrations, patent term extensions, supplemental protection certificates, renewals and foreign counterparts of any of the foregoing. 
 1.94 “Patent Assignment Agreement” shall mean the patent assignment agreement, a form of which is attached hereto as Exhibit 1.94. 

1.95 “Permitted GSK Publications” shall have the meaning in Section 4.3(c) of this Termination Agreement.

 1.96 “Person” shall mean any individual, corporation, partnership, firm, association, joint venture, joint
stock company, trust or other entity, or any government or regulatory administrative or political subdivision or agency, department or instrumentality thereof. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 10 - 

 EXECUTION COPY 
  

 1.97 “PHN” shall have the meaning set forth in paragraph A in the
preamble of this Termination Agreement. 
 1.98 “PHS” shall mean the U.S. Public Health Service. 

1.99 “PPACA” shall have the meaning set forth in Section 5.5(a) of this Termination Agreement. 

1.100 “Product” shall mean any pharmaceutical product containing a Compound, alone or in combination with one or more
other active pharmaceutical ingredients, in any dosage form or formulation, including, as and if applicable, the 300 mg and 600 mg extended-release tablet formulations. 
 1.101 “Product Event” shall have the meaning set forth in Section 4.4(c) of this Termination Agreement. 
 1.102 “Promotional Material(s)” shall mean all written, printed, video or graphic advertising, promotional, educational and communication materials (other than the labeling for the
Product) used solely for the marketing, advertising, promotion and sale of the Product in the Territory. 
 1.103
“Promotional Sample Inventory” shall mean the Product packaged as samples for use in the promotion of the Product in the Territory and maintained at the GSK Distribution Center, which will be identified on Schedule 1.103 as
of the Transition Period End Date. 
 1.104 “Quality Agreement” shall have the meaning set forth in
Section 4.4(d) of this Termination Agreement. 
 1.105 “Rebate Contracts” shall have the meaning set forth
in Section 5.8(a) of this Termination Agreement. 
 1.106 “Regulatory Authority” shall mean the FDA, or
any court, administrative agency or commission or other federal, state, or local governmental authority, body or other instrumentality with authority over the development, manufacture or commercialization of Compound or Product in the Territory, or
any such instrumentality with similar authority in any other jurisdiction. 
 1.107 “Regulatory Filing(s)”
shall mean any approvals, licenses, registrations, submissions, authorizations and related documentation and correspondence made to or received from a Regulatory Authority in a country necessary for the development, manufacture or commercialization
of a pharmaceutical product. 
 1.108 “Released Matters” shall have the meaning set forth in Section 2.2
of this Termination Agreement. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 11 - 

 EXECUTION COPY 
  

 1.109 “Restated Agreement” shall have the meaning set forth in
paragraph C in the preamble of this Termination Agreement. 
 1.110 “Retained Inventory Quantities” shall have
the meaning set forth in Section 4.2(f)(i)(B). 
 1.111 “Retained Liabilities” shall have the meaning set
forth in Section 3.7(a) of this Termination Agreement. 
 1.112 “RLS” shall have the meaning set forth in
paragraph A in the preamble of this Termination Agreement. 
 1.113 “RLS Horizant Approval Letter” shall
have the meaning set forth in Section 4.3(a)(i) of this Termination Agreement. 
 1.114 “Rules” shall have
the meaning set forth in Section 10.3 of this Termination Agreement. 
 1.115 “Safety Data Exchange Transfer
Plan” shall have the meaning set forth in Section 4.9 of this Termination Agreement. 
 1.116 “Second
Amendment” shall have the meaning set forth in paragraph B in the preamble of this Termination Agreement. 
 1.117
“Social Security Act” shall have the meaning set forth in Section 5.5(a) of this Termination Agreement. 

1.118 “SPA” shall have the meaning set forth in paragraph E in the preamble of this Termination Agreement. A form of the
SPA is attached hereto as Exhibit 1.118. 
 1.119 “SPAP” shall have the meaning set forth in
Section 5.5(h) of this Termination Agreement. 
 1.120 “Specifications” shall mean the specifications for
Product set forth on Schedule 1.120. 
 1.121 “Stability Program Transfer” shall have the meaning set
forth in Section 5.14 of this Termination Agreement. 
 1.122 “Supply Agreement” shall have the meaning
set forth in Section 4.5 of this Termination Agreement. 
 1.123 “Supply Term” shall have the meaning set
forth in Section 4.5 of this Termination Agreement. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 12 - 

 EXECUTION COPY 
  

 1.124 “Termination Agreement” shall have the meaning set forth in the
preamble of this Termination Agreement. 
 1.125 “Termination Effective Date” shall have the meaning set forth
in the preamble of this Termination Agreement. 
 1.126 “Territory” shall mean the United States. 

1.127 “Third Party” shall mean any Person other than XenoPort, GSK and their respective Affiliates. 

1.128 “Third Party Claim” shall have the meaning set forth in Section 9.1 of this Termination Agreement.

 1.129 “Tolled API” shall have the meaning set forth in Section 4.2(h)(i) of this Termination Agreement.

 1.130 “Trademark(s)” shall mean any registered and unregistered trademarks, trade names, service marks,
service names, trade dress, logos, and slogans, whether registered or unregistered, and the goodwill associated therewith, together with any registrations and applications for registration thereof, and intellectual property rights residing in the
foregoing, including copyrights and design rights. 
 1.131 “Trademark Assignment Agreement” shall mean the
trademark assignment agreement, a form of which is attached hereto as Exhibit 1.131. 
 1.132 “Transfer
Taxes” shall have the meaning set forth in Section 3.4(d) of this Termination Agreement. 
 1.133
“Transferred Assets” shall have the meaning set forth in Section 3.4(a) of this Termination Agreement. 

1.134 “Transferred Contract Recovery Rights” shall have the meaning set forth in Section 3.7(a) of this Termination
Agreement. 
 1.135 “Transferred GSK Contracts” shall mean all GSK Contracts, other than the Excluded GSK
Contracts and Expired GSK Contracts, that are solely related to Compound or Product in or for the Territory and can be assigned by GSK or its Affiliate without a Third Party’s prior consent (or for which such consent to assignment from the
applicable counterparty has been obtained), subject to Section 3.6(b), as identified on Schedule 1.135. 
 1.136
“Transferred GSK Domain Names” shall mean the Domain Names Controlled by GSK or its Affiliates as of the Termination Effective Date that relate to or are used with Compound and Product or related to RLS or PHN (but excluding any GSK
Housemarks), as identified on Schedule 1.136. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 13 - 

 EXECUTION COPY 
  

 1.137 “Transferred GSK Inventory” shall mean the Inventory existing as
of the Inventory Transfer Date (excluding Excluded GSK Inventory), which will be identified on Schedule 1.137 as of the Inventory Transfer Date as provided in Section 4.2(f)(i)(A). 

1.138 “Transferred GSK Know-How” shall mean all GSK Know-How, other than the Excluded GSK Know-How, solely related to
the Compound or Product in or for the Territory, as identified on Schedule 1.138. 
 1.139 “Transferred GSK
Patents” shall mean all GSK Patents primarily related to the manufacture, use and/or sale of Compound, Product or Improvements Controlled by GSK or its Affiliates, as identified on Schedule 1.139. 

1.140 “Transferred GSK Promotional Materials” shall mean all Promotional Materials Controlled by GSK or its Affiliate in
the Territory, as identified on Schedule 1.140. For the avoidance of doubt, the Transferred GSK Promotional Materials shall not include or be deemed to include any rights in or to the GSK Housemarks. 

1.141 “Transferred GSK Regulatory Filings” shall mean all Regulatory Filings solely related to the Compound or Product
in the Territory Controlled by GSK or its Affiliates, as identified on Schedule 1.141. 
 1.142 “Transferred GSK
Trademarks” shall mean all Trademarks Controlled by GSK or its Affiliates that relate to or are or were used with Compound or Product, prior to the Transition Period End Date (but excluding any rights in and to the Transferred GSK
Promotional Materials), as identified on Schedule 1.142. 
 1.143 “Transition Period” shall mean the
period commencing on the Termination Effective Date and ending on the Transition Period End Date. 
 1.144 “Transition
Period End Date” shall have the meaning set forth in Section 4.1 of this Termination Agreement. 
 1.145
“Transfer Taxes” shall have the meaning set forth in Section 3.4(d) of this Termination Agreement. 

1.146 “Transition Team” shall have the meaning set forth in Section 4.7 of the Termination Agreement. 

1.147 [... * ...] 
 1.148 “United States” or “U.S.” shall mean the fifty (50) states of the United States of America and the District of Columbia and the territories of the United
States of America. 
 1.149 “VA” shall have the meaning set forth in Section 5.5(c) of this Termination
Agreement. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 14 - 

 EXECUTION COPY 
  

 1.150 [... * ...]  

1.151 “WAC” shall have the meaning set forth in Section 5.5(f) of this Termination Agreement. 

1.152 “XenoPort” shall have the meaning set forth in the preamble of this Termination Agreement. 

1.153 “XenoPort Indemnitees” shall have the meaning set forth in Section 9.2 of this Termination Agreement.

 1.154 “XenoPort Know-How” shall mean all Know-How relating to Compound or Product, in each case, that are
Controlled by XenoPort or its Affiliates as of the Termination Effective Date or during the Transition Period. For the avoidance of doubt, all Transferred GSK Know-How and Transferred Regulatory Filings shall be deemed to be included in XenoPort
Know-How as of and after the Termination Effective Date. 
 1.155 “XenoPort Patents” shall mean all Patents
owned or Controlled by XenoPort that relate to the manufacture, use and/or sale of the Compound and Product. For the avoidance of doubt, all Transferred GSK Patents shall be deemed to be included in XenoPort Patents on and after the Termination
Effective Date. 
 1.156 “XenoPort Trademarks” shall mean all Trademarks owned or Controlled by XenoPort that
relate to or are used with the Compound and Product, including the tradenames, logos, brands, corporate names or similar items used by XenoPort or its Affiliates. For the avoidance of doubt, all Transferred GSK Trademarks shall be deemed to be
included in XenoPort Trademarks as of and after the Termination Effective Date. 
 1.158 “300mg Product” shall
have the meaning set forth in Section 4.11 of this Termination Agreement. 
 ARTICLE II 

TERMINATION; RELEASE; DISMISSAL 
 2.1 Termination. On the terms set forth in this Termination Agreement, the Restated Agreement is hereby terminated in its entirety as of the Termination Effective Date, and shall be of no further
force and effect from and after the Termination Effective Date. Notwithstanding any provision to the contrary in the Restated Agreement, including, without limitation, Section 15.5 of the Restated Agreement, no provisions of the Restated
Agreement shall be deemed to survive or have any further force or effect. For clarity, and without limiting the foregoing, all licenses and rights granted by XenoPort to GSK under the Restated Agreement (including the licenses and rights granted by
XenoPort to GSK pursuant to Sections 2.1 and 2.2 of the Restated Agreement) with respect to all Compound and Product (including all licenses in the Territory, and licenses to make or have made outside the Territory) shall terminate immediately, and
all such licenses and rights with 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 15 - 

 EXECUTION COPY 
  

 
respect to all Compound and Product shall revert back to XenoPort. GSK will have the limited license set forth in Section 3.1 below to conduct the activities set forth in ARTICLE IV of this
Termination Agreement. Except as set forth in this Termination Agreement (or the Supply Agreement, if entered into by the Parties), GSK shall have no rights or obligations with respect to any Compound or Product. Further, all of XenoPort’s
rights to co-promote the Product as set forth in Section 5.2 of the Restated Agreement shall terminate immediately and XenoPort shall have no right to co-promote or otherwise commercialize the Product during the Transition Period. 

2.2 Release. Except with respect to the obligations created by, acknowledged in or arising out of this Termination Agreement, each
Party does hereby for itself and its respective legal predecessors, successors and assigns, and its Affiliates (as to GSK, including without limitation GlaxoSmithKline LLC and GlaxoSmithKline Holdings (Americas) Inc.), and each of their respective
current and former trustees, officers, directors, employees, agents, attorneys and representatives, unconditionally releases, covenants not to sue, and absolutely and forever discharges the other Party, together with its respective legal
predecessors, successors and assigns, and its Affiliates, and each of their respective current and former trustees, officers, directors, employees, agents, attorneys, and representatives, from any and all Claims relating to the Restated Agreement
(including the Original Agreement), other than Claims based upon this Termination Agreement, whether known or unknown, anticipated or unanticipated, whether at law or in equity, which either Party may have or claim to have against the other Party or
the other Persons identified above in the past, now or at any time in the future relating to the Restated Agreement (including the Original Agreement), other than Claims based upon this Termination Agreement, including any and all claims for
attorneys’ fees and costs (all of which are hereinafter referred to as and included within the “Released Matters”). It is the intention of the Parties in executing this Termination Agreement that this Termination Agreement will
be effective as a full and final accord and satisfaction and mutual general release of and from all Released Matters. 
 2.3
Unknown Claims. In furtherance of the intentions set forth herein, each of the Parties acknowledges that it is familiar with Section 1542 of the Civil Code of the State of California, which provides as follows: 

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF
EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.” 
 Each Party expressly waives
and relinquishes any right or benefit which it has or may have under Section 1542 of the Civil Code of the State of California and any and all provisions, rights and benefits to similar effect conferred by any law of any state or territory of
the United States or foreign country or principle of common or civil law. In connection with such waiver and relinquishment, each of the Parties acknowledges that it is aware that it or its attorneys or accountants may hereafter discover claims or
facts in addition to or different from those which it now knows or believes to exist with respect to the subject matter of this Termination Agreement or the other Party hereto, but that it is its intention hereby fully, finally and forever to settle
and release all of the Released Matters, 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 16 - 

 EXECUTION COPY 
  

 
disputes and differences known or unknown, suspected or unsuspected, which now exist, may exist or heretofore have existed between the Parties, except as otherwise expressly provided. In
furtherance of this intention, the releases herein given will be and remain in effect as full and complete mutual releases notwithstanding the discovery or existence of any such additional or different claim or fact. 

2.4 Dismissal. Within five (5) business days after the Termination Effective Date, the Parties shall cause to be completed,
executed and filed with the United States District Court for the Northern District of California and with the United States District Court for the District of Delaware, stipulations for dismissal with prejudice of the Litigation consistent with this
Termination Agreement and in the forms attached hereto as Exhibit 2.4A and Exhibit 2.4B, respectively. 

ARTICLE III 

LICENSE GRANTS; STOCK PURCHASE; TRANSFER OF ASSETS 
 3.1 License Grant to GSK. 
 (a) Subject to the terms and conditions of this
Termination Agreement, XenoPort hereby grants to GSK the following licenses, with the right to grant sublicenses as provided in Section 3.1(b) below, under the XenoPort Patents, XenoPort Know-How and XenoPort Trademarks: (i) an exclusive
license during the Transition Period to sell, market, distribute and otherwise commercialize Product in the Territory pursuant to Section 4.4, including developing Promotional Materials for use by GSK or its Affiliates in such commercialization
of the Product in the Territory; (ii) a non-exclusive license solely for the purposes of permitting GSK to (i) perform other activities under ARTICLE IV below for the applicable periods described therein, including (A) using the
Product in the Ongoing Studies as provided in Section 4.3(a), and (B) making, having made and importing Product for the Territory solely for sale by GSK pursuant to Section 4.4, use in Ongoing Studies pursuant to Section 4.3(a),
inclusion in Inventory sold to XenoPort hereunder, [... * ...] or for sale to XenoPort under the terms of the Supply Agreement; and (iii) a non-exclusive license to continue selling and distributing Product under GSK’s patient
assistance programs as permitted under Section 5.8(d) during the time period described therein and distributing Products in accordance with Section 4.4(g) during the time period described therein. 

(b) GSK shall have the right to sublicense its rights under the license granted in Section 3.1(a) above: (i) to its Affiliates;
and (ii) to Third Parties to permit such Third Parties to provide services to and on behalf of GSK relating to the manufacturing or development of the Product solely as provided herein; in each case of (i) and (ii), without the consent of
XenoPort. GSK may sublicense its rights as provided in this Section 3.1(b) to Affiliates solely for so long as such Person remains an Affiliate. GSK and its Affiliates shall be responsible for any actions of its sublicensees in exercising the
rights under a sublicense of rights granted by XenoPort and its Affiliates under this Termination Agreement to the same extent as if such actions had been undertaken by GSK itself or its Affiliates. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 17 - 

 EXECUTION COPY 
  

 3.2 License Grant to XenoPort. 

(a) GSK hereby grants to XenoPort a worldwide license, with the right to grant and authorize sublicenses as provided in
Section 3.2(c) below, under the Licensed GSK Patents and the Licensed GSK Know-How (collectively, the “Licensed Assets”) to make, have made, use, develop, import, offer for sale, sell, distribute, market, promote and otherwise
exploit Compound and Product. The foregoing license shall be non-exclusive, perpetual and irrevocable; provided, however, that during the period from the Termination Effective Date to the Transition Period End Date, the foregoing licenses
shall be subject to the covenants of XenoPort set forth in Sections 4.4(f) and 7.2(a) below. 
 (b) GSK hereby grants to
XenoPort a non-exclusive license, with the right to grant and authorize sublicenses as provided in Section 3.2(c) below under GSK’s rights and its Affiliate’s rights in the Transferred GSK Promotional Materials (including any
copyrights therein, but excluding any rights in the GSK Housemarks), to prepare Promotional Materials not containing the GSK Housemarks (which Promotional Materials may otherwise be based, in whole or part, on the Transferred GSK Promotional
Materials, in XenoPort’s discretion), and to use, reproduce, modify, and distribute such Promotional Materials and derivatives thereof in connection with the manufacture, use, development, importation, offer for sale, sale, distribution,
marketing, promotion and other exploitation of Compound and Product. The foregoing license shall expire upon the assignment and transfer of such rights in the Transferred GSK Promotional Materials from GSK to XenoPort pursuant to Sections 3.5, 3.6,
and 3.7 below and shall be subject to GSK’s exclusive right to commercialize, promote, market and sell the Product in the Territory during the Transition Period as set forth in Section 4.4 below and the covenants of XenoPort set forth in
Sections 4.4(f) and 7.2(a) below. 
 (c) XenoPort shall have the right to grant and authorize sublicenses under the
licenses granted under Sections 3.2(a) and 3.2(b) above, without the consent of GSK, to its Affiliates and Third Parties. XenoPort and its Affiliates shall be responsible for any actions of its sublicensees in exercising the rights under a
sublicense of rights granted by GSK and its Affiliates under this Termination Agreement to the same extent as if such actions had been undertaken by XenoPort itself or its Affiliates. 

3.3 Stock Purchase Agreement. Contemporaneously with the execution of this Termination Agreement, GSK and XenoPort shall enter
into the SPA pursuant to which GSK shall purchase from XenoPort certain shares of common stock of XenoPort. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 18 - 

 EXECUTION COPY 
  

 3.4 Assignment of Transferred Assets. 

(a) Subject to GSK’s license rights as set forth in Section 3.1 of this Termination Agreement, GSK shall convey, transfer and
assign (or cause its Affiliates to convey, transfer and assign) to XenoPort all right, title and interest in and to the following (collectively, the “Transferred Assets”): 

(i) on the Termination Effective Date, Transferred GSK Know-How; 

(ii) on the Termination Effective Date, Transferred GSK Regulatory Filings; 

(iii) on the Termination Effective Date, Transferred GSK Domain Names; 

(iv) on the Termination Effective Date, Transferred GSK Trademarks; 

(v) on the Termination Effective Date, Transferred GSK Patents; 

(vi) on the Transition Period End Date, Transferred GSK Contracts; 

(vii) on the Transition Period End Date, Transferred GSK Promotional Materials; 

(viii) on the Transition Period End Date, the Promotional Sample Inventory; and 

(ix) on the Inventory Transfer Date, the Transferred GSK Inventory. 

(b) On the Transition Period End Date, GSK shall convey, transfer and assign (or cause its Affiliates to convey, transfer and assign) to
XenoPort all right, title and interest in and to any Additional Transferred Asset not conveyed by GSK to XenoPort as set forth in Section 3.4(a) above, as further set forth under Section 3.6 below. Further, upon the Completion of each
Ongoing Study and upon the end of the Supply Term, GSK shall convey, transfer and assign (or cause its Affiliates to convey, transfer and assign) to XenoPort all right, title and interest in and to any Additional Transferred Asset arising out of or
identified in connection with the conduct of the applicable Ongoing Study or the manufacture and supply of Product during the Supply Term, respectively, as further set forth under Section 3.6 below. 

(c) All properties, assets, and rights of GSK not specifically listed and identified in Section 3.4(a) above, including without
limitation, any Accounts Receivable, Excluded GSK Contracts, Expired GSK Contracts (except as otherwise provided in Sections 3.6(b) and 4.2(a)), Excluded GSK Inventory and Excluded GSK Know-How (collectively, the “Excluded
Assets”) are excluded from the Transferred Assets and shall not be conveyed, transferred or otherwise assigned by GSK or its Affiliates (and GSK and its Affiliates shall have no obligation hereunder to convey, transfer or otherwise assign)
to XenoPort or any of its Affiliates. Further, neither XenoPort nor its 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 19 - 

 EXECUTION COPY 
  

 
Affiliates shall have any right, title or interest in or to any of the Excluded Assets. For the avoidance of doubt, XenoPort shall not assume or be responsible or liable for any debts, losses,
damages, liabilities and obligations associated with the Excluded Assets. 
 (d) All transfer, documentary, sales, use,
valued-added, gross receipts, stamp, registration or other similar transfer taxes (collectively, “Transfer Taxes”) incurred in connection with the transfer and assignment of the Transferred Assets as contemplated by the terms of
this Termination Agreement, including [... * ...] The Parties hereto agree to reasonably cooperate with each other to claim any applicable exemption from, or reduction of, any applicable Transfer Taxes. 

3.5 Deliverables. 
 (a) On the Termination Effective Date, GSK shall deliver or cause to be delivered the following documents, each duly executed by GSK, and XenoPort shall deliver or cause to be delivered the following
documents, each duly executed by XenoPort: 
 (i) Assignment and Assumption Agreement with respect to the Transferred GSK
Know-How and Transferred GSK Regulatory Filings; 
 (ii) Trademark Assignment Agreement with respect to the Transferred GSK
Trademarks; 
 (iii) Domain Name Assignment Agreement with respect to the Transferred GSK Domain Names; and 

(iv) Patent Assignment Agreement with respect to the Transferred GSK Patents. 

(b) On the Transition Period End Date, GSK shall deliver or cause to be delivered, each duly executed by GSK, and XenoPort shall deliver
or cause to be delivered, each duly executed by XenoPort, (i) the Assignment and Assumption Agreement with respect to the Transferred GSK Contracts and Transferred GSK Promotional Materials; and (ii) a Bill of Sale with respect to the
Promotional Sample Inventory. Notwithstanding anything to the contrary contained in this Termination Agreement, for any Transferred GSK Contracts required by GSK to fulfill obligations following the Transition Period End Date, including without
limitation GSK’s interim supply obligations set forth in Section 4.5, GSK’s assignment of each such Transferred GSK Contracts shall be a partial assignment so that GSK is able to continue to utilize such Transferred GSK Contracts to
fulfill all such obligations. 
 (c) On the Inventory Transfer Date, GSK shall deliver or cause to be delivered, each duly
executed by GSK, and XenoPort shall deliver or cause to be delivered, each duly executed by XenoPort, a Bill of Sale with respect to the Transferred GSK Inventory (all documents referred to in Section 3.5(a) (i) through
(iv) inclusive, Section 3.5(b) and this Section 3.5(c) are collectively referred to as the “Ancillary Agreements”). 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 20 - 

 EXECUTION COPY 
  

 (d) On the first Business Day after the Termination Effective Date, GSK shall deliver to
the FDA, with copies to XenoPort (i) the letter sent from GSK to the FDA, duly executed by GSK, transferring the rights to IND 071352 to XenoPort as of the Termination Effective Date and accepting the transfer of sponsor obligations to GSK,
acting as a Contract Research Organization for the conduct of Low Dose Study under IND 071352 as of the Termination Effective Date, and (ii) the letters sent from GSK to the FDA, duly executed by GSK, transferring the rights to the other
Transferred GSK Regulatory Filings to XenoPort as of the Termination Effective Date. 
 (e) On the second Business Day after the
Termination Effective Date, GSK, on XenoPort’s behalf, shall deliver to the FDA, with copies to XenoPort (i) the letter sent from GSK on XenoPort’s behalf to the FDA, duly executed by GSK on XenoPort’s behalf, assuming
responsibility for IND 071352 from GSK as of the Termination Effective Date and transferring sponsor obligations to GSK, acting as a Contract Research Organization for the conduct of the Low Dose Study under IND 071352 as of the Termination
Effective Date, and (ii) the letters sent from GSK on XenoPort’s behalf to the FDA, duly executed by GSK on XenoPort’s behalf, assuming responsibility for the other Transferred GSK Regulatory Filings from GSK as of the Termination
Effective Date. 
 3.6 Additional Transferred Assets; Additional Licensed Assets. 

(a) The Parties recognize and acknowledge [... * ...] to identify all the Transferred Assets and Licensed Assets [...
* ...] accordingly, the Parties shall [... * ...] prior to the end of the Transition Period so that [... * ...] Except as otherwise provided under Section 3.6(b) below with respect to GSK Contracts, either Party
may notify the other Party during the Transition Period (or with respect to Transferred Assets or Licensed Assets arising out of or identified in connection with the Ongoing Studies or the manufacture and supply of Compound or Product during the
Supply Term, within thirty (30) days after such activity concludes) of [... * ...], and upon the provision or receipt of such notice, [... * ...], as applicable, and assigned or licensed, as applicable, from GSK to
XenoPort as further set forth under Sections 3.6(d) and 3.6(e) below. Except as provided hereunder with respect to Inventory and Transferred GSK Inventory and Transferred GSK Contracts, [... * ...] 

(b) During the Transition Period, either Party may notify the other Party of [... * ...] that relate to Compound or Product
(as such assets are defined without limitation to the referenced Schedule), and upon the provision or receipt of such notice, [... * ...] XenoPort shall not be required to accept assignment of any proposed Transferred GSK Contract that
is not listed on the referenced Schedule as of the Termination Effective Date until XenoPort has agreed in writing, in its discretion, whether to accept such assignment after reviewing a true and complete copy of such proposed Transferred GSK
Contract [... * ...] With respect to any Transferred GSK Contract that is listed on the referenced Schedule as of the Termination Effective Date, [... * ...] whether XenoPort, in its discretion, wishes to have such
Transferred GSK Contract assigned to XenoPort on the Transition Period End Date as set forth in Section 3.4(a)(vi), and in the event that XenoPort [... * ...] for purposes of this Termination Agreement [... * ...] With
respect to each Transferred GSK Contract or proposed Transferred GSK Contract, GSK agrees to notify XenoPort, prior to the assignment of a contract to XenoPort as a Transferred GSK Contract under this Termination

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 21 - 

 EXECUTION COPY 
  

 
Agreement, of any disputed amounts claimed or alleged by the applicable counterparty to such contract to be due, and XenoPort [... * ...] In the event XenoPort requests such GSK
Contract to be assigned and such GSK Contract can be assigned to XenoPort in accordance with the provisions set forth under Section 4.2(a) below, such GSK Contract will be deemed a Transferred GSK Contract and assigned and transferred from GSK
to XenoPort as further set forth under Section 3.6(d) below; [... * ...] For clarity, neither XenoPort nor any of its Affiliates [... * ...] Further, nothing herein shall be construed or deemed as [... *
...] 
 (c) On the Transition Period End Date (or, for Transferred GSK Inventory, the Inventory Transfer Date),
(i) GSK shall deliver to XenoPort updated Schedules to include any assets identified as a Transferred Asset or Licensed Asset in accordance with Section 3.6(a) above, so that such Schedules set forth a true, complete and correct
description of all such Transferred Assets and Licensed Assets (as such assets are defined without limitation to the referenced Schedule) as of the Transition Period End Date (or, for Transferred GSK Inventory, the Inventory Transfer Date), and
(ii) GSK shall deliver to XenoPort updated Schedules to include any assets identified as a Transferred GSK Contract or Excluded GSK Contract in accordance with Section 3.6(b) above (and in accordance with Section 1.43 with respect to
the Excluded GSK Contracts), so that such Schedule set forth a true, complete and correct description of all GSK Contracts as of the Transition Period End Date. Further, upon Completion of each Ongoing Study and upon the end of the Supply Term, GSK
shall deliver to XenoPort updated Schedules to include any assets identified as a Transferred Asset or Licensed Asset (as such assets are defined without limitation to the referenced Schedule) arising out of or identified in the conduct of the
applicable Ongoing Study or the manufacture and supply of Product during the Supply Term, respectively. All assets identified as a Transferred Asset or Licensed Asset and added to the referenced Schedule as provided under this Section 3.6(c)
shall be deemed an “Additional Transferred Asset” or “Additional Licensed Asset,” respectively. 
 (d) Pursuant to Section 3.4(b) above, GSK shall convey, transfer and assign (or cause to be conveyed, transferred and assigned) to XenoPort all right, title and interest in and to any Additional
Transferred Asset, and each Party shall deliver or cause to be delivered to the other Party, along with the updated Schedules as provided in Section 3.6(c) above, duly executed copies of the applicable Ancillary Documents in order to convey,
assign and otherwise transfer the Additional Transferred Assets as contemplated herein. All provisions in this Termination Agreement applicable to the Transferred Assets shall apply, mutatis mutandis, to the Additional Transferred Assets such
that each reference to the applicable Transferred Asset(s) shall be deemed to include the applicable Additional Transferred Asset(s); provided that XenoPort shall not assume any liability for any debts, losses, damages and/or obligations associated
with any Additional Transferred Asset unless and until such Additional Transferred Asset is assigned or transferred from GSK to XenoPort and XenoPort assumes such liability in accordance with this Section 3.6. 

(e) GSK hereby grants (and shall cause its Affiliates to hereby grant) to XenoPort a license under any Additional Licensed Asset as set
forth under Section 3.2(a) above and all provisions in this Termination Agreement applicable to the Licensed Assets shall apply, mutatis mutandis, to the Additional Licensed Assets such that each reference to the applicable Licensed
Asset(s) shall be deemed to include the applicable Additional Licensed Asset(s). 
 (f) For a period of [... * ...]
following the Transition Period End Date, in the event that [... * ...] the Transferred Assets or Licensed Assets and that are necessary [... * ...] such Party shall notify the other Party, and [... * ...]

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 22 - 

 EXECUTION COPY 
  

 3.7 Assumed and Retained Liabilities. 

(a) Except as otherwise set forth in Sections 5.3, 5.4, 5.5, 5.6, 5.7 and 5.8 and Articles VII and IX of this Termination Agreement,
and subject to Section 3.7(c), GSK shall retain liability for any debts, losses, damages and/or obligations associated with any Transferred Assets that are incurred prior to the date on which the Transferred Assets are assigned and transferred
from GSK to XenoPort or its designee as provided in Section 3.4(a), 3.4(b) and 3.6 above (the “Retained Liabilities”) and neither XenoPort nor any of its Affiliates shall have any liability for such Retained Liabilities;
provided, however, that if, in accordance with this Termination Agreement, GSK has transferred a Transferred GSK Contract to XenoPort that allows for recovery of any debts, losses, damages and/or obligations associated with any Transferred
Assets from the counterparty to such Transferred GSK Contract, then, [... * ...], XenoPort shall assume the right to recover any such debts, losses, damages and/or obligations from the counterparty to such Transferred GSK Contract
[... * ...] (the “Transferred Contract Recovery Rights”). 
 (b) Except as otherwise set forth in
Sections 5.3, 5.4, 5.5, 5.6, 5.7 and 5.8 and Articles VII and IX of this Termination Agreement, and subject to Section 3.7(c), XenoPort shall assume (i) liability for any debts, losses, damages, and/or obligations associated with any
Transferred Assets that are incurred on or after the date on which such Transferred Assets are assigned and transferred from GSK to XenoPort or its designee as provided in Section 3.4(a), 3.4(b) and 3.6 above, and (ii) the Transferred
Contract Recovery Rights (collectively, the “Assumed Liabilities”) and neither GSK nor any of its Affiliates shall have any liability for such Assumed Liabilities. 

(c) Except to the extent that this Termination Agreement provides for a payment from one Party to the other or otherwise specifies that
certain costs or expenses shall be borne by one Party or the other, each Party shall bear the cost and expense of conducting its (and its Affiliates’ and Third Party contractors’) activities under this Termination Agreement. 

3.8 Further Assurances. The Parties further agree to execute such other documents and take such other actions as the other Party
may reasonably request in order to convey, license, assign and otherwise transfer the Transferred Assets or Licensed Assets from GSK to XenoPort as contemplated in this Termination Agreement. 

ARTICLE IV 

TRANSITION ACTIVITIES 
 4.1 Transition Period. The “Transition Period” shall be that period of time commencing on the Termination Effective Date and continuing up to 11:59 p.m. (Eastern) on April 30,
2013 (the “Transition Period End Date”), after which time the Transition Period shall expire; provided, 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 23 - 

 EXECUTION COPY 
  

 
however, that XenoPort may change the Transition Period End Date to an earlier date, and thus shorten the duration of the Transition Period, if XenoPort provides at least thirty
(30) days’ prior written notice to GSK of the new Transition Period End Date, which new Transition Period End Date must occur on the last day of the calendar month (e.g., January 31, 2013, February 28, 2013, etc.).

 4.2 Transfer of Assets. 
 (a) GSK Contracts. 
 (i) GSK shall deliver to XenoPort true and correct
and complete [... * ...] of the Transferred GSK Contracts, Expired GSK Contracts and Excluded GSK Contracts (other than GSK Contracts between GSK and its Affiliates and GSK Contracts between GSK or its Affiliate and a Third Party
[... * ...] within [... * ...] Business Days of the Termination Effective Date for XenoPort’s review. To the extent not previously provided to XenoPort during the Transition Period, the Transition Team shall use
Commercially Reasonable Efforts to identify the Transferred GSK Contracts, Expired GSK Contracts and Excluded GSK Contracts, and GSK shall deliver to XenoPort true and correct and complete electronic copies of any newly identified Transferred GSK
Contracts, Expired GSK Contracts or Excluded GSK Contracts (other than GSK Contracts between GSK and its Affiliates and GSK Contracts between GSK or its Affiliate and a Third Party [... * ...] as provided in Section 3.6, on the
Transition Period End Date. For clarity, [... * ...] Nothing herein shall be construed or deemed as obligating GSK to breach any provision in a GSK Contract, including, without limitation, any obligations of confidentiality with respect
to such GSK Contract. Further, GSK [... * ...] 
 (ii) To the extent that XenoPort requests in writing, no less
than thirty (30) days prior to the Transition Period End Date, that an Excluded GSK Contract or Expired GSK Contract, in each case, [... * ...] that is not assignable without the consent of another Person (a “Non-Assignable
Contract”) be assigned to XenoPort, GSK shall [... * ...] prior to the Transition Period End Date. GSK shall be deemed [... * ...] If consent to assign a Non-Assignable Contract is not granted [... *
...] prior to the Transition Period End Date, then [... * ...] If, however, such Person consents to the assignment of a Non-Assignable Contract [... * ...] prior to the Transition Period End Date, then such
Non-Assignable Contract shall (subject to Section 3.6(b)) be deemed to be included within the Transferred GSK Contracts and assigned and transferred from GSK to XenoPort as set forth under Sections 3.4, 3.5, and 3.6 above; provided however,
[... * ...], or to obtain consent for assignment, of such Non-Assignable Contract. Further, nothing herein shall obligate or be deemed to obligate [... * ...] If XenoPort notifies GSK in writing prior to the Transition
Period End Date, and subject to Section 3.6(b), that XenoPort requests an Expired GSK Contract that is assignable without the consent of another Person be included as a Transferred GSK Contract and assigned to XenoPort, such Expired GSK
Contract shall be included within the Transferred GSK Contracts and assigned and transferred from GSK to XenoPort as set forth under Sections 3.4, 3.5, and 3.6 above. 
 (iii) With respect to any Expired GSK Contract or any Non-Assignable Contract, in each case that has been identified by the Parties prior to the date [... * ...] after the Transition Period
End Date and unless and until such Expired GSK Contract or Non-Assignable Contract is assigned to XenoPort as set forth in Section 4.2(a)(ii) above (each a “Non-Assigned Contract”), at XenoPort’s written request, GSK shall
[... * ...] as reasonably necessary for the purposes of making, having made, using, developing, importing, offering for sale, selling, distributing, marketing, promoting and otherwise exploiting Compound or Product; provided,
however, [... * ...] and further provided, however, that such obligation shall continue [... * ...] If, in order for GSK to fulfill any commitments under this Section 4.2(a)(iii), XenoPort [...
* ...] GSK’s exercise of its rights [... * ...] Nothing herein shall [... * ...] provided, however that XenoPort shall be [... * ...] The Parties acknowledge and agree that, depending on the
circumstances in a given case, GSK’s obligation [... * ...]  

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 24 - 

 EXECUTION COPY 
  

 (b) GSK Know-How. 

(i) GSK shall deliver to XenoPort true and correct and complete [... * ...] of the Transferred GSK Know-How and Licensed
GSK Know-How (except as otherwise noted on Schedule 4.2B as Transferred GSK Know-How that has been previously delivered and assigned to XenoPort pursuant to the Restated Agreement) on timelines to be determined and agreed by the Transition
Team, but no later than within [... * ...] Business Days after the Termination Effective Date with respect to Transferred GSK Know-How and Licensed GSK Know-How that is related to distribution, shipping or safety, no later than
[... * ...] Business Days with respect to Transferred GSK Know-How and Licensed GSK Know-How related to manufacturing, and no later than within [... * ...] Business Days after the Termination Effective Date for other
Transferred GSK Know-How and Licensed GSK Know-How. In determining and agreeing to such timelines, the Transition Team may specify [... * ...] for delivery of various portions of the Transferred GSK Know-How and Licensed GSK Know-How,
and shall discuss and consider whether certain portions of the Transferred GSK Know-How and Licensed GSK Know-How may need to be [... * ...] than other portions in order to facilitate XenoPort’s ability to assume commercialization
of the Product on the Transition Period End Date but in any event taking into account resources required for GSK to meet its obligations hereunder. To the extent not previously provided to XenoPort during the Transition Period, GSK shall deliver to
XenoPort true and correct and complete [... * ...] electronic copies of any newly identified Transferred GSK Know-How or Licensed GSK Know-How (including with respect to an Ongoing Study), as provided in Section 3.6(a), on the
Transition Period End Date or upon Completion of each Ongoing Study or the end of the Supply Term, as applicable. For clarity, [... * ...] To the extent that the Parties agree that the delivery of such Transferred GSK Know-How or
Licensed GSK Know-How as set forth herein [... * ...] The Parties acknowledge that GSK has previously assigned and transferred to XenoPort pursuant to the Restated Agreement all GSK Know-How (other than the Excluded GSK Know-How)
related to the Compound or Product outside the Territory, including the GSK Know-How identified on Schedule 4.2B. 

(ii) To the extent any [... * ...] GSK or its Affiliates, and except to the extent that [... * ...] of GSK (or
any of its Affiliates) in accordance with Applicable Laws, GSK shall provide (or cause its Affiliates to provide) such [... * ...] to XenoPort. In the event that 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 25 - 

 EXECUTION COPY 
  

 
XenoPort believes [... * ...] and GSK believes that [... * ...] the Parties shall discuss the matter to consider possible resolutions that would meet the needs of both
Parties. Notwithstanding the foregoing, in the event that GSK [... * ...] that are related to an Ongoing Study in order to perform such Ongoing Study, GSK may [... * ...] the Completion of such Ongoing Study. 

(c) To the extent that any copies of documents reflecting or containing Transferred GSK Know-How or Licensed GSK Know-How has not been
provided by GSK or its Affiliates and is in possession of a Third Party (“Non-Transferred GSK Know-How”), GSK shall [... * ...] and (ii) provide XenoPort (or its designees) with [... * ...] GSK shall
be deemed to have satisfied its obligation [... * ...] If, in order for GSK to fulfill any commitments under this Section 4.2(c), XenoPort [... * ...] with respect to access to any such Non-Transferred GSK Know-How.
GSK shall not require [... * ...] Further, nothing herein shall obligate or be deemed to obligate GSK or any of its Affiliates [... * ...] Additionally, nothing contained herein shall [... * ...] 

(d) Transferred GSK Regulatory Filings. GSK shall deliver to XenoPort true and correct and complete electronic copies [... *
...] of the Transferred GSK Regulatory Filings within [... * ...] Business Days of the Termination Effective Date. For clarity, such electronic copies of the Transferred GSK Regulatory Filings shall be provided in [... *
...] 
 (e) Transferred GSK Promotional Materials. 

(i) [... * ...] of the Transferred GSK Promotional Materials (including underlying layouts, typesets, print proofs, etc.)
within [... * ...] Business Days of the Termination Effective Date. To the extent not previously provided to XenoPort during the Transition Period, GSK shall deliver to XenoPort true and correct and complete electronic copies of any
newly created or identified Transferred GSK Promotional Materials, as provided in Section 3.6, on the Transition Period End Date. For clarity, such electronic copies of the Transferred GSK Promotional Materials shall [... * ...] 

 (ii) Subject to GSK’s exclusive right to commercialize, promote, market and sell the Product in the Territory during
the Transition Period as set forth in Section 4.4 below and the covenant(s) of XenoPort set forth in Sections 4.4(f) and 7.2(a) below, XenoPort shall have the right to use and disclose all such Transferred GSK Promotional Materials
following the Termination Effective Date for sole purpose of preparing (at any time after the Termination Effective Date) Promotional Materials not containing the GSK Housemarks (which Promotional Materials may otherwise be based, in whole or part,
on the Transferred GSK Promotional Materials, in XenoPort’s discretion) for use by or under authority of XenoPort after the Transition Period End Date. 
 (iii) The Parties acknowledge and agree that such Transferred GSK Promotional Materials are being conveyed, transferred, assigned and provided by GSK to XenoPort “as is, where is, with all
faults” and with no express or implied representations or warranties of any kind, including without limitation, whether such Transferred GSK Promotional Materials comply with Applicable Laws. XenoPort shall have sole responsibility for
determining whether any promotional materials used by XenoPort to commercialize, promote or otherwise market Product in the Territory on and after the Transition Period End Date comply with Applicable Laws. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 26 - 

 EXECUTION COPY 
  

 (f) Transferred GSK Inventory. 

(i) An initial schedule of the Inventory as of the Termination Effective Date (excluding the Excluded Inventory) is attached hereto as
Schedule 1.69. The Parties acknowledge that items on the initial Schedule attached hereto will be used by GSK in its manufacture, development and commercialization activities under Sections 4.3(a) and 4.4(c) and/or in connection
with manufacture of Product for XenoPort as provided under Section 4.5, and that accordingly the initial Schedule attached hereto as of the Termination Effective Date is not a statement of the Transferred GSK Inventory that will in fact be
transferred to XenoPort on the Inventory Transfer Date as provided herein. An updated, final binding schedule identifying the Transferred GSK Inventory will be provided to XenoPort as of the Inventory Transfer Date as set forth below. 

(A) By January 30, 2013, GSK shall deliver Schedule 1.137 to XenoPort, which shall identify the Transferred GSK
Inventory to be transferred to XenoPort pursuant to this Termination Agreement (the “Final Transferred GSK Inventory Quantities”). 
 (B) The Final Transferred GSK Inventory Quantities shall exclude quantities of Inventory retained by GSK to fulfill its obligations (whether by or through GSK, its Affiliates or Third Party contractor(s))
to manufacture and supply Product in support of or to conduct GSK’s obligations set forth in Section 4.3(a), 4.4(a), 4.4(c) and 4.5 (collectively, the “Retained Inventory Quantities”). For the avoidance of doubt, GSK shall
retain ownership of the Retained Inventory Quantities, except as such Retained Inventory Quantities may be subsequently transferred to XenoPort pursuant to Section 4.2(f)(iii) below. 

(ii) To effect the transfer of Final Transferred GSK Inventory Quantities to XenoPort, GSK and XenoPort shall enter into customary
documents, including the Bill of Sale as set forth in Section 3.5(c), which shall transfer right, title and ownership of such Final Transferred Inventory Quantities to XenoPort. Such transfer (and delivery) of Final Transferred GSK Inventory
Quantities to XenoPort shall occur as promptly as possible following January 30, 2013 (the date of such transfer, the “Inventory Transfer Date”). Delivery of the Final Transferred GSK Inventory Quantities shall be made to
XenoPort [... * ...]; provided, however, [... * ...] 
 (iii) If after the Transition Period
End Date, Retained Inventory Quantities are still available and are no longer required by GSK to manufacture and supply Product in support of or to conduct its obligations set forth in Section 4.3(a), 4.4(a), 4.4(c) and 4.5, then GSK shall
promptly transfer such remaining Retained Inventory Quantities to XenoPort. Any such transfer of additional Inventory shall be delivered under the same terms under Section 4.2(f)(ii) above for Final Transferred GSK Inventory Quantities without
charge to XenoPort [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 27 - 

 EXECUTION COPY 
  

 (iv) In the event that the Retained Inventory Quantities are not sufficient to
manufacture and supply those quantities of Product required to support GSK’s obligations set forth in Sections 4.3(a), 4.4(a), 4.4(c) and 4.5 (whether due to unexpected increases in demand, rejected batches, or otherwise), GSK shall be
permitted to place orders for additional API in accordance with the principles set forth in Section 4.2(h) below, and any such API supplied to GSK pursuant to this Section 4.2(f)(iv) shall be included within the meaning of “Tolled
API” (and, if applicable, subject to the terms agreed in Section 4.2(h) below). [... * ...] 
 (v)
[... * ...] 
 (vi) XenoPort acknowledges and agrees that API [... * ...] XenoPort agrees that it
shall comply with cGMP and Applicable Laws regarding [... * ...] Such Final Transferred GSK Inventory Quantities is being transferred to XenoPort [... * ...] set forth in Section 7.3(g), and subject to
Section 7.4). 
 (vii) Notwithstanding the above, GSK acknowledges that XenoPort may require certain limited quantities of
API prior to the Inventory Transfer Date (“Limited API”). GSK shall provide those Limited API quantities as reasonably requested by XenoPort, without additional charge for purchase thereof other than amounts to be paid pursuant to
Section 6.2, with any such delivery of Limited API to be under the same terms set forth in Section 4.2(f)(ii) above for Final Transferred GSK Inventory Quantities; provided, however, that unless conflicting obligations or commitments are
waived by XenoPort, any such request for Limited API shall not conflict with GSK’s obligations under this Termination Agreement or the Supply Agreement. Supply of Limited API shall be made on documentation reasonably agreed by the Parties to
establish transfer of ownership and risk of loss to XenoPort, with such Limited API considered for purposes of this Termination Agreement “Transferred GSK Inventory” and included within “Final Transferred GSK Inventory
Quantities”. 
 (viii) Notwithstanding anything to the contrary contained in this Termination Agreement, if pursuant to
this Termination Agreement GSK assigns and transfers a Transferred GSK Contract to XenoPort that directly relates to the manufacture and supply of any Transferred GSK Inventory or Promotional Sample Inventory, [... * ...] 

(g) Promotional Sample Inventory. The Promotional Sample Inventory shall be transferred to XenoPort within thirty (30) days
after the Transition Period End Date. Any inventory of sample Products held by GSK’s sales representatives as of the Transition Period End Date shall be destroyed by GSK. GSK shall notify XenoPort in writing of the quantity of Promotional
Sample Inventory being transferred to XenoPort ten (10) Business Days prior to the Transition Period End Date. 
 (h)
Tolled API. 
 (i) In the event XenoPort elects for GSK to provide interim supply pursuant to Section 4.5, then
(i) for Product to be so supplied under a Firm Order provided from 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 28 - 

 EXECUTION COPY 
  

 
XenoPort to GSK prior to the Inventory Transfer Date, GSK shall supply the API therefor from the API in GSK’s Inventory, and (ii) for Product so supplied under a Firm Order provided to
GSK after the Inventory Transfer Date, GSK may from time to time place orders with XenoPort for those quantities of API required to manufacture and supply such Product (any such API supplied back to GSK after the Inventory Transfer Date referred to
herein as the “Tolled API”). Such Tolled API shall be provided to GSK (or as directed by GSK) free of charge, in sufficient quantity and in accordance with the requested delivery time to allow GSK to meet any Firm Order commitments
(and delivery dates agreed therein); provided that GSK shall in the normal course give at least [... * ...] to XenoPort prior to the requested date of delivery and for any unexpected events (e.g., batch failure) as promptly as
practicable. In the event that XenoPort fails to deliver (in whole or in part) the Tolled API (or fails to deliver in the time period requested by GSK), GSK shall make appropriate adjustments to the quantities (or delivery phasing) of Product
included in the relevant Firm Order without such adjustment(s) deemed a breach by GSK of any Firm Order commitments (or a breach of any obligations under this Termination Agreement or the Supply Agreement by reason of GSK’s failure to supply,
to the extent so prevented). Any such adjustment to quantities of Product (or timing of delivery) shall be based on those quantities of Tolled API that XenoPort is not able to provide (or based on the delayed receipt of Tolled API), which, for the
avoidance of doubt, shall not prevent GSK’s use of Commercially Reasonable Efforts to supply those quantities of Product able to be supplied using Tolled API actually received (or based on reasonably adjusted delivery times). 

(ii) XenoPort acknowledges and agrees that Tolled API will be delivered directly to GSK’s Third Party contractor and utilized at
such Third Party contractor’s site in the manufacture of Bulk Product. In the event that any such Tolled API delivered by (or on behalf of) XenoPort in accordance with this Section [... * ...] or for any failure to satisfy Firm
Order quantities requested by XenoPort to the extent caused by the delivery of Tolled API [... * ...] Any Tolled API will be supplied to such Third Party contractor under an existing contractual agreement with GSK, which provides
assurance to GSK that materials (including Tolled API) will be stored in compliance with an existing quality agreement, cGMPs, and Applicable Laws. In the event of any loss or damage to Tolled API, GSK shall [... * ...] for all such
losses and/or damages, and GSK shall [... * ...]  
 (iii) For the avoidance of doubt, neither GSK nor its
Affiliates shall be responsible for any [... * ...] delivered pursuant to a Firm Order to the extent any such [... * ...] from shipping, handling, re-testing, or storage of such Tolled API after such API is transferred to
XenoPort pursuant to Section 4.2(f) and prior to delivery to GSK’s Third Party contractor pursuant to Section 4.2(h)(ii). 
 (i) GSK Housemarks License. To the extent that the Transferred GSK Inventory of Finished Product (or any Product supplied pursuant to interim supply terms below) and Promotional Sample Inventory
delivered to XenoPort is in packaging that bears (or contains inserts or other documentation bearing) trademarks, tradenames, logos, brands, corporate names or similar items used by GSK or any of GSK’s Affiliates other than the Transferred GSK
Trademarks (collectively, the “GSK Housemarks”), then as of the Inventory Transfer Date with respect to the Finished Product and the Transition Period End Date with respect to the Promotional Sample

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 29 - 

 EXECUTION COPY 
  

 
Inventory, GSK hereby grants to XenoPort, and XenoPort hereby accepts, a limited non-exclusive, royalty-free license, with the right to grant and authorize sublicenses, to use the GSK Housemarks,
solely to the extent necessary to allow XenoPort to distribute and sell such Finished Product or distribute and use the Promotional Sample Inventory containing the GSK Housemarks in accordance with the terms of this Termination Agreement (the
“GSK Housemarks License”). XenoPort acknowledges that the GSK Housemarks License is being granted solely for transitional purposes and that XenoPort shall use its Commercially Reasonable Efforts to cease its use of the GSK
Housemarks and exhaust its inventory of such Finished Product and Promotional Sample Inventory labeled with GSK Housemarks as quickly as is reasonably possible after the Inventory Transfer Date or Transition Period End Date, as applicable. XenoPort
shall not: (A) add any other labels or marks to, or otherwise alter, the GSK Housemarks as used by GSK as of the Inventory Transfer Date or Transition Period End Date, as applicable; (B) change in any way the style of the GSK Housemarks as
used by GSK as of the Inventory Transfer Date or Transition Period End Date, as applicable; or (C) otherwise use the GSK Housemarks in any manner other than as specifically permitted in this Section 4.2(i). XenoPort acknowledges GSK’s
(or its Affiliates’) ownership of the GSK Housemarks, and XenoPort shall not knowingly do anything inconsistent with such ownership, and agrees that all use of the GSK Housemarks by XenoPort shall inure to the benefit and be on behalf of GSK
(or its Affiliates). Nothing in this Termination Agreement shall give XenoPort any right, title or interest in the GSK Housemarks other than the right to use the GSK Housemarks strictly in accordance with this Section 4.2(i). All use of the GSK
Housemarks by XenoPort under this Section 4.2(i) shall conform to the standards followed by the GSK (or its Affiliates) prior to the Inventory Transfer Date or Transition Period End Date, as applicable, and upon reasonable notice to XenoPort,
GSK (or its Affiliates) shall have the right to review XenoPort’s use of the GSK Housemarks after the Transition Period End Date or Transition Period End Date, as applicable, to ensure XenoPort’s compliance with this requirement related to
the GSK Housemarks. XenoPort shall not have the right to, and shall not, sublicense, assign, pledge, grant or otherwise encumber or transfer to any Third Party any rights licensed by GSK (or its Affiliates) to XenoPort under this Section 4.2(i)
without GSK’s prior written consent; provided, however, for the avoidance of doubt, the foregoing shall not be construed to require GSK’s consent for XenoPort or its Affiliate to engage and use distributors for the distribution and sale,
on behalf of XenoPort or its Affiliate, of Products bearing the GSK Housemarks. The Parties understand and agree that, in addition to all other legal remedies, [... * ...] If XenoPort shall breach this Section 4.2(i) (whether or
not cured), GSK shall have the right to immediately terminate the GSK Housemarks License by providing written notice to XenoPort. Nothing in this Section 4.2(i), or any other provision of this Termination Agreement shall grant XenoPort any
rights in any of GSK’s Domain Names, registrations or applications for registration, or renewals thereof, registered in the Territory or any other country or jurisdiction throughout the world, except for the Transferred GSK Domain Names.

 4.3 Development Activities; Maintenance of Regulatory Filings; Publications. 

(a) Conduct of the Ongoing Studies. 
 (i) Following the Termination Effective Date, GSK shall continue to conduct, and shall use Commercially Reasonable Efforts to conduct, the Ongoing Studies in

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 30 - 

 EXECUTION COPY 
  

 
accordance with the development plan attached hereto as Exhibit 4.3A (the “Development Plan”), including the timelines therein, even if such Ongoing Studies continue after
the Transition Period End Date. Promptly following transfer of the NDA for the Product to XenoPort, the Parties shall enter into a mutually agreed written Transfer of Obligations statement in connection with GSK’s performance of activities to
complete such Ongoing Studies. With respect to the low-dose RLS efficacy study RXP114025 (the “Low Dose Study”), GSK agrees to use Commercially Reasonable Efforts to conduct and complete the Low Dose Study in accordance with the
timeline as stipulated in the approval letter from the FDA to GSK, dated April 6, 2011, approving the NDA for Horizant (gabapentin enacarbil) Extended-Release Tablets as a treatment for moderate-to-severe primary restless legs syndrome
(the “RLS Horizant Approval Letter”), attached hereto as Exhibit 4.3B (or a revised timeline proposed or approved by the FDA). Without limiting the foregoing, the Low Dose Study shall be conducted in accordance with
the applicable protocols therefor, Applicable Laws and GSK’s Applicable Policies and Procedures. GSK shall have discretion regarding the manner in which it conducts the Low Dose Study; provided, however, that GSK shall keep XenoPort reasonably
informed regarding the status and results of the Low Dose Study and all other Ongoing Studies, and GSK shall not materially amend or modify the protocol for the Low Dose Study, or conduct the Low Dose Study in a manner that is materially
inconsistent with the protocol therefor, without the prior written approval of XenoPort. In the event that a material modification to a protocol for the Low Dose Study is reasonably required to comply with Applicable Laws, GSK’s Applicable
Policies and Procedures or with the request or suggestion of an applicable Regulatory Authority, the Parties shall reasonably cooperate to agree upon mutually acceptable modifications to such protocol to accommodate such requirement, request or
suggestion. GSK may in its discretion, but subject to advance consultation and discussion with XenoPort, terminate early or wind-down any such Low Dose Study for safety reasons or to comply with Applicable Laws or GSK’s Applicable Policies and
Procedures. Subject to XenoPort’s prior consultation and approval, GSK shall interpret the results of the Low Dose Study, determine whether any additional analyses are required (provided that GSK shall not initiate any such additional analyses
without the prior approval of XenoPort), and prepare and deliver to XenoPort a second draft of the clinical study report for the Low Dose Study promptly upon collection of all data for such Low Dose Study, or upon early termination or wind-down of
such Low Dose Study as permitted in this Section 4.3(a)(i) above, but no later than [... * ...] For the purposes of this Section 4.3(a), the term [... * ...] With respect to each Ongoing Study other than the Low
Dose Study, GSK shall provide to XenoPort a copy of the manuscript with respect to such Ongoing Study. As between the Parties, GSK shall be responsible for all costs (including wind-down or close-out costs) associated with the Ongoing Studies, even
if such costs are incurred or paid following the Termination Effective Date. Further as between the Parties, XenoPort will be solely responsible, at XenoPort’s expense, for any additional clinical trials (i.e., beyond the Ongoing
Studies) initiated and conducted after the Termination Effective Date (including, without limitation, any pediatric studies (PMRs 1588-1, 2, 3, and 4) and the adult driving simulation study (PMR 1588-8), as required by the FDA under the terms of the
RLS Horizant Approval Letter); provided, however that XenoPort will not directly or indirectly, initiate or conduct any clinical trials relating to Compound or Product in the Territory prior to the Transition Period End Date, unless
otherwise required or requested by a Regulatory Authority. For the avoidance of doubt, nothing herein shall restrict XenoPort from conducting development activities relating to Compound or 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 31 - 

 EXECUTION COPY 
  

 
Product after the Transition Period End Date or outside the Territory. After the Termination Effective Date, GSK shall not undertake any clinical study of Product other than the Ongoing Studies
as outlined in the Development Plan unless approved in writing by XenoPort prior to the commencement of any such clinical study. 
 (ii) GSK shall have the right to publish in its clinical trial register the results or summaries of the results of the Low Dose Study. The Parties shall review and discuss such results or summary of
results of the Low Dose Study to be published prior to publication, provided, however that GSK shall have final say on what is published in its clinical trial register. Further, notwithstanding anything in this Termination Agreement to the
contrary, GSK shall have the right to submit and publish information and data pertaining to the Low Dose Study to meet GSK’s obligations under Applicable Laws or under GSK’s Applicable Policies and Procedures; provided, however,
that (A) as between the Parties, XenoPort shall determine and be responsible for publishing information pertaining to the Low Dose Study and the results thereof on clinicaltrials.gov (or any substitute website established by the FDA or another
Regulatory Authority for similar purposes), including any such publication that may be required under Applicable Laws, and (B) GSK shall provide to XenoPort information for such publication on clinicaltrials.gov and discuss such information
(including discussion of reasonable questions XenoPort may have regarding such information) with XenoPort. 
 (b)
Responsibility For and Interactions with Regulatory Authorities Concerning the Transferred GSK Regulatory Filings. 

(i) The Parties acknowledge and agree that as of the Termination Effective Date, XenoPort will have sole control and responsibility for
maintaining the Transferred GSK Regulatory Filings and all other Regulatory Filings for the Compound and Product in the Territory. Notwithstanding the forgoing, XenoPort hereby designates and appoints GSK as an agent of XenoPort during the
Transition Period for the purposes of filing and maintaining all Regulatory Filings in the Territory relating to the Compound and Product, including without limitation the Transferred GSK Regulatory Filings. During the Transition Period, GSK or its
Affiliate shall use Commercially Reasonable Efforts to file and maintain, on behalf of XenoPort, all Regulatory Filings relating to the Compound and Product in the Territory, and in consultation with and at the direction of XenoPort, GSK shall be
responsible for liaising with and managing all interactions with Regulatory Authorities in the Territory with respect to Product, except to the extent that XenoPort is required by Applicable Laws to liaise directly with any Regulatory Authority. For
the avoidance of doubt, the foregoing shall not be construed to preclude XenoPort from participating in any such interactions with Regulatory Authorities in the Territory with respect to Product. As between the Parties, each Party shall bear the
expense of its own and its Affiliates’ personnel and contractors in conducting such activities. XenoPort shall be responsible for fees paid to the FDA in connection with the Product on and after the Termination Effective Date; provided,
however, that with respect to Establishment Fees, Product Fees and other fees paid to the FDA that are assessed annually or in respect to another set time period, GSK shall bear that portion (based on number of days) that is attributable to the
part of the applicable time period up to the Transition Period End Date, and XenoPort shall bear that portion (based on number of days) that is attributable to the part of the 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 32 - 

 EXECUTION COPY 
  

 
applicable time period that follows the Transition Period End Date. XenoPort shall, within thirty (30) days after receipt of an invoice from GSK or its Affiliate, reimburse GSK or its
Affiliate for XenoPort’s portion of any such fees paid to the FDA by GSK or its Affiliate in filing and maintaining all Regulatory Filings relating to the Compound and Product in the Territory as provided herein, and GSK shall, within thirty
(30) days after receipt of an invoice from XenoPort or its Affiliate, reimburse XenoPort or its Affiliate for GSK’s portion of any such fees paid to the FDA by XenoPort or its Affiliate in filing and maintaining all Regulatory Filings
relating to the Compound and Product in the Territory as provided herein. 
 (ii) During the Transition Period, GSK shall use
Commercially Reasonable Efforts to participate in all of XenoPort’s interactions with Regulatory Authorities (including the Office of Prescription Drug Promotion) related to Product in the Territory. Each Party shall provide the other Party
reasonable advanced notice (and in no event less than [... * ...] of substantive meetings with a Regulatory Authority in the Territory relating to the Compound or Product. GSK shall be entitled to have [... * ...]
representatives [... * ...] attend any such meetings, and if requested by XenoPort GSK will actively participate in all substantive meetings with such Regulatory Authority. For the avoidance of doubt, XenoPort shall not be restricted
hereunder with respect to the number of XenoPort representatives participating in such meetings. Each Party shall keep the other Party informed as to all material interactions with Regulatory Authorities in the Territory during the Transition
Period. Any activities relating to Product Events arising during the Transition Period shall be handled as set forth in Section 4.4(c). During the Transition Period, and except to the extent expressly agreed otherwise in the last sentence of
Section 4.4(c), each Party shall provide the other Party with electronic copies of any material documents, information and correspondence submitted to a Regulatory Authority in the Territory during the Transition Period relating to the Compound
or Product as soon as reasonably practicable. Further, each Party shall promptly provide the other Party with electronic copies of all material documents, information and correspondence received from a Regulatory Authority in the Territory during
the Transition Period directly related to any Compound or Product. During the Transition Period, all submissions to Regulatory Authorities in the Territory with respect to the Compound or Product shall be subject to XenoPort’s review and prior
approval, and the Parties shall consult regarding matters to be discussed, positions to be taken and messaging before any scheduled meetings or teleconferences, and before initiating any unscheduled meetings or teleconferences, with Regulatory
Authorities in the Territory with respect to the Compound or Product. In the event that GSK and XenoPort do not agree with respect to any such submissions to Regulatory Authorities, or positions to be taken or messaging in such meetings or
teleconferences with Regulatory Authorities, and subject to Section 4.4(c), XenoPort’s view shall prevail and the Parties shall implement the course of action directed by XenoPort; provided, however, that if GSK determines in good faith in
its sole discretion that such course of action would violate Applicable Laws or GSK’s Applicable Policies or Procedures, GSK may so notify XenoPort and GSK shall not be obligated to participate in implementing such course of action (and, for
the avoidance of doubt, XenoPort may in its discretion proceed, on its own or with another agent, to institute such course of action without GSK’s participation). 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 33 - 

 EXECUTION COPY 
  

 (iii) Notwithstanding anything contained herein, GSK shall have no obligation under
this Termination Agreement to take or abstain from taking any action with respect to the filing and/or maintenance of any Regulatory Filings in the Territory relating to the Compound and Product as provided herein or with respect to interactions
with Regulatory Authorities in the Territory regarding Regulatory Filings relating to the Compound or Product that, in any case as determined by GSK in good faith in its sole discretion, violates Applicable Laws or GSK’s Applicable Policies or
Procedures. Further, GSK shall have no liability to XenoPort or XenoPort’s Affiliates for taking or abstaining from taking any action with respect to the filing and/or maintenance of any Regulatory Filings in the Territory relating to the
Compound and Product as provided herein or with respect to interactions with Regulatory Authorities in the Territory concerning Regulatory Filings relating to the Compound or Product in order to, in any case as determined by GSK in good faith in its
sole discretion, to comply with Applicable Laws or GSK’s Applicable Policies or Procedures. 
 (iv) For the avoidance of
doubt, after the Transition Period End Date, GSK shall have no further responsibilities on behalf of XenoPort or any of XenoPort’s Affiliates with respect to any Regulatory Filings in the Territory relating to the Compound and Product,
including the Transferred GSK Regulatory Filings. 
 (c) Publications. After the Termination Effective Date, GSK shall
not publish, present publicly, or submit for written or oral publication any manuscript, abstract presentation or the like that includes Transferred GSK Know-How other than those publications set forth on Schedule 4.3C attached hereto
(“Permitted GSK Publications”). Prior to GSK publishing, publicly presenting and/or submitting for written or oral publication any Permitted GSK Publications, GSK shall provide XenoPort a copy thereof for review at
least [... * ...] in advance (unless GSK is required by Applicable Laws or GSK’s Applicable Policies and Procedures to publish such information sooner, in which event GSK shall provide a copy for review as far in advance as
practicable). GSK shall consider in good faith, but shall in no event be obligated to incorporate, any comments provided by XenoPort during such [... * ...] period. In the event that XenoPort fails to provide any comments during such
[... * ...] period (or such shorter period if required under Applicable Laws), XenoPort shall be deemed to have no comments to such Permitted GSK Publication. In addition, GSK shall, at the request of XenoPort within such [... *
...]period, remove any Confidential Information of XenoPort therefrom, except GSK shall have the right to publicly disclose any information, including Confidential Information, pertaining to safety of Product that GSK reasonably believes in
good faith it is obligated to disclose to comply with Applicable Laws or GSK’s Applicable Policies and Procedures. During the Transition Period, XenoPort may submit for publication a manuscript, abstract or the like in the Territory that
includes data or other information relating to Compound or Product only with GSK’s consent, not to be unreasonably withheld (provided that such manuscript, abstract or like would not be published until after the Transition Period End Date), and
after the Transition Period End Date, XenoPort may publish, publicly present or submit for publication a manuscript, abstract or the like that includes data or other information relating to Compound or Product. For the avoidance of doubt, XenoPort
may at any time submit for publication a manuscript, abstract or the like outside the Territory that includes data or other 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 34 - 

 EXECUTION COPY 
  

 
information relating to Compound or Product, but for any such publication a manuscript, abstract or the like submitted prior to the Transition Period End Date shall provide GSK a copy thereof for
its clinical review for at least [... * ...] (unless XenoPort is required by Applicable Laws to publish such information sooner), and shall consider in good faith any comments provided by GSK during such [... * ...] period.
In the event that GSK fails to provide any comments during such [... * ...] period (or such shorter period if required under Applicable Laws), GSK shall be deemed to have no comments thereto. In addition, XenoPort shall, at the request
of GSK within such [... * ...] period, remove any Confidential Information of GSK therefrom, except XenoPort shall have the right to publicly disclose any information, including Confidential Information, pertaining to safety of Product
that XenoPort reasonably believes in good faith it is obligated to disclose to comply with Applicable Laws. The contribution of each Party shall be noted in all publications or presentations by acknowledgment or co-authorship, whichever is
appropriate. Further, nothing herein shall be deemed as preventing GSK or any of its Affiliates from publishing data or other information relating to the Compound or Product, or relating to RLS, PHN or any related medical condition, that is publicly
known or that was generated independently of GSK’s program with respect to the Compound or Product prior to the Termination Effective Date and independently of GSK’s activities with respect to the Compound or Product under this Termination
Agreement (including the Ongoing Studies), in any manuscript, abstract or the like. 
 4.4 Commercialization and Sale of the
Product. 
 (a) During the Transition Period, GSK shall use Commercially Reasonable Efforts, and in a manner consistent with
Applicable Laws and GSK’s Policies and Procedures, to exclusively (i.e., even as to XenoPort) sell, market, promote, distribute and otherwise commercialize the Product, solely in the Territory in accordance with the terms and conditions
of the commercialization transition plan attached hereto as Exhibit 4.4 (the “Commercialization Transition Plan”). GSK shall have the exclusive right, using Commercially Reasonable Efforts and its sole discretion, to create
and develop Promotional Materials for use in the commercialization and promotion of the Product in the Territory during the Transition Period. Notwithstanding the foregoing, GSK shall cease any particular activities set forth in the
Commercialization Transition Plan prior to the Transition Period End Date in the event that XenoPort provides GSK with at least [... * ...] prior written notice requesting that such activities or portion thereof be ceased prior to the
Transition Period End Date; provided, however, that in no event shall XenoPort have the right to take over the conduct of such activities directly or through others prior to the Transition Period End Date in the event that GSK is engaging in
any commercialization, promotion or marketing activities with respect to the Product during the Transition Period. 
 (b) GSK
shall use the Transferred GSK Trademarks in accordance with past practice prior to the Termination Effective Date, and in accordance with Applicable Laws, in a manner that will not reflect adversely upon the goodwill and reputation associated with
XenoPort or the Transferred GSK Trademarks. GSK acknowledges XenoPort’s ownership of the Transferred GSK Trademarks, and GSK shall not knowingly do anything inconsistent with such ownership and agrees that all use of the Transferred GSK
Trademarks by GSK shall inure to the benefit and be on behalf of XenoPort. Nothing in this Termination Agreement shall give GSK any right, title or 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 35 - 

 EXECUTION COPY 
  

 
interest in the Transferred GSK Trademarks or any other XenoPort Trademark other than the right to use the Transferred GSK Trademarks strictly in accordance with this Section 4.4(b). GSK
shall not have the right to, and shall not, sublicense (except solely to the extent otherwise provided in Section 3.1(b)), assign, pledge, grant or otherwise encumber or transfer to any Third Party any rights licensed by XenoPort to GSK with
respect to the Transferred GSK Trademark without XenoPort’s prior written consent; provided, however, for the avoidance of doubt, the foregoing shall not be construed to require XenoPort’s consent for GSK or its Affiliate to engage and use
distributors for the distribution and sale, on behalf of GSK or its Affiliate, of Products bearing Transferred GSK Trademark. The Parties understand and agree that, in addition to all other legal remedies, [... * ...] If GSK shall
breach this Section 4.4(b) (whether or not cured), XenoPort shall have the right to immediately terminate the license to GSK with respect to the GSK Transferred Trademark by providing written notice to GSK. Nothing in this Section 4.4(b),
or any other provision of this Termination Agreement shall grant XenoPort any rights in any of GSK’s Domain Names, registrations or applications for registration, or renewals thereof, registered in the Territory or any other country or
jurisdiction throughout the world, except for the Transferred GSK Domain Names. 
 (c) GSK shall have the sole right and
responsibility to manufacture and supply Product for use by GSK, its Affiliates, or their respective designees in connection with the commercialization and sale of Product in the Territory as set forth in this Section 4.4. During the Transition
Period, GSK shall continue to have sole oversight over all aspects of the manufacturing relating to such Product to be sold by GSK and, in no event, will XenoPort interfere (or attempt to change) any manufacturing processes related to such Product;
provided, however, that XenoPort shall have the right to review and consent to any change to manufacturing processes, if any, that may supplement, alter, or change the Regulatory Filings. GSK acknowledges that nothing in this Termination Agreement
shall preclude XenoPort from manufacturing Compound or Product at any time following the Termination Effective Date for sale outside the Territory or for sale in the Territory following the Transition Period End Date. Notwithstanding anything to the
contrary contained in this Termination Agreement, during the period of time prior to the Transition Period End Date, GSK shall have the sole right to determine whether any recall, withdrawal, field correction, field alert report, or comparable
report with respect to any Product in the Territory (a “Product Event”) is required to be made, and shall develop (if applicable) appropriate correspondence and communications regarding such Product Event for submission to a
Regulatory Authority, provided that GSK shall in good faith consult with XenoPort regarding any such decision and/or submission. [... * ...] XenoPort, if required as the owner of the Regulatory Filings after the Termination Effective
Date, shall submit any such correspondence and/or communications developed as part of a Product Event in accordance with this Section 4.4(c) (and within the time periods required by Applicable Laws); provided, however, that XenoPort shall not
be obligated to take any action (including filing such correspondence or communication) which XenoPort determines in good faith in its sole discretion would not be in compliance with Applicable Laws; and further provided, however, that to the extent
that GSK is able to make any such submissions to a Regulatory Authority as XenoPort’s agent (as set forth in Section 4.3(b)(i)), then GSK shall make such submissions on XenoPort’s behalf. XenoPort and GSK each agree [... *
...] In the event that GSK is required to separately notify a Regulatory Authority regarding a Product Event to comply with Applicable Laws (including any corporate integrity agreement that may be in effect), GSK shall have the right to
provide such notice without consultation with XenoPort; provided that [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 36 - 

 EXECUTION COPY 
  

 (d) Within thirty (30) days after the Termination Effective Date, the Parties agree
to enter into a quality agreement that outlines each Party’s responsibilities with respect to the manufacture of Product during the Transition Period (the “Quality Agreement”). Each Party shall comply with the terms and
conditions of the Quality Agreement. 
 (e) Notwithstanding anything contained herein, GSK shall have no obligation under this
Termination Agreement to commercialize, market, promote, sell and/or distribute the Product in the Territory (including using any Promotional Materials) in any manner that, in any case as determined by GSK in good faith in its sole discretion,
violates Applicable Laws or GSK’s Applicable Policies or Procedures. Further, GSK shall have no liability to XenoPort or XenoPort’s Affiliates for taking or refraining from taking any action to commercialize, market, promote, sell and/or
distribute the Product in the Territory in order to, in each case as determined in GSK’s sole discretion, comply with Applicable Laws or GSK’s Applicable Policies or Procedures. 

(f) Without limiting Section 4.8, XenoPort acknowledges and agrees that during the Transition Period, it will not, directly or
indirectly through Affiliates or Third Parties, commercialize, market or otherwise promote the Product in the Territory. Further, during the Transition Period, XenoPort [... * ...] provided, however, that the foregoing shall [...
* ...] In the event of a breach by XenoPort of this Section 4.4(f), GSK shall have a right, upon providing written notice to XenoPort, to immediately cease commercializing, marketing, promoting and selling the Product in the Territory
for the remainder of the Transition Period; provided, however, that GSK would continue using its Commercially Reasonable Efforts to distribute the Product in the Territory in accordance with Applicable Laws and GSK’s Policies and
Procedures for the remainder of the Transition Period. 
 (g) In the event that Applicable Laws prevent XenoPort from
distributing or selling the Product in the Territory after the Transition Period End Date and XenoPort requests GSK to continue distributing and selling Product, GSK shall, using Commercially Reasonable Efforts and in its sole discretion, distribute
the Product in the Territory until such time as agreed to by the Parties (or, if the Parties do not or cannot mutually agree, no later than [... * ...] days following written notice by XenoPort requesting GSK to discontinue such
distribution and sales). GSK shall provide to XenoPort all payments (if any) received by GSK or its Affiliates with respect to Product sold by or on behalf of GSK or its Affiliates after the Transition Period End Date pursuant to this
Section 4.4(g), and invoice XenoPort for all costs and expenses incurred by GSK, its Affiliates or their respective designees in distributing such Product after the Transition Period End Date, and XenoPort shall reimburse GSK for such costs and
expenses within thirty (30) days after receipt of such invoice. Notwithstanding the foregoing, GSK shall have no obligation whatsoever to commercialize, market or otherwise promote the Product in the Territory after the Transition Period End
Date. 
 (h) GSK agrees that it and its Affiliates shall not sell Product during the period from the Termination Effective Date
to the Transition Period End Date in quantities that are materially higher than quantities of such Product sold by GSK and its Affiliates in the calendar quarter prior to the Termination Effective Date (or, if higher, the volumes specified in the
mutually agreed Commercialization Transition Plan); provided, however, that the foregoing shall not be construed to prevent GSK and its Affiliates from selling such quantities of Product as are reasonably required to meet demand for Product
in the Territory up to the Transition Period End Date. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 37 - 

 EXECUTION COPY 
  

 4.5 Supply Agreement. By written notice provided to GSK not later than [...
* ...] (the “Interim Supply Notice”), XenoPort may request that GSK manufacture and supply (or arrange for the manufacture and supply of) quantities of Product, for commercialization by or on behalf of XenoPort in the
Territory, with such supply obligation to commence on the date XenoPort submits to GSK the Interim Supply Notice in accordance with this Section 4.5 and continue until October 30, 2013 (the “Supply Term”), at a supply
price and upon terms to be agreed by the Parties in a separate supply agreement. Any such supply agreement entered into by the Parties shall be consistent with the terms set forth on Schedule 4.5 attached hereto (the “Supply
Agreement”). The Parties shall use Commercially Reasonable Efforts to negotiate and execute the definitive written Supply Agreement promptly following the Termination Effective Date, [... * ...] (provided, however, that the
Parties shall have entered into an appropriate quality agreement covering responsibilities that will apply to the Product sold to XenoPort pursuant to this Section 4.5, including responsibilities for relevant quality assurance and quality
control activities related thereto), [... * ...]. If, in accordance with the above, XenoPort requests that GSK provide interim supply of Product, the following shall apply: 

(a) XenoPort shall issue firm purchase orders (each, a “Firm Order”) for those quantities of Product to be supplied to
XenoPort during the term of the Supply Agreement, which shall be provided to GSK [... * ...] XenoPort may issue up to [... * ...]. 
 (b) The Firm Orders may be delivered electronically or by other means to such location as GSK shall designate and shall include (i) [... * ...]. Product quantities shall be ordered by
XenoPort in accordance with agreed minimum quantities and consistent with agreed forecasted demand in effect for such Product, in each case, as set forth on Schedule 4.5B. 

(c) If after GSK’s review of XenoPort’s Firm Orders, questions arise based on [... * ...] Once all questions
relating to [... * ...] GSK shall be deemed to have accepted such Firm Order; provided, however, that any delay in resolving such questions may impact the [... * ...]. In the event that the Parties are not reasonably able
to agree to quantities included in any Firm Order, [... * ...] GSK shall proceed with supplying those quantities of Product that are agreed to by the Parties (and, therefore, not under review). XenoPort [... * ...]

 (d) [... * ...] 
 (e) If XenoPort issues the Interim Supply Notice to GSK, then on that same date, XenoPort shall provide to GSK all required artwork to update Labels and/or Labeling (the “Artwork”) for
use on Product supplied pursuant to the Supply Agreement, which shall include, among other things, XenoPort’s NDC number(s) for the Product, and the following terms of this 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 38 - 

 EXECUTION COPY 
  

 
Section 4.5(e) shall apply. XenoPort shall ensure that all labels, packaging, or trade dress for use on Product supplied under the Supply Agreement shall be approved by the appropriate
Regulatory Authority prior to commercial distribution of such Product. XenoPort shall be solely responsible for ensuring the accuracy of all information contained on the Labels and/or Labeling for the Product and for the compliance of all such
Labels and/or Labeling with Applicable Laws and the specifications contained in the applicable NDA. If (i) XenoPort is required pursuant to Applicable Laws to revise or change Labels and/or Labeling or (ii) XenoPort requests a revision or
change of Labels and/or Labeling for reasons other than compliance with Applicable Laws, [... * ...] 
 (f) After the
Transition Period End Date or, if effective, the expiration or termination of the Supply Agreement, XenoPort will be solely responsible for the manufacturing and packaging of Product (including, without limitation, API, Bulk Product, and Finished
Product) and shall ensure, at its own cost and expense, that any approvals or certifications required by any Regulatory Authority are in place prior to the manufacture, distribution or sale of Products. 

(g) Except to the extent otherwise directed by the FDA or required by Applicable Laws, GSK shall not knowingly make any material
modifications to its manufacturing process for Product during the Transition Period without providing prior written notice to XenoPort (or as provided under mutually agreed terms, if any, of the definitive written Supply Agreement). 

4.6 Manufacturing Technology Transfer. Following the Termination Effective Date, [... * ...] to effect the technical
transfer relating to the manufacturing and packaging of Product by (i) [... * ...] and (ii) with [... * ...] In the event that additional technical transfer support is required, and for a period not to exceed
[... * ...] following the Termination Effective Date, and in accordance with the technology transfer plan set forth on Exhibit 4.6 attached hereto (the “Manufacturing Technology Transfer Plan”), [... *
...] with the object of transitioning the manufacture and packaging of commercial Product to XenoPort. [... * ...] XenoPort will be responsible for all activities related to the development and preparation of data for use in
regulatory submissions. 
 4.7 Transition Team. The Parties acknowledge and agree that effective upon the Termination
Effective Date, all of the committees (and subcommittees, if applicable) established pursuant to Article III of the Restated Agreement shall be immediately disbanded. Within ten (10) days after the Termination Effective Date, the Parties shall
form a team composed of five (5) representatives of each Party (the “Transition Team”) to facilitate the transition of the manufacture, development and commercialization of Compound and Product from GSK to XenoPort pursuant to
this Termination Agreement and to facilitate communication of information to be exchanged under this Termination Agreement, in each case, during the Transition Period. The Transition Team shall coordinate and facilitate communications between
personnel of the various operational groups of the Parties involved in the transfer of information and transition of activities under this Termination Agreement, which shall be consistent with (and subject to) any project plans agreed in this
Termination Agreement (including, without limitation, the Manufacturing Technology Transfer Plan) and shall assist in the delivery and transfer of the Transferred Assets and Licensed Assets, including undertaking the duties set forth in Sections
4.2(a), 4.2(b) and 5.4(a). During the Transition Period, the Transition Team shall meet periodically (but not less than once every two (2) weeks), by 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 39 - 

 EXECUTION COPY 
  

 
telephone or in person, to discuss the status of the transition (including any material modification or additions to the items or matters listed in the various Schedules that identify the
Transferred Assets) and to attempt to amicably resolve any disagreements or miscommunications between the Parties that may arise in connection with information to be exchanged, timelines for transfer of documents or information, transition of
Regulatory Filings or the like. The Transition Team is intended to facilitate the smooth transition of activities and responsibilities regarding Compound and Product pursuant to this Termination Agreement, and may serve as a contact point and
initial forum for discussing any matters arising in connection with the performance of this Termination Agreement, and shall cooperate when necessary to facilitate referring any such matters to appropriate decision-makers of each Party for prompt
resolution; however, the Transition Team shall not have authority to amend or modify the Commercialization Transition Plan, the Development Plan, the Manufacturing Technology Transfer Plan, or the terms of this Termination Agreement, the Supply
Agreement or the GSK Safety Agreement (as defined below). The Transition Team may designate other personnel from the relevant operation group(s) of the Parties to be the primary contact to facilitate discussions or transfer of documents and
information related to particular matters. The Parties shall make available to the Transition Team the applicable functional area experts and personnel necessary to further facilitate the communication of information to be exchanged under this
Termination Agreement. [... * ...] and GSK will reasonably cooperate with XenoPort to identify other GSK personnel with comparable familiarity with the Product and comparable experience to assist and participate with such transition
matters in the event such an individual leaves employment or becomes unavailable. 
 4.8 XenoPort Activities During
Transition. 
 (a) Notwithstanding the provisions of Section 4.4 (stating that GSK may sell, market, promote,
distribute and otherwise commercialize Product “exclusively” in the Territory) or any other provision of this Termination Agreement, and except for activities that would interfere with GSK’s ability to comply with Applicable Laws or
GSK’s Applicable Practices and Policies, XenoPort shall have the right during the Transition Period to perform such activities as XenoPort deems reasonably necessary or appropriate in connection with its preparation to take over the
manufacture, development, commercialization, promotion and distribution of the Compound and Product in or for the Territory after the Transition Period End Date, and nothing in this Termination Agreement shall be construed to prohibit or preclude
XenoPort from conducting such activities during the Transition Period: including (i) negotiating and entering into contracts for the manufacture, conduct of clinical trials, licensing, distribution, storage, or promotion of Product
(provided, however, that XenoPort may not commence promoting the Product or selling Product prior to the Transition Period End Date); (b) manufacturing or obtaining inventories of Compound or Product in advance of the Transition Period
End Date in preparation for sales of Product in the Territory by or under authority of XenoPort after the Transition Period End Date; (c) negotiating and entering into agreements with managed care organizations and others regarding Product to
be sold in the Territory by or under authority of XenoPort after the Transition Period End Date; (d) contacting and negotiating with Regulatory Authorities and others with regard to reimbursement for Product sold in the Territory by or under
authority of XenoPort after the Transition Period End Date; (e)

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 40 - 

 EXECUTION COPY 
  

 
preparing and obtaining quantities of Promotional Materials and product labeling for Product that will be commercialized and sold by or under authority of XenoPort after the Transition Period End
Date; (f) organizing a physician advisory board, and preparing and conducting meetings therefor, which would only occur after the Transition Period End Date; (g) planning and entering into commitments for medical congresses or trade shows
that would only occur after the Transition Period End Date; and (h) planning of sales activities and medical education activities, and preparing related materials, and hiring and training sales representatives, medical liaisons and other
personnel who will be involved in the commercialization of the Product in the Territory after the Transition Period End Date. For the avoidance of doubt, none of the foregoing, nor the covenants of XenoPort set forth in Sections 4.4(f) and
7.2(a), nor any other provision of this Termination Agreement shall be construed to limit or restrict XenoPort’s activities with respect to Compound or Product sold in, or manufactured or developed in or for, any country outside the Territory.

 (b) Prior to the Transition Period End Date, XenoPort shall initiate the process to obtain an MDRP Agreement
(“MDRP”), Pharmaceutical Pricing Agreement and FSS Agreement. In addition, XenoPort will ensure that the Government Price Reports under Section 5.5 will be administered by XenoPort or a Third Party consultant specializing in
government price reporting on the Transition Period End Date. 
 4.9 Safety Data Exchange. Until the Transition Period
End Date or, if earlier, such time as XenoPort has a functioning safety database, GSK shall continue to be responsible for pharmacovigilance and adverse event reporting within the Territory as provided in that certain Safety Data Exchange Agreement,
dated as of February 13, 2012, between the Parties (the “GSK Safety Agreement”). Thereafter, the Parties will enter into a new safety data exchange agreement (the “New Safety Agreement”) with respect to the Low
Dose Study which will set forth the procedure pursuant to which serious adverse events from the Low Dose Study will be forwarded by GSK to XenoPort and expedited to the FDA. Further, as between the Parties, pursuant to the New Safety Agreement
and thereafter, XenoPort shall be responsible for pharmacovigilance and adverse event reporting within the Territory with respect to Compound and Product. The Parties shall each use Commercially Reasonable Efforts to cooperate such that XenoPort (or
XenoPort’s designee) will be in a position to take over, as of the Transition Period End Date and pursuant to the New Safety Agreement, the maintenance of the worldwide safety database for the Product, including transferring all Transferred GSK
Know-How pertaining to pharmacovigilance and adverse event reporting of Compound pursuant to the plan set forth in Exhibit 4.9 attached hereto (the “Safety Data Exchange Transfer Plan”). In the event that XenoPort is not in a
position to take over, as of the Transition Period End Date and pursuant to the New Safety Agreement, the maintenance of the worldwide safety database for the Product after the Transition Period End Date, GSK shall continue to be responsible for
pharmacovigilance and adverse event reporting within the Territory as provided in the GSK Safety Agreement, and shall invoice XenoPort for all costs and expenses incurred by GSK, its Affiliates and/or their respective designees in conducting such
activities. XenoPort shall reimburse GSK for such costs and expenses within thirty (30) days after receipt of such invoice. The Parties shall promptly implement any appropriate amendments to the GSK Safety Agreement in accordance with this
Section 4.9. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 41 - 

 EXECUTION COPY 
  

 4.10 Cooperation Regarding Third Party Contractors. The Parties acknowledge that
GSK and its Affiliates have used or are using certain Third Party contractors for the manufacture of the Compound or Product (including without limitation [... * ...]), the conduct of clinical trials and other development activities
(including without limitation stability testing) related to the Compound or Product in the Territory, and storage and distribution of the Compound or Product in the Territory, and anticipate that XenoPort may contact one or more such Third Party
contractors to negotiate potential agreements for such Third Party contractors to conduct similar activities with respect to Compound or Product in the Territory for XenoPort or its designee; accordingly, the Parties agree as follows with respect to
such Third Party Contractors: 
 (a) During the Transition Period (and with respect to the contract research organization(s)
involved with the conduct of the Low Dose Study, until Completion of the Ongoing Studies), if requested by XenoPort, GSK shall use Commercially Reasonable Efforts to identify to XenoPort the Third Party contractors so used by GSK or its Affiliates,
to facilitate an introduction of XenoPort or its designee to such Third Party contractors. [... * ...] If, in order for GSK to fulfill any commitments under this Section 4.10(a), XenoPort is required to agree to terms of
confidentiality, provide certain assurances, or to take any other actions that may be required in order to obtain access to such Third Party contractors, then any failure by XenoPort to comply with these requirements will be deemed a waiver by
XenoPort of its rights under this Section 4.10(a) with respect to access to any such Third Party contractors. XenoPort shall not be required to make any payment for access to any such Third Party contractor. Further, [... * ...]
Nothing herein shall be construed or deemed as obligating GSK to breach any provision in any Contract with a Third Party contractor, including, without limitation, any obligations of confidentiality with respect to such Contract. Further, neither
GSK nor its Affiliates shall have any liability of any kind whatsoever under or with respect to any Contract that may be entered into by XenoPort, its Affiliates and/or their respective designees and a Third Party contractor; and 

(b) In the event and to the extent that any such Third Party contractor as described in this Section 4.10 that is a contract
manufacturer or contract research organization has possession of, or a right or license to use, any Know-How (including without limitation clinical Data or manufacturing Know-How) or Patent directly and primarily related to the Compound or Product,
GSK hereby waives on behalf of itself and its Affiliates any restrictions or limitations (including, if applicable, licenses to GSK or its Affiliate) contained in any contract between such Third Party contractor and GSK or its Affiliate that
(i) would restrict, limit or preclude such Third Party contractor from (A) disclosing or providing such Know-How or Patent to XenoPort or its designee and licensing or otherwise authorizing its use for the manufacture, development and
commercialization of the Compound or Product, or (B) accessing and using such Know-How or Patent itself in conducting activities for the manufacture, development and commercialization of the Compound or Product for XenoPort or its designee, or
(ii) would impose a requirement for payment from the applicable Third Party to GSK or its Affiliate for any actions described in the receding clause (i). If requested by XenoPort or the applicable Third Party contractor, GSK agrees that it
or its Affiliate will confirm any waiver in writing to the applicable Third Party contractor. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 42 - 

 EXECUTION COPY 
  

 4.11 Validation Activities. XenoPort acknowledges that certain validation
activities have been on-going with respect to the 300mg (gabapentin enacarbil) strength Product (the “300mg Product”) to allow for commercial supply of the 300mg Product. [... * ...] With respect to any API required to
[... * ...] (i) for such quantities as are required prior to the Inventory Transfer Date to conduct such activities, GSK shall use quantities of API from the Inventory in GSK’s possession, and (ii) for such quantities as
are required after the Inventory Transfer Date to conduct such activities, GSK may place orders for such quantities of additional API in accordance with the principles set forth in Section 4.2(h) above, and any such API supplied to GSK pursuant
to this Section 4.11 shall be included within the meaning of “Tolled API” (and, if applicable, subject to the terms agreed in Section 4.2(h) above). For the avoidance of doubt, in the event that XenoPort is not able to provide
additional quantities of API in accordance with this Section 4.11, and in such case, GSK is prevented from fulfilling its agreed obligations in this Section 4.11 (and only to the extent it is precluded from fulfilling these obligations),
[... * ...] Notwithstanding anything to the contrary contained in this Termination Agreement, XenoPort acknowledges and agrees that GSK will be under no further obligation to create (or attempt to create), or assist XenoPort in creating
(or attempting to create) any Improvements with respect to the Product after the Termination Effective Date, including, without limitation, Improvements to the manufacturing processes of the Product. 

ARTICLE V 

ADDITIONAL AGREEMENTS BETWEEN THE PARTIES 
 5.1 Return of Materials. Within thirty (30) days after the Transition Period End Date and upon the written request by XenoPort, GSK shall use Commercially Reasonable Efforts to destroy (and
certify in writing to XenoPort) all tangible items comprising Confidential Information of XenoPort that are in GSK’s possession (other than, for the avoidance of doubt, any Transferred Assets to be transferred to XenoPort under the terms of
this Termination Agreement), except that GSK shall be permitted to retain one (1) copy of such tangible items including such Confidential Information of XenoPort as necessary to permit GSK to perform its obligations after the Transition Period
End Date under this Termination Agreement. 
 5.2 Inspection. 

(a) To the extent any Regulatory Authority requests an inspection or audit of, or XenoPort otherwise reasonably requests to inspect or
audit, the clinical trial sites and/or manufacturing sites of GSK or its Affiliates or other applicable GSK facilities with respect to Compound or Product (including inspection or audit of any underlying raw or original source data at the clinical
trial sites and/or manufacturing sites), or XenoPort or its licensee is otherwise required by Applicable Laws to conduct such audits or inspections, GSK shall permit such Regulatory Authority and XenoPort (together with its licensee, as applicable)
to enter the relevant clinical trial sites and, if applicable, manufacturing sites or other applicable facilities of GSK and its Affiliates during normal business hours and upon reasonable advance notice to inspect such sites and to verify
compliance with applicable regulatory requirements. GSK shall provide reasonable assistance for a full and correct carrying out of the inspection. Such inspection shall not relieve GSK of any of its obligations under this Termination Agreement.
Notwithstanding the above, XenoPort acknowledges 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 43 - 

 EXECUTION COPY 
  

 
and agrees that any inspection of GSK (or its Affiliate’s) manufacturing facility(ies) by XenoPort or its licensee (but not by any Regulatory Authority) shall be limited to those portions of
the facility(ies) related to the manufacture of Product and for the sole purpose of ensuring such facility’s compliance with cGMP and Applicable Laws and [... * ...] 

(b) GSK shall use Commercially Reasonable Efforts to secure the rights of inspection set forth under Section 5.2(a) above from
GSK’s trial sites and other contractors (including, but not limited to, manufacturers of Compound or Product) for Product. [... * ...]  
 (c) Any inspection by XenoPort or its licensee (but not by any Regulatory Authority) of any manufacturing facility(ies) (whether pursuant to Section 5.2(a) or Section 5.2(b)) will be [...
* ...] 
 5.3 Product Responsibility. 
 (a) Except as otherwise set forth in this Termination Agreement or in the Supply Agreement, as applicable, from and after the Transition Period End Date, XenoPort shall have the sole control and
responsibility for (i) all regulatory matters with respect to Product, including without limitation relating to communicating and corresponding, preparing and filing reports, making adverse drug experience reports, and paying applicable fees,
with and to applicable Regulatory Authorities, under all Applicable Laws, including the United States Federal Food, Drug and Cosmetic Act, as amended from time to time, including all regulations promulgated thereunder, the Prescription Drug
Marketing Act of 1987, and the Prescription Drug User Fee Act of 1992; (ii) taking all actions and conducting all communication with Third Parties in respect of Product (whether sold before or after the Transition Period End Date), including
responding to all complaints in respect thereof (except for any complaints managed by GSK as set forth below in Section 5.14(b)) and all medical information requests; and (iii) investigating all complaints and adverse drug experiences in
respect of Product (except for any complaints managed by GSK as set forth below in Section 5.14(b)). 
 (b) Notwithstanding
anything to the contrary contained in this Termination Agreement or in the Supply Agreement, if applicable, during the period of time from and after the Transition Period End Date, XenoPort shall have the sole right to determine whether any Product
Event is required to be made, and to develop (if applicable) appropriate correspondence and communications regarding such Product Event for submission to a Regulatory Authority, and shall have the sole control and be responsible for conducting,
handling or processing all such Product Events (including withdrawals or voluntary and involuntary recalls of units of Product, regardless of whether such unit of Product was sold before or after the Transition Period End Date); provided, however,
that if any such Product Event involves Product sold prior to the Transition Period End Date, then (i) XenoPort shall notify GSK of, and if requested consult with GSK regarding, any decision (or requirement) to withdraw or recall Product sold
before the Transition Period End Date, (ii) GSK shall in good faith consult with XenoPort as XenoPort may reasonably request regarding any such matters, (iii) XenoPort and GSK each agree [... * ...] and (iv) XenoPort
shall destroy, or cause to be destroyed, in either case at XenoPort’s expense, all recalled Product in a manner consistent with Applicable Laws. [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 44 - 

 EXECUTION COPY 
  

 (c) [... * ...] following the Transition Period End Date, XenoPort shall
use Commercially Reasonable Efforts to institute appropriate procedures (including any appropriate procedures for tracking of lot number information) to ensure that the Product sold by or on behalf of XenoPort can be distinguished from the Product
sold by or on behalf of GSK. 
 (d) [... * ...] XenoPort shall use Commercially Reasonable Efforts to establish new
NDC numbers for Product and thereafter shall use Commercially Reasonable Efforts to cause such NDC numbers to be used on the labeling and packaging for Product. 
 5.4 Product Returns. 
 (a) During the Transition Period and for [...
* ...] after the Transition Period End Date, GSK shall be financially responsible for, and shall be responsible for processing, all returns of Product packaged for commercial sale in the Territory (“Finished Product”) labeled
with GSK’s NDC number. During the Transition Period and for [... * ...] thereafter, all returns of Finished Product labeled with GSK’s NDC number shall be sent to GSK or GSK’s return vendor. Returns of Finished Product
will be processed GSK as provided in this Section 5.4(a) in accordance with GSK’s then-current returned goods policy, regardless of which Party made the corresponding original sale. XenoPort will provide to GSK an invoice for all
out-of-pocket costs incurred by XenoPort and its Affiliates with respect to returns of any Finished Product during the Transition Period and for [... * ...] after the Transition Period End Date, and GSK will pay to XenoPort such amount
within thirty (30) days of receipt of such invoice. 
 (b) XenoPort shall be financially responsible for, and shall be
responsible for processing, all returns of Finished Product labeled with XenoPort’s NDC number, and on and after the [... * ...] after the Transition Period End Date, XenoPort shall be financially responsible for, and shall be
responsible for processing, all returns of Finished Product labeled with GSK’s NDC number. Returns of Finished Product will be processed by XenoPort as provided in this Section 5.4(b) in accordance with XenoPort’s then-current
returned goods policy, regardless of which Party made the corresponding original sale. GSK will provide to XenoPort an invoice for all out-of-pocket costs incurred by GSK and its Affiliates with respect to returns of any Finished Product on and
after the [... * ...] after the Transition Period End Date, and XenoPort will pay GSK such amount within thirty (30) days of receipt of such invoice. 
 (c) The Parties, through the Transition Team, shall agree upon a joint notice, which will notify all customers of the foregoing changes in trade return procedures as soon as practicable following the
Transition Period End Date, but in any event no later than ten (10) Business Days prior to the Transition Period End Date. For any Finished Product that is returned to one Party but is the processing responsibility of the other Party pursuant
to this Section 5.4, the Party receiving such returned Finished Product will destroy, or cause to be destroyed, all such Finished Product. Each of XenoPort and GSK shall destroy, or cause to be destroyed, all such returned Finished Product in a
manner consistent with Applicable Laws and the costs of such destruction shall not be reimbursed. 
 (d) Neither XenoPort nor
GSK shall instruct, recommend or attempt to induce customers who have previously purchased any Finished Product from it to (i) return such Finished Product when that would not otherwise have been the case but for such Party’s instructions,
recommendations or inducement or (ii) delay the return of such Finished Product. For the avoidance of doubt, a Party’s shipment of units of Products to customers in the ordinary course will not be deemed to violate this Section 5.4.

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 45 - 

 EXECUTION COPY 
  

 5.5 Governmental Price Reporting. 

(a) “Governmental Price Reports” means (i) any and all data required to be reported relating to the Product under
the MDRP, including without limitation the Average Manufacturer Price (as defined at 42 U.S.C. § 1396r-8(k)(1)) (“AMP”) and the Best Price (as defined at 42 U.S.C. § 1396r-8(c)(1)(C)); (ii) any and all data required
to be reported relating to the Product(s) under state drug price reporting requirements; (iii) Federal Ceiling Prices required to be reported relating to the Product under 38 U.S.C. § 8126, and the master agreements issued thereunder;
(iv) any and all data required to be reported relating to the Product under a Tricare retail rebate agreement or otherwise under 10 U.S.C. § 1074f(g); (v) any and all data required to be reported relating to the Product under a
Pharmaceutical Pricing Agreement under section 340B of the PHS Act, 42 U.S.C. 256b; (vi) any and all data required to be reported relating to the Medicare Coverage Gap Discount Program (“Coverage Gap Program”) for purposes of
sections 1860D-14A and 1860D-43 of the Social Security Act (the “Social Security Act”), as set forth in the Patient Protection and Affordable Care Act of 2010 (“PPACA”), Pub. L. 111-148, and the Health Care and
Education Reconciliation Act of 2010, (“HCERA”) Pub. L. 111-152; and (vii) any and all data required to be reported relating to the Product under the Pharmaceutical Manufacturer Industry Fee Program pursuant to section 9008 of
the PPACA, Public Law 111-148 (124 Stat. 119 (2010)), as amended by section 1404 of the HCERA, Public Law 111-152 (124 Stat. 1029 (2010)). 
 (b) GSK shall be responsible for submitting all Governmental Price Reports for all Product bearing an NDC of GSK for all reporting periods ending on or before the Transition Period End Date. Beginning
with the reporting period in which the Transition Period End Date occurs, XenoPort shall be responsible for submitting all Governmental Price Reports for Product bearing an NDC of GSK. Effective with the reporting period in which the Transition
Period End Date occurs, GSK shall name XenoPort as a designee, with certification access, in the Drug Data Reporting for Medicaid (“DDR”) system for purposes of reporting the AMP and the Best Price and other required pricing data
for the Product bearing an NDC of GSK. If other Product is reported to the Centers for Medicare and Medicaid Services (“CMS”) by GSK under the labeler code of any Product, GSK shall remain as the technical, invoice and legal
contacts for such Product with CMS. 
 (c) GSK acknowledges that XenoPort will require certain information from GSK in order to
submit the Governmental Price Reports after the Transition Period End Date. Accordingly, GSK agrees that, (i) for the calendar month in which the Transition Period End Date 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 46 - 

 EXECUTION COPY 
  

 
occurs, GSK shall provide to XenoPort, within [... * ...] after the end of such calendar month, relevant Product information for use in calculating AMP, and if requested by XenoPort,
GSK would provide 12 months of summary monthly historical commercial sales and sales deduction data; (ii) for the calendar quarter in which the Transition Period End Date occurs, GSK shall provide to XenoPort, within [... * ...]
after the end of such calendar quarter, the Best Price, customary prompt pay discounts, and sales at nominal price, and any additional data needed to comply with state price reporting requirements, and (iii) GSK shall provide to XenoPort,
within [... * ...] after the Transition Period End Date, baseline AMPs for the Product. GSK further agrees that, for Product, it shall provide to XenoPort, within [... * ...] after the Transition Period End Date, the
following: (i) if the Transition Period End Date occurs in calendar quarters 1, 2, or 3, GSK shall provide the Federal Ceiling Prices in effect during the calendar year in which the Transition Period End Date occurs; (ii) if the Transition
Period End Date occurs in calendar quarter 4, GSK shall provide both the Federal Ceiling Price in effect during the calendar year in which the Transition Period End Date occurs and the calculated Federal Ceiling Price for the next calendar year. Per
the Department of Veteran Affairs (“VA”) Product transfer rules, depending on the calendar quarter in which the Transition Period End Date occurs, XenoPort is required to sell at a price no greater than GSK’s calculated Federal
Ceiling Prices in effect during the calendar year in which the Transition Period End Date occurs, or if the Transition Period End Date occurs in calendar quarter 4, XenoPort is required to sell at a price no greater than GSK’s calculated
Federal Ceiling Prices for the next calendar year; (iii) all commercial sales and sales deduction data required for Non-FAMP calculation for the current calendar quarter through the Transition Period End Date, as well as such data for preceding
calendar quarters within the Federal Fiscal Year (October 1 – September 30) in which the Transition Period End Date occurs; (iv) relevant Non-FAMPs necessary to complete Annual Public Law Update; (v) all commercial sales and
sales deduction data for the current calendar quarter through the Transition Period End Date, as well as all such data for the preceding calendar quarters within the Federal Fiscal Year (October 1 – September 30) in which the Transition
Period End Date occurs; and (vi) the most recent Tricare retail pharmacy dispensing data report for the previous four quarters made available by the Department of Defense either on or before the Transition Period End Date. All pricing data
furnished by GSK pursuant to this subsection shall be provided in the same format that such data are provided by GSK to CMS and/or the VA in connection with GSK’s own Governmental Price Reports, or in a format otherwise prescribed by GSK. For
pricing and sales data that are required in order to submit Governmental Price Reports, but that are not themselves provided to the CMS and/or the VA, GSK will furnish that data in a format prescribed by XenoPort. Without limiting the foregoing, any
and all data furnished by GSK that are required for the reporting of the Product under the MDRP (and under Medicare Part B) pursuant to this subsection shall be certified in the same format provided by GSK to CMS. 

(d) Without limiting the foregoing, GSK agrees that, from and after the Transition Period End Date until [... * ...] bearing
an NDC of GSK, GSK shall provide to XenoPort, within [... * ...] after the end of each reporting period, all data or other information to the Governmental Price Reports for such Product reasonably requested by XenoPort for use by
XenoPort in completing such Governmental Price Reports. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 47 - 

 EXECUTION COPY 
  

 (e) GSK shall promptly notify XenoPort upon discovery of any errors on or corrections to
the data or other information provided to XenoPort pursuant to Sections 5.5(b), (c) or (d) above. 
 (f) XenoPort
shall notify GSK of any change in the wholesale acquisition cost (“WAC”) of any Product(s) bearing GSK’s NDC no later than the same time that XenoPort notifies third party vendors of the change in such WAC. 

(g) XenoPort shall notify GSK of the date(s) of last lot expiration of Product when the NDC(s) therefor are discontinued. 

(h) For use in the payment of any and all Medicaid rebates (including Medicaid supplemental rebates, state pharmaceutical assistance
program (“SPAP”) rebates, and AIDS drug assistance program (“ADAP”) rebates) payable for all Product bearing an NDC of GSK, XenoPort shall immediately notify GSK in writing of any quarterly AMP or Best Prices,
including re-stated values, submitted to CMS bearing the NDC of GSK for periods in and after the Transition Period End Date occurs. 
 5.6 GSK Governmental Payments and Other Contractual Obligations. 
 (a) GSK
shall be solely and exclusively responsible for processing and payment of any and all Medicaid rebates (including Medicaid supplemental rebates, SPAP rebates, and ADAP rebates) payable for all Product bearing an NDC of GSK for periods prior to and
including the calendar quarter in which the Transition Period End Date takes place. 
 (b) GSK shall be solely and exclusively
responsible for processing and payment of any and all Tricare retail refunds owed based on Tricare retail pharmacy dispensing of all Product(s) bearing an NDC of GSK for which utilization data is available or has been made available electronically
or in writing for periods prior to and including the calendar quarter in which the Transition Period End Date takes place. In the event that XenoPort does not have an existing Tricare agreement, GSK shall continue to pay such Product retail refunds
until such Product has been deleted from GSK’s Pricing Agreement with Tricare Management Activity and added to XenoPort’s Pricing Agreement with Tricare Management Activity (even if the due date for refund payment falls after the
Transition Period End Date). 
 (c) GSK shall be solely and exclusively responsible for processing and payment of any and all
rebates, chargeback claims and related fees payable under a PHS pharmaceutical pricing agreement for [... * ...] after the Transition Period End Date and providing the initial PHS prices within [... * ...] of the Transition
Period End Date for the Product and the subsequent quarter’s PHS prices within [... * ...] of the start of the quarter to XenoPort. In the event XenoPort does not have an existing PHS agreement, GSK shall continue to pay
rebates/chargebacks for Product bearing an NDC of GSK. XenoPort shall reimburse GSK for all rebates, chargeback claims and related fees on distributor invoices dated [... * ...] or more after the Transition Period End Date. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 48 - 

 EXECUTION COPY 
  

 (d) GSK shall be solely and exclusively responsible for processing and payment of any
and all rebates, chargebacks claims and related fees (i.e., Industrial Funding Fee) payable under GSK’s FSS contract for all Product bearing an NDC of GSK issued in writing or electronically on or prior to the Transition Period End Date
up through the effective date on which the VA National Acquisition Center approves the Request for Modification to add Product to XenoPort’s FSS contract; in the event XenoPort does not have an existing FSS agreement, GSK shall continue to pay
rebates, chargeback claims and related fees for Product bearing an NDC of GSK. XenoPort shall reimburse GSK for all rebates, chargeback claims and related fees (i.e., Industrial Funding Fee) on invoices dated on or after the Transition Period End
Date up through the effective date on which the VA National Acquisition Center approves the Request For Modification to add Product to XenoPort’s FSS contract, but GSK shall not issue an invoice pursuant to Section 5.6(h) with respect to
such amounts sooner than [... * ...] following the Transition Period End Date. 
 (e) GSK shall be solely and
exclusively responsible for processing and payment of any and all payments required under the Medicare Coverage Gap Discount Agreement for all GSK NDCs that are dispensed before and after the Transition Period End Date under the Coverage Gap
Program. Accordingly, with respect to discount claims under such program on or after the Transition Period End Date, XenoPort will reimburse GSK for one hundred percent (100%) of all such paid discounts with a Pharmacy Claim Payment Date on or
after Transition Period End Date. In the event that XenoPort is not able to obtain a Medicare Coverage Gap labeler agreement until 2015, GSK will continue to utilize XenoPort’s labeler code under GSK’s current Medicare Coverage Gap
Discount Agreement for the Products until December 31, 2014 and XenoPort will reimburse GSK for one hundred percent (100%) of such claims for XenoPort labeler paid discounts on behalf of GSK. XenoPort shall be responsible for transferring
its labeler code for the Product(s) to XenoPort Medicare Coverage Gap Discount agreement effective January 1, 2015 and such payments with respect to such discount claims for the XenoPort’s labeler will thereafter be made by XenoPort. GSK
shall provide quarterly corresponding utilization summary and state payment reports within [... * ...] after the end of the applicable Calendar Quarter that describe the requested rebate payments in reasonable detail. 

(f) GSK shall be solely and exclusively responsible for processing and payment of any and all payments required under the Pharmaceutical
Manufacturer Industry Fee under the Affordable Care Act for all GSK NDCs dispensed before and after the Transition Period End Date. With respect to the Pharmaceutical Manufacturer Industry Fees invoiced to GSK during 2012, which are based on a prior
year’s sales data (e.g., 2011), and subject to any true-ups and adjustments, GSK will be responsible for payment upon receipt of invoice for such fees. With respect to Pharmaceutical Manufacturer Industry Fees invoiced to GSK during 2013 and
subsequent years, which are based on prior year’s sale data (e.g., 2012 and forward), and subject to any true-ups and adjustments, GSK will be responsible for payment upon receipt of invoice for such fees. To the extent that GSK is invoiced for
Product labeled with GSK NDCs after the Transition Period End Date and subsequent years, that was sold by XenoPort in 2012 and subsequent years, GSK will bill XenoPort for such portion. The amount billed to XenoPort shall be equal to the proportion
of the fee that XenoPort would pay, assuming such sales of Product with GSK’s NDC are included as part of 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 49 - 

 EXECUTION COPY 
  

 
GSK’s total sales in the Secretary of Treasury’s calculation of the Pharmaceutical Manufacturer Industry Fee owed by GSK. GSK shall provide detailed support of the invoiced
Pharmaceutical Manufacturer Industry Fee. The Parties acknowledge that the provisions of this Section are intended to allocate responsibilities for Pharmaceutical Manufacturer Industry Fees on the basis of their respective periods of ownership. In
the event that the United States Department of Treasury subsequently issues regulatory guidance with respect to the determination of such fees that mandates a mechanism the effect of which a Party believes is materially and substantially different
from that contemplated herein such that it would render the allocation method described herein impracticable, inequitable, or not in compliance with any Applicable Law, it shall so notify the other Party and propose an alternative allocation method,
and the Parties shall meet in good faith to discuss and agree on the alternative method. 
 (g) GSK shall notify XenoPort within
[... * ...] of notice of any inspection, investigation or other inquiry by, or other material governmental notice or communication from CMS, the Department of Health and Human Services Office of the Inspector General, or any other
Regulatory Authority directly relating to the manufacture, sale, marketing, promotion, distribution, or use of the Product or relating to any Governmental Price Reports submitted by GSK. This obligation extends to any subsequent revisions to such
claims even if made after the Transition Period End Date. 
 (h) With respect to all payments due to GSK under this
Section 5.6 or Section 5.7(b), GSK shall invoice XenoPort on a quarterly basis starting after the Transition Period End Date. Payment from XenoPort shall be due within 30 days of receipt. 

5.7 XenoPort Governmental Payments and Other Contractual Obligations. 

(a) XenoPort shall be solely and exclusively responsible for: (i) reimbursement to GSK of any and all Medicaid rebates (including
Medicaid supplemental rebates, SPAP rebates, and ADAP rebates) paid for claim quarters beginning with the calendar quarter immediately following the calendar quarter during which the Transition Period End Date takes place for all Product bearing an
NDC of GSK within 30 days of receipt of an invoice for such payments from GSK; (ii) payment of any and all Medicaid rebates (including Medicaid supplemental rebates, SPAP rebates, and ADAP rebates) payable for all Product bearing an NDC of
XenoPort; and (iii) notifying GSK of any state supplemental contracts for the Product bearing a GSK NDC in effect after the Transition Period End Date. With respect to section 5.7(a)(i), XenoPort’s duty to pay GSK will begin on or after
October 1, 2013. 
 (b) XenoPort shall be solely and exclusively responsible for Tricare retail refunds relating to Product
(i) bearing an NDC of GSK for which utilization data are first made available by the United States Department of Defense for periods including and after the calendar quarter after the calendar quarter in which the Transition Period End Date
takes place. In the event that XenoPort does not have an existing Tricare agreement and GSK continues to pay Product retail refunds as set forth in Section 5.6(b) for some portion of such periods, XenoPort shall reimburse such amounts to GSK.

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 50 - 

 EXECUTION COPY 
  

 (c) XenoPort shall be solely and exclusively responsible for PHS rebates, chargeback
claims and related fees on: (i) distributor invoices dated [... * ...] or more after the Transition Period End Date for Product bearing an NDC of GSK; and (ii) any Product bearing an NDC of XenoPort. 

(d) XenoPort shall be solely and exclusively responsible for Federal Supply Schedule rebates, chargeback claims and related fees (i.e.,
Industrial Funding Fee) for (i) distributor invoices dated [... * ...] or more after the Transition Period End Date for Product bearing an NDC of GSK; and (ii) any Product bearing an NDC of XenoPort. 

(e) XenoPort shall be solely and exclusively responsible for (i) reimbursement to GSK for any and all payments required under the
Medicare Coverage Gap Discount Agreement for all GSK NDCs that are dispensed after the Transition Period End Date under the Coverage Gap Program; and (ii) all payments required under the Medicare Coverage Gap Discount Agreement for XenoPort
NDCs. 
 (f) To the extent that GSK is invoiced for Product labeled with GSK NDCs, that was sold by XenoPort, XenoPort shall be
solely and exclusively liable for reimbursement to GSK for any and all payments required after the Transition Period End Date under the Pharmaceutical Manufacturer Industry Fee bearing GSK NDC. XenoPort shall be solely and exclusively liable for
reimbursement to GSK of any and all payments required under the Pharmaceutical Manufacturer Industry Fee under the Affordable Care Act for XenoPort NDC after the Transition Period End Date. 

5.8 Processing and Payment of Commercial Rebates, Customer Contracts or Other Contractual Obligations. 

(a) Commercial Rebates. GSK shall use Commercially Reasonable Efforts to remove the Product from all contracts providing for the
payment of commercial rebates in the Territory (“Rebate Contracts”), effective [... * ...] following the Transition Period End Date. For clarity, the term “Rebate Contract” shall include Medicare Part D
prescription drug plans, but shall exclude the Coverage Gap Program. GSK shall not assign to XenoPort, and XenoPort shall not assume, any of the Rebate Contracts. GSK shall be solely responsible for the processing, handling and payment of all
rebates owed under the Rebate Contracts with respect to Product bearing an NDC of GSK dispensed prior to and including the effective date of the Product termination for each such Rebate Contract. As soon as practicable following the Transition
Period End Date, GSK shall notify all relevant Third Parties of the Product termination date for all Rebate Contracts and that any future Rebate Contracts for Product must be entered into with XenoPort or its distributors. For all commercial rebate
claims that are submitted to one Party but are the processing responsibility of the other Party, the Party receiving the claim shall deny the claim. 
 (b) Customer Contracts (Commercial Chargebacks). GSK shall use Commercially Reasonable Efforts to remove the Product from all contracts providing for the payment of chargebacks and associated
contracted fees with respect to the Product(s) in the Territory (“Chargeback Contracts”), effective [... * ...] following the Transition Period End Date. GSK shall

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 51 - 

 EXECUTION COPY 
  

 
not assign to XenoPort, and XenoPort shall not assume, any of the Chargeback Contracts. GSK shall process and be financially responsible for all chargeback claims and associated contracted fees
related to the Product sold in the Territory by distributors with distributor invoice to the chargeback customer (“Distributor Invoice”) on dates up to and including the Product termination date for each such Chargeback Contract
(the “Chargeback Product Termination Date”). GSK shall not process and shall not be financially responsible for any chargeback claims and associated contracted fees related to Product sold by distributors with Distributor Invoice
dates after such Chargeback Product Termination Date, and XenoPort shall or shall cause its distributor to process and be financially responsible for all chargeback claims and associated contracted fees related to Product sold by distributors with
Distributor Invoice dates after such Chargeback Product Termination Date. 
 (c) Other Direct Customer Discounts. GSK
shall use Commercially Reasonable Efforts to remove the Product from all contracts with direct customers providing for the issuance of rebates and other discounts to such direct customers in or for the Territory (“Direct Customer
Contracts”), effective on the Transition Period End Date. GSK shall not assign to XenoPort, and XenoPort shall not assume, any of the Direct Customer Contracts. GSK shall be solely responsible for the processing, handling and payment of all
rebates and other discounts owed under the Direct Customer Contracts with respect to Product sold to direct customers up to the Transition Period End Date. As soon as practicable following the Transition Period End Date, GSK shall
notify all relevant Third Parties of the Product termination date for all Direct Customer Contracts and that any future Direct Customer Contracts for any Product must be entered into with XenoPort or its distributors. For all direct customer
discount program claims that are submitted to one Party but are the processing responsibility of the other Party, the Party receiving the claim shall deny the claim. 
 (d) Patient Assistance Programs. GSK shall be authorized to continue its patient assistance programs for the Product for all patients enrolled and active in such programs as of the Transition
Period End Date. XenoPort hereby authorizes GSK to reserve and utilize Product and to pay claims for eligible patients for a minimum of [... * ...] following the Transition Period End Date and up to [... * ...] following
the Transition Period End Date, after which time, patients will be removed from such patient assistance programs. GSK shall be responsible for all costs associated with such programs, and for ensuring that such programs comply with Applicable Laws.
Any reasonable, documented costs incurred by XenoPort, at GSK’s request, in connection with GSK’s patient assistance programs shall be reimbursed by GSK. 
 5.9 GSK’s Accounts Receivable; Payments for XenoPort Sales. XenoPort agrees to promptly deliver to GSK any amounts received by or on behalf of XenoPort (including but not limited to negotiable
instruments, which shall be endorsed to the order of GSK) with respect to any and all Accounts Receivable. GSK agrees to promptly deliver to XenoPort any amounts received by or on behalf of GSK or its Affiliates (including but not limited to
negotiable instruments, which shall be endorsed to the order of XenoPort) with respect to any and all payments for Products sold by or under authority of XenoPort after the Transition Period End Date. 

5.10 Cooperation. With respect to Sections 5.3 through 5.9, the Parties agree to use Commercially Reasonable Efforts to cooperate
in good faith, and in consultation with each other, to 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 52 - 

 EXECUTION COPY 
  

 
establish appropriate processes and procedures for implementing the foregoing and to facilitate and manage the smooth transition of responsibilities and activities with respect to reimbursement,
pricing and payment matters for the Product and related government reporting, consistent with industry standards, GSK’s Applicable Policies and Procedures and Applicable Laws. 

5.11 Financial Information; Records; Audit. 
 (a) In accordance with the timelines set forth in Schedule 1.47, GSK shall provide to XenoPort true and complete electronic copies of all Financial Information. Such copies of Financial Information
shall be provided in an electronic format [... * ...] 
 (b) Within [... * ...] Business Days after
the Termination Effective Date, GSK shall provide to XenoPort a true and complete copy of the final close-out of the detailed Joint P&L (as defined in the Restated Agreement) for the Product through the Termination Effective Date, prepared in
accordance with Section 6.5(c) of the Restated Agreement, such final close-out of the detailed Joint P&L to be provided for informational purposes only. No payment from either Party to the other will be due in connection with such final
close-out of the detailed Joint P&L. 
 (c) GSK acknowledges and agrees that it has kept, and has required its Affiliates to
keep, complete, true and accurate books of accounts and records for the purpose of determining amounts payable to XenoPort pursuant to the Restated Agreement. Each Party shall keep, and require its Affiliates to keep, complete, true and accurate
books of accounts and records for the purpose of determining amounts to be paid by either Party (or its Affiliate) to the other Party (or its Affiliate) under this Termination Agreement or the Supply Agreement. All such books and records shall be
kept for at least three (3) years following the end of the calendar quarter to which they pertain and shall be open for inspection and audit by the other Party such three (3) year period on the terms of this Section 5.11(c). Upon not
less than [... * ...] prior written notice, such Party shall permit an independent, certified public accountant selected by the other Party and reasonably acceptable to the Party whose books and records are to be inspected, which
acceptance will not be unreasonably withheld or delayed (for the purposes of this Section 5.11(c), the “Auditor”), to audit or inspect those books or records of such Party or its Affiliate that relate to the transition
activities and obligations pursuant to this Termination Agreement. Such inspections may be made no more than once each calendar year and during normal business hours. Such records for any particular calendar quarter shall be subject to no more than
one inspection. The Auditor shall be obligated to execute a reasonable confidentiality agreement prior to commencing any such inspection. Inspections conducted under this Section 5.11(c) shall be at the expense of the Party conducting such
audit, unless non-compliance with the transition activities and obligations pursuant to this Termination Agreement is established or unless a variation or error producing an underpayment in amounts payable hereunder to the Party conducting the
audit, or an overpayment in amounts paid hereunder by the Party conducting the audit, exceeding [... * ...] of the amount paid for a period covered by the inspection is established. In any such case, all reasonable costs relating to the
inspection for such period and any unpaid amounts that are discovered shall be paid by the audited Party, together with interest on such unpaid amounts or overpaid amounts at (i) the prime rate as reported by Citibank N.A., plus [... *
...] per year; or (ii) if lower, the maximum rate permitted by 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 53 - 

 EXECUTION COPY 
  

 
law; calculated on the number of days such payment is delinquent, compounded annually and computed on the basis of a three hundred sixty five (365) day year; provided, however that
interest will not be charged in instances where payments are disputed or subject to interpretation resolution, payment has been delayed by reason of the Party to whom such payment is to be made (e.g., due to invalid or late changes to bank
details, non-compliant invoices, etc.), or the Party to whom such payment is to be made has not responded to reasonable questions or queries from the other Party. The Parties will endeavor in such inspection to minimize disruption of the audited
Party’s (and its Affiliates’) normal business activities to the extent reasonably practicable. 
 5.12 Ownership of
Inventions. Except with respect to the Transferred GSK Patents (which all right, title and interest shall be assigned and transferred to XenoPort pursuant to Sections 3.4(a)(v), 3.4(b) and 3.6 above), title to all inventions and other
intellectual property (other than Trademarks) made jointly by personnel of XenoPort and GSK in connection with the Restated Agreement (including the Original Agreement) or this Termination Agreement shall be jointly owned by XenoPort and GSK.
Prosecution of any Patent with respect to such jointly-owned inventions and intellectual property shall be solely as mutually agreed. Except as expressly provided in this Termination Agreement, it is understood that neither Party shall have any
obligation to obtain any approval of, nor pay a share of the proceeds to, the other Party to practice, enforce, license, assign or otherwise exploit such jointly-owned inventions or intellectual property, and each Party hereby waives any right it
may have under the Applicable Laws of any jurisdiction to require such approval or accounting. 
 5.13 Equipment. As of
the Termination Effective Date, GSK is the owner of the manufacturing equipment set forth on Schedule 5.13 attached hereto (the “Equipment”), which is currently located at the facility of GSK’s contract manufacturer for
Bulk Product (the “Bulk Manufacturer”). [... * ...] 
 5.14 Stability Program; Complaint
Handling. 
 (a) GSK shall continue to manage the on-going stability studies to support Product distributed by GSK to the
extent such studies were initiated before the Termination Effective Date or are subsequently initiated during the Transition Period (the “On-Going Stability Studies”). Any communications regarding the data generated from On-Going
Stability Studies will be shared between the Parties as set forth in the Quality Agreement. For the avoidance of doubt, any additional or future stability studies for the Product that are required to be made or conducted beyond those studies
supporting Product distributed by GSK prior to the Transition Period End Date shall be the responsibility of XenoPort. 
 (b)
For those lots of Product distributed by GSK before or during the Transition Period, GSK shall manage any complaints arising with respect to such Product, including communication regarding such complaint and any related investigation of such
complaint. Any communications regarding such complaints (and the related investigation) will be shared between the Parties as set forth in the Quality Agreement. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 54 - 

 EXECUTION COPY 
  

 ARTICLE VI 
 FINANCIAL TERMS 
 6.1 GSK and its Affiliates shall have no obligation to
pay, and XenoPort and its Affiliates shall have no right to receive, any portion of amounts received by GSK or its Affiliates from sales of the Product during the Transition Period. 

6.2 Payment for Inventory. Subject to the terms and conditions of this Termination Agreement, in consideration for the Inventory
to be transferred and conveyed to XenoPort under the terms of this Termination Agreement, XenoPort shall pay GSK a total of Six Million Dollars (US$6,000,000), in six equal installments of One Million United States Dollars (US$1,000,000) each, as
follows: The first such payment shall be due by June 30th of each of calendar years 2016 through 2021. For clarity, it is understood that no payment shall be due under this Section 6.2 prior to June 30, 2016 or after June 30,
2021, and that no more than a total of US$6,000,000 in the aggregate shall be due under this Section 6.2. XenoPort shall be solely responsible for the payment of all Transfer Taxes incurred in connection with the transfer and assignment of the
Inventory as set forth in this Termination Agreement. 
 ARTICLE VII 

REPRESENTATIONS AND WARRANTIES 
 7.1 General Representations. Each Party hereby represents and warrants to the other Party as follows as of the Termination Effective Date: 

(a) Such Party is a company duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation
or organization, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such would not
prevent such Party from performing its obligations under this Termination Agreement. 
 (b) This Termination Agreement is a
legal and valid obligation binding upon such Party and enforceable in accordance with its terms. The execution, delivery and performance of this Termination Agreement by such Party have been duly authorized by all necessary corporate action and do
not and will not: (i) require any consent or approval of its stockholders; (ii) to such Party’s knowledge, violate any Applicable Laws; nor (iii) conflict with, or constitute a default under, any agreement, instrument or
understanding, oral or written, to which such Party is a party or by which it is bound, except for any conflicts or defaults that (A) would not prevent such Party from performing its obligations under this Termination Agreement, (B) would
not prevent the other Party from exercising its rights under this Termination Agreement, and (C) would not adversely affect the conveyance of all right title and interest in the Transferred Assets or the grant of rights and licenses hereunder.
In particular, and without limiting the generality of the foregoing, each Party represents and warrants to the other Party that it is fully entitled to grant the releases, enter into the covenants, and undertake the obligations set forth herein.

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 55 - 

 EXECUTION COPY 
  

 (c) Such Party has not sold, assigned, conveyed, pledged, encumbered, or otherwise in
any way transferred to any Person any Claim released by such Party pursuant to this Termination Agreement. 
 (d) Such Party has
not filed, and has no actual knowledge, that any Third Party has filed, any legal or administrative proceeding of any kind or nature against the other Party relating to the Restated Agreement (including the Original Agreement), other than the Claims
filed in the Litigation. 
 (e) Such Party is not relying in any manner on any statement, promise, representation or omission,
whether oral or written, express or implied, made by any Person or entity, not specifically set forth in this Termination Agreement. 
 (f) The Parties acknowledge that they have worked together and participated on joint committees with respect to the Compound and Product during the term of the Original Agreement and Restated Agreement,
and in connection therewith have from time to time exchanged information concerning the development and commercialization of the Compound and Product. 
 7.2 Additional Covenant and Warranties of XenoPort. 
 (a) XenoPort
covenants to GSK that during the Transition Period, it will not, directly or indirectly through Affiliates or Third Parties, promote, market or sell the Product in the Territory or engage in any of the activities set forth in Section 4.4(f)
(other than, for the avoidance of doubt, activities permitted under Section 4.8). 
 (b) XenoPort covenants to GSK that it
shall comply with Applicable Laws in connection with XenoPort’s handling and storage of Transferred Inventory and with respect to XenoPort’s activities relating to with the manufacture and sale of Products made therefrom, including any
quality assurance or quality release activities that may not be delegated to GSK, its Affiliates, or a Third Party. 
 (c)
XenoPort represents, warrants and covenants as follows to GSK: 
 (i) As of the Termination Effective Date, XenoPort has
sufficient right, title and interest in and to the XenoPort Patents, XenoPort Trademarks and XenoPort Know-How to convey to GSK the licenses as provided in this Termination Agreement, free and clear of any liens or encumbrances (other than
obligations and restrictions set forth in this Termination Agreement). 
 (ii) As of the Termination Effective Date, XenoPort
has the full right and authority to grant the licenses under the XenoPort Patents, XenoPort Trademarks and XenoPort Know-How as provided herein. XenoPort and its Affiliates have not previously granted, and during the Transition Period (and during
any portion of the periods described in Section 5.8(d) or 4.4(g) following the Transition Period End Date in which GSK continues to distribute and sell Product as provided under such Section(s)) XenoPort and its Affiliates shall not grant, any
right, license or 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 56 - 

 EXECUTION COPY 
  

 
interest in or to the XenoPort Patents, XenoPort Trademarks and XenoPort Know-How, or any portion thereof, that is in conflict with the licenses granted to GSK under this Termination Agreement.

 (iii) To its knowledge as of the Termination Effective Date, there are no actual, pending, anticipated, alleged or
threatened actions, suits, claims, interference or governmental investigations involving the XenoPort Patents, XenoPort Trademarks and XenoPort Know-How by or against XenoPort or any of its Affiliates. 

(iv) All necessary consents, approvals and authorizations of all Regulatory Authorities, other governmental authorities and other
persons or entities required to be obtained by XenoPort in order to enter into this Termination Agreement have been obtained. 

(v) To its knowledge as of the Termination Effective Date, there is no actual, pending, anticipated, alleged or threatened infringement
by a Third Party of any of the XenoPort Patents or misappropriation by a Third Party of any of the XenoPort Know-How. 
 7.3
Additional Warranties of GSK. In addition, GSK represents, warrants and covenants as follows to XenoPort: 
 (a)
Title; Rights to Transfer and Assign or License. 
 (i) As of the Termination Effective Date (and, with respect to any
Transferred Assets assigned or transferred to XenoPort after the Termination Effective Date, as of the date of such assignment or transfer), (A) GSK has good and marketable title, and owns all right, title and interest, in and to the
Transferred Assets, and has the right to transfer and assign rights in or to each of the foregoing to XenoPort or its designee as provided in this Termination Agreement, free and clear of any liens or encumbrances, (B) no Person (including any
Affiliate of GSK) other than GSK (or XenoPort) has any right, title or interest in or to such Transferred Assets (other than any Transferred GSK Contract), and (C) no Person (including any Affiliate of GSK) other than GSK has any right, title
or interest in any Transferred GSK Contract other than the applicable counterparty thereto. To its actual knowledge as of the Termination Effective Date, GSK has sufficient right, title and interest in and to the Licensed Assets to convey to
XenoPort the licenses as provided in this Termination Agreement, free and clear of any liens or encumbrances (other than obligations and restrictions set forth in this Termination Agreement). 

(ii) As of the Termination Effective Date, GSK has the full right and authority to grant the rights and licenses as provided herein, and
GSK and its Affiliates have not previously granted (and during the period from the Termination Effective Date until the Transition Period End Date, GSK and its Affiliates shall not grant) any right, license or interest in or to the Transferred GSK
Patents, Transferred GSK Know-How, Transferred GSK Trademarks or, to its actual knowledge as of the Termination Effective Date, the Licensed Assets, or any portion thereof, that is in conflict with the rights or licenses granted to XenoPort under
this Termination Agreement. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 57 - 

 EXECUTION COPY 
  

 (iii) To its knowledge as of the Termination Effective Date, there are no actual,
pending, anticipated, alleged or threatened actions, suits, claims, interference or governmental investigations involving Compound, Product, Transferred GSK Patents or Transferred GSK Know-How by or against GSK or any of its Affiliates (other than
the Litigation). 
 (iv) All necessary consents, approvals and authorizations of all Regulatory Authorities, other governmental
authorities and other persons or entities required to be obtained by GSK in order to enter into this Termination Agreement have been obtained. 
 (v) To its knowledge as of the Termination Effective Date, there is no actual, pending, anticipated, alleged or threatened infringement by a Third Party of any of the Transferred GSK Patents or
misappropriation by a Third Party of any of the Transferred GSK Know-How. 
 (vi) It has not, up through and including the
Termination Effective Date, knowingly withheld any material information in its possession from XenoPort in response to XenoPort’s reasonable inquiries in connection with XenoPort’s due diligence relating to Compound or Product in or for
the Territory, and to its knowledge, the information related to Compound or Product in or for the Territory that GSK has provided to XenoPort prior to the Termination Effective Date is up-to-date and accurate in all material respects. 

(b) Schedules. 
 (i) To GSK’s knowledge and subject to each Party’s rights under Sections 3.6 and 4.7 of this Termination Agreement, the Schedules attached to this Termination Agreement that identify the
Transferred Assets and Licensed Assets, both as of the Termination Effective Date and [... * ...] XenoPort as of the Transition Period End Date pursuant to Section 3.6 above, set forth a true, complete and correct description of
all Transferred Assets and Licensed Assets (as each such asset is defined without limitation to the referenced Schedule) as of the Termination Effective Date and as of the Transition Period End Date, respectively, except to the extent that the
omission from any Schedule attached to this Termination Agreement of any Transferred Asset or Licensed Asset is not a material omission. 
 (ii) To GSK’s knowledge, the Schedules attached to this Termination Agreement as of the Termination Effective Date and [... * ...] XenoPort as of the Transition Period End Date pursuant
to Section 3.6 above that identify the Transferred GSK Contracts and Excluded GSK Contracts (other than GSK Contracts between GSK and its Affiliates (i.e., inter-company agreements)) set forth a true, complete and correct description of
all GSK Contracts as of the Termination Effective Date and as of the Transition Period End Date, respectively, except to the extent that the omission from such Schedule attached to this Termination Agreement of any of any Transferred GSK Contracts
or Excluded GSK Contracts is not a material omission. 
 (iii) The Transferred Assets, Licensed Assets, Excluded GSK Contracts,
Expired GSK Contracts, Excluded GSK Inventory, Excluded GSK Know-How, and GSK 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 58 - 

 EXECUTION COPY 
  

 
Housemarks (as each such asset is defined without limitation to the referenced Schedule) include all material tangible and intangible assets primarily related to, or used by or on behalf of GSK
or its Affiliates in, the development, manufacture or commercialization of Compound or Product in or for the Territory prior to the Termination Effective Date and as of the Transition Period End Date, respectively. Schedule 1.90 attached
hereto sets forth a true, complete and correct description of all Ongoing Studies. 
 (c) Compliance with Applicable
Laws. Except to the extent that non-compliance would not have a Material Adverse Effect, as of the Termination Effective Date, GSK has conducted the development, manufacture and commercialization (including marketing, promotion and distribution
by or on behalf of GSK and its Affiliates) of Compound and Product, as applicable, for and in the Territory in compliance with all applicable Transferred GSK Regulatory Filings and Applicable Laws, including cGMP, regulations, “Good Clinical
Practice,” or GCP, regulations, “Good Laboratory Practice,” or GLP, regulations, “Informed Consent” and “Institutional Review Board” regulations, patient privacy and security regulations and all applicable
requirements relating to the protection of human subjects for its clinical trials as required by the FDA. To the knowledge of GSK, as of the Termination Effective Date, GSK has not received any written notice from any Regulatory Authority relating
to any violation of any applicable Transferred GSK Regulatory Filing or Applicable Laws in conducting the development, manufacture and commercialization of Compound and Product for and in the Territory. 

(d) Regulatory Matters. 
 (i) To the knowledge of GSK, as of the Termination Effective Date, no notification, written or oral, has been received by GSK or any of its Affiliates from the FDA regarding the following that remains
unresolved: (A) any FDA Form 483 Notice of Observation, or similar notice from any other Regulatory Authority, relating to Product or, during the period of time that such facilities manufactured Product, the facilities in which Product is
manufactured; (B) any FDA Notices of adverse events, or similar notice from any other Regulatory Authority, with respect to Product; (C) any “warning letters,” or “untitled letters,” or other similar Regulatory
Authority notice of inspectional observations or deficiencies or other written correspondence from the FDA or any other Regulatory Authority concerning Product or, during the period of time that such facilities manufactured Product, the facilities
in which Product is manufactured or (D) any notice indicating that any Product is misbranded or adulterated as defined in 21 U.S.C. §321, et seq., as amended, and the rules and regulations promulgated thereunder. 

(ii) Neither GSK nor any of its Affiliates (including their respective current and former officers and employees) has been convicted of
any crime or engaged in any conduct that would reasonably be expected to result in exclusion under 42 U.S.C. Section 1320a-7 or any similar state law or regulation or been debarred by the FDA under Article 306 of the FDCA, 21 U.S.C.
§335a(a) or (b), in each case, with respect to the development, manufacture or commercialization of Compound or Product. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 59 - 

 EXECUTION COPY 
  

 (iii) As of the Termination Effective Date, there has been no recall or market
withdrawal of any Product in the Territory by, or on behalf of, GSK or any of its Affiliates, whether voluntary or involuntary, or any termination or suspension of the marketing, or seizure, of any Product sold by or on behalf of GSK or any of its
Affiliates, or any material change in the U.S. package inserts for the Product that has not been communicated to XenoPort prior to the Termination Effective Date. 
 (iv) On or before the Termination Effective Date, GSK has not knowingly withheld any information from XenoPort concerning any (i) adverse drug experience information; and (ii) medical inquiries
and complaints, in each case, relating to the Product in the Territory. 
 (e) Transferred Contracts. All of the
Transferred GSK Contracts are valid and binding agreements of GSK or its Affiliates, enforceable as of Termination Effective Date (or, if later, the date of assignment of such Transferred GSK Contract to XenoPort) in accordance with their terms.
Neither GSK nor its Affiliates is in breach or default of such Transferred GSK Contracts, and, to GSK’s knowledge, no event has occurred that with notice or lapse of time, or both, would constitute a default by GSK or its Affiliates under any
Transferred GSK Contract. To the knowledge of GSK and its Affiliates, no other party to a Transferred GSK Contract is in breach or default of such Transferred GSK Contract, and no event has occurred that with notice or lapse of time, or both, would
constitute a default by such other party under any Transferred GSK Contract. No party has repudiated in writing or expressed any intention in writing to repudiate any provision of a Transferred GSK Contract. Subject to each Party’s rights under
Sections 3.6 and 4.7 of this Termination Agreement, GSK has disclosed and made available to XenoPort true and complete and accurate copies of all Transferred GSK Contracts (or written summaries of the material terms thereof, if such contracts are
not in writing), including all amendments, supplements, modifications and waivers thereof, as in effect on the Termination Effective Date (or, if later, the date of assignment of such Transferred GSK Contract to XenoPort). GSK has paid, or shall pay
when due (even if after the date of transfer), all undisputed payments under each Transferred GSK Contracts that have accrued on or prior to the date of assignment of such Transferred GSK Contract to XenoPort. 

(f) Product Liability. GSK has not received any written notice concerning any legal proceedings or, to the knowledge of GSK and
its Affiliates, investigations by Regulatory Authorities with respect to the safety of Product sold or advertised for sale by GSK or any of its Affiliates in the Territory, in each case during the last [... * ...]. GSK has also not
received any written notice concerning any product liability claims relating to the development, manufacture or commercialization of the Product involving amounts in excess of [... * ...] (or, to the knowledge of GSK or any of its
Affiliates, threatened) within the past five (5) years. 
 (g) Inventory. GSK and its Affiliates represent and
warrant as of the date of delivery to or as directed by XenoPort hereunder that (i) each unit of Transferred GSK Inventory has been manufactured, stored, and handled materially in compliance with the applicable then-current Specifications,
cGMPs and other Applicable Laws, [... * ...]; (ii) to GSK’s knowledge, all facilities and equipment used for the manufacture of each unit of Transferred GSK Inventory have been and

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 60 - 

 EXECUTION COPY 
  

 
are in material compliance with all Applicable Laws; and (iii) except to the extent title and interest may be impacted while payment to the relevant Third Party supplier is pending, title to
each unit of Transferred GSK Inventory shall pass to XenoPort, free and clear of any liens or encumbrances. 
 (h)
Promotional Sample Inventory. GSK and its Affiliates represent and warrant as of the Transition Period End Date that (i) each unit of Promotional Sample Inventory has been manufactured, stored, and handled materially in compliance with
the applicable then-current Specifications, cGMPs and other Applicable Laws; (ii) to GSK’s knowledge, all facilities and equipment used for the manufacture of each unit of Promotional Sample Inventory have been and are in material
compliance with all Applicable Laws; and (iii) except to the extent title and interest may be impacted while payment to the relevant Third Party supplier is pending, title to each unit of Promotional Sample Inventory shall pass to XenoPort,
free and clear of any liens or encumbrances. 
 (i) GSK’s Applicable Policies and Procedures. To its knowledge as of
the Termination Effective Date, GSK’s Applicable Policies and Procedures do not preclude GSK from materially performing its obligations hereunder or conducting the activities to be conducted by GSK hereunder (including without limitation
conducting Ongoing Studies, interacting with Regulatory Authorities as provided in Section 4.3, transferring Inventory, or supplying Product pursuant to Section 4.5 and the Supply Agreement), as such activities are contemplated to be
conducted as of the Termination Effective Date. During the Transition Period, GSK shall not enact any new policies or procedures where such policy or procedure is enacted with the sole intent of relieving GSK from the obligation to materially
perform its obligations hereunder or conduct the activities to be conducted by GSK hereunder. 
 7.4 DISCLAIMER. EXCEPT
AS OTHERWISE EXPRESSLY SET FORTH IN THIS TERMINATION AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, (I) WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OR VALIDITY OF ANY PATENTS ISSUED OR PENDING, (II) THE USE, MARKETING, DISTRIBUTION, OFFER FOR SALE, SALE, COMMERCIALIZATION OR MANUFACTURE OF COMPOUND AND/OR PRODUCT AFTER THE TRANSITION PERIOD END DATE BY
XENOPORT, ITS AFFILIATES OR ANY THIRD PARTY IN ANY MANNER, (III) THE PROBABLE SUCCESS OR PROFITABILITY OF PRODUCT AFTER THE TERMINATION EFFECTIVE DATE OR (IV) AS TO THE CONDITION, VALUE OR QUALITY OF THE TRANSFERRED ASSETS. WITHOUT LIMITING THE
FOREGOING, THE TRANSFERRED GSK PROMOTIONAL MATERIALS ARE BEING TRANSFERRED AS IS, WHERE IS, WITH ALL FAULTS. FURTHERMORE, NOTWITHSTANDING ANY REPRESENTATION OR WARRANTY MADE PURSUANT TO SECTION 7.3(G), FOR ANY TRANSFERRED GSK INVENTORY TO THE EXTENT
COVERED BY A TRANSFERRED GSK CONTRACT ASSIGNED TO XENOPORT PURSUANT TO THIS TERMINATION AGREEMENT, GSK WILL BE DEEMED TO HAVE MADE NO REPRESENTATION OR WARRANTY WITH RESPECT TO SUCH TRANSFERRED GSK INVENTORY TO THE EXTENT APPLICABLE TO OR BASED ON
ACTIVITIES BY THE COUNTERPARTY TO SUCH TRANSFERRED GSK CONTRACT OR DELIVERABLES 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 61 - 

 EXECUTION COPY 
  

 
(INCLUDING, IF APPLICABLE, COMPOUND OR PRODUCT SUPPLIED) THEREUNDER FROM SUCH COUNTERPARTY, AND XENOPORT SHALL SOLELY RELY ON THE RELEVANT REPRESENTATIONS AND WARRANTIES INCLUDED IN SUCH
TRANSFERRED GSK CONTRACT WITH RESPECT TO SUCH MATTERS IN CONNECTION WITH SUCH TRANSFERRED GSK INVENTORY. 
 ARTICLE VIII

 CONFIDENTIALITY; PRESS RELEASE 
 8.1 Confidential Information. Except as expressly provided in this Termination Agreement, the Parties agree that the receiving Party shall not publish or otherwise disclose and shall not use for
any purpose any information furnished to it by the other Party hereto pursuant to the Restated Agreement (including the Original Agreement) or this Termination Agreement (collectively, “Confidential Information”). Notwithstanding
the foregoing, for purposes of this Article VIII, the Parties agree that from and after the Termination Effective Date, GSK shall treat as Confidential Information of XenoPort all information within the Transferred Assets in its possession or
Control without regard to the exceptions under subsections (a) or (e) below, and shall not publish or otherwise disclose such information within the Transferred Assets other than as provided in Sections 4.3(c) and 8.2. Notwithstanding
the foregoing, Confidential Information shall not include information that, in each case as demonstrated by written documentation: 
 (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure or, as shown by written documentation, was developed by the receiving Party prior
to its disclosure by the disclosing Party; 
 (b) was generally available to the public or otherwise part of the public domain
at the time of its disclosure to the receiving Party; 
 (c) became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of the receiving Party in breach of the Restated Agreement or this Termination Agreement; 
 (d) was subsequently lawfully disclosed to the receiving Party by a person other than the disclosing Party, and who did not directly or indirectly receive such information from disclosing Party; or

 (e) is developed by the receiving Party without use of or reference to any Confidential Information disclosed by the
disclosing Party. 
 8.2 Permitted Disclosures. Notwithstanding the provisions of Section 8.1 above, and subject to
Section 8.3 below, each Party hereto may use and disclose the other Party’s Confidential Information to its Affiliates, licensees, contractors and any other Third Parties to the extent such use and/or disclosure is: (a) reasonably
necessary to perform its obligations hereunder, (b) necessary to comply with Applicable Laws, including applicable court orders or other legal process or (c) in the 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 62 - 

 EXECUTION COPY 
  

 
case of XenoPort, is made in connection with the development, manufacture, commercialization or other exploitation of Compound or Product in or outside the Territory. If a Party proposes to make
a disclosure of Confidential Information under clause (b), above, of this Section 8.2, to the extent it may legally do so, it will give reasonable advance notice to the latter Party of such disclosure and will use its good faith efforts to
secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise). For any other disclosures of the other Party’s Confidential Information, including to Affiliates,
licensees, contractors and other Third Parties, a Party shall ensure that the recipient thereof is bound by appropriate confidentiality provisions consistent with the nature of the information disclosed. 

8.3 Confidentiality of Terms. Each Party agrees not to disclose to any Third Party the terms of this Termination Agreement,
without the prior written consent of the other Party hereto, except each Party may disclose the terms of this Termination Agreement: (a) to advisors (including financial advisors, attorneys and accountants), actual or potential acquisition
partners or private investors, potential licensees of XenoPort, and others on a need to know basis, in each case under appropriate confidentiality provisions consistent with the nature of the information disclosed; (b) to the extent necessary
to comply with Applicable Laws, including securities laws, regulations or guidances; provided that in the case of clause (b) the disclosing Party shall promptly notify the other Party and (other than in the case where such disclosure is
necessary, in the reasonable opinion of the disclosing Party’s legal counsel, to comply with securities laws, regulations or guidances) allow the other Party a reasonable opportunity to oppose with the body initiating the process and, to the
extent allowable by Applicable Laws, to seek limitations on the portion of the Termination Agreement that is required to be disclosed. Notwithstanding the foregoing, the Parties shall agree upon press releases of each Party to announce the execution
of this Termination Agreement, drafts of which are attached in Exhibit 8.3; thereafter, each Party may each disclose to Third Parties the information contained in such press releases without the need for further approval by the other
Party. 
 ARTICLE IX 
 INDEMNIFICATION 
 9.1 Indemnification of GSK. XenoPort shall
indemnify and hold harmless each of GSK, and its Affiliates and the directors, officers and employees of GSK and its Affiliates and the successors and assigns of any of the foregoing (the “GSK Indemnitees”), from and against any and
all liabilities, damages, penalties, fines, costs, expenses (including, reasonable attorneys’ fees and other expenses of litigation) (“Liabilities”) from any claims, actions, suits or proceedings brought by a Third Party (a
“Third Party Claim”) incurred by any GSK Indemnitee, arising from, or occurring as a result of (a) gross negligence or willful misconduct in the conduct of the research and development activities conducted by XenoPort or its
Affiliates related to Compound and/or any Product, (b) the use, marketing, distribution, or sale of any Product by or under authority of XenoPort, its Affiliates or licensees (other than by or under the authority of GSK, its Affiliates and
sublicensees) inside or outside the Territory, (c) the manufacture of any Compound or Product by or on behalf of XenoPort, its Affiliates or licensees (other than by or on behalf of GSK, its Affiliates and sublicensees); or (d) any
material breach of any representations, warranties or covenants by XenoPort in ARTICLE VII above, except to the extent such Third Party Claims arise from and are attributable to causes described in clauses (a)-(d) of Section 9.2 below or
result from the negligence or fault of an GSK Indemnitee. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 63 - 

 EXECUTION COPY 
  

 9.2 Indemnification of XenoPort. GSK shall indemnify and hold harmless each of
XenoPort, its Affiliates and the directors, officers, stockholders and employees of such entities and the successors and assigns of any of the foregoing (the “XenoPort Indemnitees”), from and against any and all Liabilities from any
Third Party Claims incurred by any XenoPort Indemnitee, arising from, or occurring as a result of: (a) the use, marketing, distribution, importation or sale of any Product by or under authority of GSK (or its Affiliates); (b) the
manufacture of any Compound or Product by or on behalf of GSK (or its Affiliates) for sale by GSK or its Affiliates prior to the Transition Period End Date, but (to the extent that Tolled API is supplied by XenoPort to GSK as set forth in
Section 4.2(f)(iv)) excluding any Liabilities arising from the storage, handling, or alteration of such Tolled API after such Tolled API is transferred from GSK to XenoPort (or its designee) but before such Tolled API is subsequently
transferred to GSK’s Third Party contractor pursuant to Section 4.2(h)(ii); (c) gross negligence or willful misconduct in the conduct of the research and development activities conducted by GSK, or any of its Affiliates, related to
the Compound and/or any Product; and (d) any material breach of any representations, warranties or covenants by GSK in Article VII above; except to the extent such Third Party Claims arise from and are attributable to causes described in
clauses (a)-(d) of Section 9.1 above or result from the gross negligence or fault of a XenoPort Indemnitee. 
 9.3
Procedure. A Party that intends to claim indemnification under this ARTICLE IX (the “Indemnitee”) shall promptly notify the other Party (the “Indemnitor”) in writing of the assertion or the commencement of
Third Party Claim and will provide the Indemnitor such information with respect thereto that the Indemnitor may reasonably request. The Indemnitor shall be entitled to participate in the defense of any Third Party Claim and, subject to the
limitations set forth in this Section 9.3, shall be entitled to control and appoint lead counsel for such defense, in each case at its expense. If the Indemnitor shall assume the control of the defense of any Third Party Claim in accordance
with the provisions of this Section 9.3, the Indemnitor shall obtain the prior written consent of the Indemnitee (which shall not be unreasonably withheld) before entering into any settlement of such Third Party Claim. The failure to deliver
written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee
under this Section 9.3, but the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability that it may have to any Indemnitee otherwise than under this Section 9.3. The Indemnitee under this
Section 9.3 shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by this indemnification. 

9.4 Limitation of Liability. 
 (a) Notwithstanding anything to the contrary contained herein, and except in the event of fraud or willful misconduct by GSK or its Affiliates, in no event shall GSK be responsible for any Liabilities
from Third Party Claims or any other losses, expenses, costs, liabilities, damages, 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 64 - 

 EXECUTION COPY 
  

 
penalties, or fines arising out of or relating to any Transferred GSK Inventory transferred by (or on behalf of) GSK to XenoPort, however arising, to the extent that such amounts (in the
aggregate) exceed Six Million US Dollars ($6,000,000). 
 (b) EXCEPT IN THE EVENT OF FRAUD OR WILLFUL MISCONDUCT BY THE
APPLICABLE PARTY OR ANY OF ITS AFFILIATES, IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS AFFILIATES) BE LIABLE TO THE OTHER (OR ANY OF ITS AFFILIATES) FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES ARISING OUT OF, OR AS
THE RESULT OF, THIS TERMINATION AGREEMENT OR ANY BREACH OF THIS TERMINATION AGREEMENT, OR THE EXERCISE BY EITHER PARTY OF RIGHTS CONVEYED HEREUNDER, OR THE SALE, TRANSFER, DELIVERY, USE, OR LOSS OF USE OF ANY INVENTORY, REGARDLESS OF WHETHER SUCH
CLAIM IS BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT, NEGLIGENCE, STRICT LIABILITY, OR ANY LEGAL THEORY, AND REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. 
 ARTICLE X 
 DISPUTE RESOLUTION 

10.1 Dispute Resolution. Except as otherwise provided herein, any dispute, controversy or claim arising under, out of or in
connection with this Termination Agreement, including any subsequent amendments, or the validity, enforceability, interpretation, performance or breach hereof (and including the applicability of this Article X to any such dispute, controversy or
claim) and any dispute within the Transition Team (each a “Dispute”), shall first be presented to the Chief Executive Officer of XenoPort and the Chief Operating Officer of GSK, or their respective designees, for resolution. Any
Party may give the other Party written notice of any Dispute not resolved in the normal course of business. If the Chief Executive Officer of XenoPort and the Chief Executive Officer of GSK, or their respective designees, cannot resolve the Dispute
within [... * ...] of the request to do so, either Party may, upon written notice to the other, then refer such Dispute be resolved by mediation in accordance with the provisions of Section 10.2 below or final, binding arbitration
in accordance with the provisions of Section 10.3 below. All negotiations pursuant to this Section 10.1 are confidential and will be treated as compromise and settlement negotiations for purposes of applicable rules of evidence.

 10.2 Mediation. If the Dispute has not been resolved by negotiation as provided in Section 10.1 above, the
Parties will endeavor to settle the dispute by mediation conducted by the Judicial Arbitration and Mediation Services, Inc. (or any successor entity thereto) (“JAMS”) under its procedures regarding mediation then currently in
effect; provided, however that if one Party fails to participate in the negotiation under Section 10.1 above within a reasonable period after delivery of the notice of Dispute, the other Party may initiate mediation prior to the
expiration of the initial [... * ...] period referenced above. 
 10.3 Arbitration. Except as otherwise
provided in Section 10.3(c) with respect to Disputes involving the intellectual property rights of a Party, the Parties agree that any Dispute arising out of 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 65 - 

 EXECUTION COPY 
  

 
or relating to this Termination Agreement, including the breach, termination or validity thereof, which has not been resolved by mediation as provided in Section 10.2 above within [...
* ...] after either Party provides notice to JAMS and the other Party submitting such matter for mediation as contemplated by Section 10.2 above, will be finally resolved by binding arbitration conducted by JAMS under its rules of
arbitration then in effect (“Rules”), except as modified herein. If the amount in controversy is [... * ...] there shall be [... * ...] shall be agreed upon by the Parties within [... * ...] of
receipt by respondent of a copy of the demand for arbitration. If the amount in controversy is [... * ...] there shall be [... * ...] of the arbitral tribunal [... * ...] If any arbitrator is not appointed
within the time limit provided herein, such arbitrator shall be appointed in accordance with the Rules, or if the Rules do not provide for such selection, by the chief executive of JAMS. Notwithstanding the foregoing, if one Party fails to
participate in either the negotiation or mediation as agreed herein, the other Party can commence arbitration pursuant to this Section 10.3 prior to the expiration of the time periods set forth therein. The arbitration will be governed by the
Federal Arbitration Act, 9 U.S.C. §§1 et. seq. and judgment upon the award rendered by the arbitrator(s) may be entered by any court having jurisdiction thereof. 

(a) The Parties agree that the decision of the arbitrator(s) shall be the binding remedy between them regarding the Dispute presented to
the arbitrator(s). Any decision of the arbitrator(s) may be entered in a court of competent jurisdiction for judicial recognition of the decision and an order of enforcement. The arbitration proceedings and the decision of the arbitrator(s) shall
not be made public without the joint consent of the Parties and each Party shall maintain the confidentiality of such proceedings and decision unless each Party otherwise agrees in writing; provided that either Party may make such disclosures as are
permitted for Confidential Information of the other Party under Article VIII above. 
 (b) Unless otherwise mutually agreed upon
by the Parties, the arbitration proceedings shall be conducted in [... * ...] The Parties agree that they shall share equally the cost of the arbitration filing and hearing fees, the cost of any independent expert retained by the
arbitrator(s), and the cost of the arbitrator(s) and administrative fees. Each Party shall bear its own costs and attorneys’ and witnesses’ fees and associated costs and expenses. 

(c) Notwithstanding the foregoing provisions of this Section 10.3, either Party may initiate legal proceedings with respect to any
Disputes related to intellectual property rights of a Party that are not resolved under Sections 10.1 or 10.2, including any such Disputes regarding the validity or enforceability of any Patent owned or Controlled by either Party. 

(d) Nothing in this Termination Agreement shall limit the right of either Party to seek to obtain in any court of competent jurisdiction
any equitable or interim relief or provisional remedy, including injunctive relief, that may be necessary to protect the rights or property of that Party pending resolution of a Dispute under this Section 10.3. Seeking or obtaining such
equitable or interim relief or provisional remedy in a court shall not be deemed a waiver of the agreement to arbitrate. For clarity, any such equitable remedies shall be cumulative and not exclusive and are in addition to any other remedies that
either Party may have under this Termination Agreement or Applicable Laws. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 66 - 

 EXECUTION COPY 
  

 10.4 Waiver of Jury Trial. EXCEPT AS OTHERWISE PROVIDED IN SECTION 10.3(C)
WITH RESPECT TO DISPUTES INVOLVING THE INTELLECTUAL PROPERTY RIGHTS OF A PARTY, EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY. 
 ARTICLE XI 
 GENERAL PROVISIONS 

11.1 Governing Law. The validity or interpretation, or the breach or performance of this Termination Agreement, and any dispute,
controversy or claim arising under, out of or in connection with this Termination Agreement, including any tort and statutory claims, shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without
reference to conflict of law principles. 
 11.2 Waiver of Breach. Except as otherwise expressly provided in this
Termination Agreement, any term of this Termination Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require
performance of any provision of this Termination Agreement shall in no manner affect such Party’s rights at a later time to enforce the same. No waiver by either Party of any condition or term in any one or more instances shall be construed as
a further or continuing waiver of such condition or term or of another condition or term. 
 11.3 Modification. No
amendment or modification of any provision of this Termination Agreement shall be effective unless in writing signed by a duly authorized representative of each Party. No provision of this Termination Agreement shall be varied, contradicted or
explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

11.4 Severability. In the event any provision of this Termination Agreement should be held invalid, illegal or unenforceable in
any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Termination Agreement shall remain in full
force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction. 

11.5 Entire Agreement. This Termination Agreement (including the Schedules and Exhibits attached hereto), together with the SPA,
Ancillary Agreements, GSK Safety Agreement and Supply Agreement (if applicable), constitute the entire agreement between the Parties relating to its subject matter and supersedes all prior or contemporaneous agreements, understandings or
representations, either written or oral, including the Original Agreement and the Restated Agreement, between XenoPort and GSK with respect to such subject matter. 
 11.6 Notices. Unless otherwise agreed by the Parties or specified in this Termination Agreement, all communications between the Parties relating to, and all written documentation to be

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 67 - 

 EXECUTION COPY 
  

 
prepared and provided under, this Termination Agreement shall be in the English language. Any notice required or permitted under this Termination Agreement shall be in writing in the English
language: (a) delivered personally; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing evidence of receipt, postage pre-paid where applicable; or
(d) sent by facsimile (receipt verified and a copy promptly sent by another permissible method of providing notice described in paragraphs (b), (c) or (d) above), to the following addresses of the Parties or such other address
for a Party as may be specified by like notice: 
  

			
	To XenoPort:	 	To GSK:
		
	XenoPort, Inc.	 	Glaxo Group Limited
	3410 Central Expressway	 	Glaxo Wellcome House, Berkeley Avenue
	Santa Clara, CA 95051	 	Greenford, Middlesex, UB6 0NN, England
	Telephone: (408) 616-7200	 	Telephone:
	Facsimile: (408) 616-7211	 	Facsimile:
	Attention: Secretary	 	Attention: Company Secretary
		
	With a copy to:	 	With a copy to:
		
	Wilson, Sonsini, Goodrich & Rosati	 	GlaxoSmithKline
	650 Page Mill Road	 	709 Swedeland Road
	Palo Alto, CA 94304	 	P.O. Box 1539 King of Prussia, PA 19406-0939 USA
	Telephone: (650) 493-9300	 	Telephone:
	Facsimile: (650) 493-6811	 	Facsimile:
	Attention: Kenneth A. Clark	 	Attention : Senior Vice President, Worldwide Business Development
		
		 	and
		
		 	GlaxoSmithKline
		 	2301 Renaissance Boulevard
		 	Mailcode RN0220
		 	 King of Prussia, PA 19406-2772

Telephone:

		 	Facsimile:
		 	Attention: Vice President and Associate General Counsel, Business Development Transactions

 Any notice required or permitted to be given concerning this Termination Agreement shall be effective
upon receipt by the Party to whom it is addressed or within [... * ...] of dispatch whichever is earlier. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 68 - 

 EXECUTION COPY 
  

 11.7 Assignment. This Termination Agreement shall not be assignable by either
Party to any Affiliate or Third Party hereto without the written consent of the other Party hereto; except XenoPort may assign this Termination Agreement without GSK’s consent to an entity that acquires substantially all of the business or
assets of XenoPort to which this Termination Agreement relates, whether by merger, acquisition or otherwise, provided that the entity to whom this Termination Agreement is assigned assumes this Termination Agreement in writing or by operation of
law. Subject to the foregoing, this Termination Agreement shall inure to the benefit of each Party, its successors and permitted assigns. Any assignment of this Termination Agreement in contravention of this Section 11.7 shall be null and void.

 11.8 Compromise Agreement. This Termination Agreement is a compromise and settlement of disputed Claims and is not
intended to be, nor shall be construed as, any admission of liability or wrongdoing by any Party. This Termination Agreement and any performance or conduct under this Termination Agreement shall not be admissible in any arbitration, lawsuit or other
proceeding except as necessary to enforce the terms and conditions hereof. The Parties agree that this Termination Agreement fully resolves the Litigation. GSK and XenoPort each shall be responsible for their respective legal and other fees and
expenses associated with all aspects of the Litigation, and the negotiation of this Termination Agreement and any other related agreements. 
 11.9 No Partnership, Joint Venture or Principal-Agent Relationship. Nothing in this Termination Agreement is intended, or shall be deemed, to establish a joint venture, partnership or
principal-agent relationship between XenoPort and GSK, except as provided in Section 4.3(b)(i). Neither Party to this Termination Agreement shall have any express or implied right or authority to assume or create any obligations on behalf of,
or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any Third Party. 

11.10 Force Majeure. If the performance of any part of this Termination Agreement (except for any payment obligation under this
Termination Agreement) by either Party is prevented, restricted, interfered with or delayed by reason of force majeure (including, fire, flood, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism, strike, lockout or
other labor disturbance or acts of God), the Party so affected shall, upon giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected
Party shall use its reasonable efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

11.11 Interpretation. The captions to the several Articles and Sections of this Termination Agreement are not a part of this
Termination Agreement, but are included for convenience of reference and shall not affect its meaning or interpretation. In this Termination Agreement: (a) the word “including” shall be deemed to be followed by the phrase
“without limitation” or like expression; (b) the singular shall include the plural and vice versa; and (c) masculine, feminine and neuter pronouns and expressions shall be interchangeable. Each accounting term used herein that is
not specifically defined herein shall have the meaning given to it under International Generally Accepted Accounting Principles. All references to a “business day” or “business days” in this Termination Agreement means any day
other than a day which is a Saturday, a Sunday or any day banks are authorized or required to be closed in the United States or in the United Kingdom. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 69 - 

 EXECUTION COPY 
  

 11.12 Counterparts. This Termination Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. 

[Remainder of This Page Intentionally Blank. Signature Page Follows.] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 - 70 - 

 IN WITNESS WHEREOF, the Parties have executed this Termination Agreement as of the date
first set forth above. 
  

			
	XENOPORT, INC.
		
	BY:	 	 /s/ Ronald Barrett, PhD

	Ronald Barrett, PhD
	Chief Executive Officer

			
	
	GLAXO GROUP LIMITED
		
	BY:	 	 /s/ Paul Williamson

		
	NAME:	 	Paul Williamson
		
	TITLE:	 	Authorized Signatory
		 	For and on behalf of
		 	Edinburgh Pharmaceutical Industries Limited
		 	Corporate Director

 [Signature Page for Termination and Transition Agreement] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 EXECUTION COPY 
  

			
	SCHEDULES	  	
		
	Schedule 1.26	  	Compound
	Schedule 1.41	  	Excluded GSK Contracts
	Schedule 1.42	  	Excluded GSK Inventory
	Schedule 1.43	  	Excluded GSK Know-How
	Schedule 1.44	  	Expired GSK Contracts
	Schedule 1.47	  	Financial Information
	Schedule 1.69	  	Inventory (as of Termination Effective Date)
	Schedule 1.75	  	Licensed GSK Know-How
	Schedule 1.76	  	Licensed GSK Patents
	Schedule 1.90	  	Ongoing Studies
	Schedule 1.103	  	Promotional Sample Inventory (as of the Transition Period End Date)
	Schedule 1.120	  	Specifications
	Schedule 1.135	  	Transferred GSK Contracts
	Schedule 1.136	  	Transferred GSK Domain Names
	Schedule 1.137	  	Transferred GSK Inventory (as of the Inventory Transfer Date)
	Schedule 1.138	  	Transferred GSK Know-How
	Schedule 1.139	  	Transferred GSK Patents
	Schedule 1.140	  	Transferred GSK Promotional Materials
	Schedule 1.141	  	Transferred GSK Regulatory Filings
	Schedule 1.142	  	Transferred GSK Trademarks
	Schedule 4.2B	  	Transferred GSK Know-How (not delivered)
	Schedule 4.3C	  	Permitted GSK Publications
	Schedule 4.5	  	Key Terms of Supply Agreement
	Schedule 4.5B	  	Minimum Quantities and Forecast Requirements
	Schedule 5.13	  	Equipment
		
	EXHIBITS	  	
		
	Exhibit 1.11	  	Form of Assignment and Assumption Agreement
	Exhibit 1.14	  	Form of Bill of Sale
	Exhibit 1.38	  	Form of Domain Name Assignment Agreement
	Exhibit 1.94	  	Form of Patent Assignment Agreement
	Exhibit 1.118	  	Form of Stock Purchase Agreement
	Exhibit 1.131	  	Form of Trademark Assignment Agreement
	Exhibit 2.4A	  	California Dismissal Letter
	Exhibit 2.4B	  	Delaware Dismissal Letter
	Exhibit 3.5E	  	XenoPort FDA Letter
	Exhibit 4.3A	  	Development Plan

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 1 

 EXECUTION COPY 
  

			
	Exhibit 4.3B	  	RLS Horizant Approval Letter
	Exhibit 4.4	  	Commercialization Transition Plan
	Exhibit 4.6	  	Manufacturing Technology Transfer Plan
	Exhibit 4.9	  	Safety Data Exchange Transfer Plan
	Exhibit 8.3	  	Form of Press Releases

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 2 

 EXECUTION COPY 
  

 SCHEDULE 1.26 

Compound 
  

 
 Gabapentin Enacarbil 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 3 

 EXECUTION COPY 
  

 SCHEDULE 1.41 

Excluded GSK Contracts 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 4 

 EXECUTION COPY 
  

 SCHEDULE 1.42 

Excluded GSK Inventory 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 5 

 EXECUTION COPY 
  

 SCHEDULE 1.43 

Excluded GSK Know-How 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 6 

 EXECUTION COPY 
  

 SCHEDULE 1.44 

Expired GSK Contracts 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 7 

 EXECUTION COPY 
  

 SCHEDULE 1.47 

Financial Information 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 8 

 EXECUTION COPY 
  

 Attachment 1.47 

Schedule Detailing RAR Expense Lines 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 9 

 EXECUTION COPY 
  

 SCHEDULE 1.69 

Inventory 

(as of the Termination Effective Date) 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 10 

 EXECUTION COPY 
  

 SCHEDULE 1.76 

Licensed GSK Patents 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 11 

 EXECUTION COPY 
  

 SCHEDULE 1.90 

Ongoing Studies 
  

	•	 	 RXP114025: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of
3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS) 

 [... * ...]

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 12 

 EXECUTION COPY 
  

 SCHEDULE 1.103 

Promotional Sample Inventory 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 13 

 EXECUTION COPY 
  

 SCHEDULE 1.120 

Specifications 

Commercial Product: Those product specifications listed in NDA 022399 for drug substance and for finished product. 

Clinical/R&D Product: Those product specifications for material used in clinical studies listed in IND 71352 and/or IND 68341 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 14 

 EXECUTION COPY 
  

 SCHEDULE 1.135 

Transferred GSK Contracts 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 15 

 EXECUTION COPY 
  

 SCHEDULE 1.136 

Transferred GSK Domain Names 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 16 

 EXECUTION COPY 
  

 SCHEDULE 1.137 

Transferred GSK Inventory 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 17 

 EXECUTION COPY 
  

 SCHEDULE 1.138 

Transferred GSK Know-How 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 18 

 EXECUTION COPY 
  

 SCHEDULE 1.139 

Transferred GSK Patents 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 19 

 EXECUTION COPY 
  

 SCHEDULE 1.140 

Transferred GSK Promotional Materials 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 20 

 EXECUTION COPY 
  

 SCHEDULE 1.141 

Transferred GSK Regulatory Filings 
  

	•	 	 US IND 071352 for the treatment of restless legs syndrome, including electronic filing and all correspondence and associated logs pertaining to this
IND between GSK and the FDA 

  

	•	 	 US NDA 022399 for the treatment of moderate-to-severe primary restless legs syndrome and for the management of post-herpetic neuralgia, including
electronic filing and all correspondence and associated logs pertaining to this NDA between GSK and the FDA (e.g., promotional materials filed and correspondence with OPDP but excluding approval histories for such promotional materials which are
maintained in the PromoNet history archives) 

  

	•	 	 US IND 068341 for the treatment of neuropathic pain, including electronic filing and all correspondence and associated logs pertaining to this IND
between GSK and the FDA 

  

	•	 	 US Orphan Drug Application 10-3307 for the management of post-herpetic neuralgia in adults, including all correspondence 

 

	•	 	 US Labeling files for NDA 022399, including label version and approval history 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 21 

 EXECUTION COPY 
  

 SCHEDULE 1.142 

Transferred GSK Trademarks 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 22 

 EXECUTION COPY 
  

 SCHEDULE 4.2B 

Transferred GSK Know-How (not delivered) 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 23 

 EXECUTION COPY 
  

 SCHEDULE 4.3C 

Permitted GSK Publications 
  

	•	 	 Study XP083/RXP111463 – manuscript submission anticipated Nov 2012; may require revision based on reviewer comments 

 

	•	 	 Study RXP114111 – manuscript submission anticipated Nov 2012; may require revision based on reviewer comments 

 

	•	 	 Study RXP114112 – manuscript submission anticipated Jan 2013; may require revision based on reviewer comments 

 

	•	 	 Study RXP115720 – manuscript submission anticipated Feb 2013; may require revision based on reviewer comments 

 

	•	 	 Study RXP116672 – manuscript submission anticipated Jan 2013; may require revision based on reviewer comments 

 

	•	 	 Study RXP116688 – manuscript submission anticipated Nov 2012; may require revision based on reviewer comments 

 

	•	 	 Study RXP115391 – manuscript submitted 24 Sep 2012; may require revision based on reviewer comments 

 

	•	 	 Study PXN110527 – manuscript submitted 10 Aug 2012; may require revision based on reviewer comments 

 

	•	 	 Study PXN110748 – manuscript submitted 21 Aug 2012; may require revision based on reviewer comments 

 

	•	 	 WEUSKOP4087 (Kaiser CV Study; disease specific, does not involve any mention of Product) 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 24 

 EXECUTION COPY 
  

 SCHEDULE 4.5 

Key Terms of Supply Agreement 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 25 

 EXECUTION COPY 
  

 SCHEDULE 4.5B 

Minimum Quantities and Forecast Requirements 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 26 

 EXECUTION COPY 
  

 SCHEDULE 5.13 

Equipment 

[... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 27 

 EXECUTION COPY 
  

 EXHIBIT 1.11 

Form of Assignment and Assumption Agreement 
 THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assignment and Assumption”) is made and entered into as of [            
    ,] 2012 between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410 Central Expressway, Santa Clara, CA 95051 (“Assignee” or “XenoPort”), and [Glaxo Group
Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England]1 (“Assignor” or “GSK”). 

BACKGROUND 
 A.
Assignor and Assignee are parties to that certain Termination and Transition Agreement (“Termination Agreement”), dated as of November [    ], 2012 (“Termination Effective Date”), pursuant
to which Assignor and Assignee have agreed to settle the Litigation and terminate the Restated Agreement, as set forth in, and subject to the terms and conditions of, the Termination Agreement and the Stock Purchase Agreement between XenoPort and
GSK, dated as of the Termination Effective Date (the “SPA”), to provide for, among other matters, the reversion to XenoPort of all rights with respect to the Product, and for GSK to purchase certain shares of Common Stock of
XenoPort pursuant to the SPA. Capitalized terms used herein and not otherwise defined herein shall have the meanings respectively ascribed to such capitalized terms in the Termination Agreement; and 

B. Pursuant to Sections 3.4(a) and 3.4(b) of the Termination Agreement, Assignor and Assignee have agreed that Assignor will assign to
Assignee, and Assignee will assume from Assignor, the [Transferred GSK Know-How / Transferred GSK Regulatory Filings / Transferred GSK Contracts / Transferred GSK Promotional Materials] set forth on Exhibits [A – D] attached. 

NOW, THEREFORE, for and in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the
receipt, adequacy and legal sufficiency of which are hereby acknowledged, the parties do hereby agree as follows: 
 1.
Assignment and Assumption of Contracts. In accordance with, and subject to the terms of, the Termination Agreement, effective as of the [Transition Period End Date] (the “Contract Assignment and Assumption Effective Date”),
Assignor hereby assigns, transfers and conveys to Assignee, and Assignee hereby accepts, all of Assignor’s right, title and interest in, to and under the Transferred GSK Contracts, and Assignee hereby assumes and agrees to perform and discharge

  

	1 	Note to draft: Appropriate entity to be confirmed. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 28 

 EXECUTION COPY 
  

 
when due, all of Assignor’s obligations and liabilities in, to and under the Transferred GSK Contracts; provided, however, that Assignee shall not assume and shall not be liable for any
obligations or liabilities of any nature whatsoever of Assignor, whether known or unknown, accrued or not accrued, fixed or contingent, arising prior to the Contract Assignment and Assumption Effective Date (“Contract Excluded
Liabilities”), and the parties hereto agree that all such Excluded Liabilities shall remain the sole responsibility of Assignor. 
 2. Assignment of Other Assets. In accordance with, and subject to the terms of, the Termination Agreement, effective as of the [Termination Effective Date / Transition Period End Date / Completion
of the Ongoing Studies / end of the Supply Term] (the “Other Asset Assignment Effective Date”), Assignor hereby assigns, transfers, and conveys to Assignee, and Assignee hereby accepts, all of Assignor’s right, title and
interest in, to and under [Transferred GSK Know-How / Transferred GSK Regulatory Filings / Transferred GSK Promotional Materials], including all intellectual property rights residing in the foregoing, including copyrights and trade secrets to the
extent available (collectively, the “Transferred Asset”), for Assignee’s own use and enjoyment, and for the use and enjoyment of Assignee’s successors, assigns or other legal representatives, as fully and entirely as the
same would have been held and enjoyed by Assignor if this assignment had not been made, together with all income, royalties or payments due or payable as of the Other Asset Assignment Effective Date or thereafter, including, without limitation, all
claims for damages by reason of past, present or future infringement or misappropriation, with the right to sue for and collect the same for Assignee’s own use and enjoyment and for the use and enjoyment of its successors, assigns or other
legal representatives. 
 3. Terms of the Termination Agreement. Nothing herein will, or will be deemed to, modify or
otherwise affect any provisions of the Termination Agreement or affect or modify any of the rights or obligations of the parties under the Termination Agreement, including, but not limited to, Assignor’s representations, warranties, covenants,
agreements and indemnities relating to the [Transferred GSK Know-How / Transferred GSK Regulatory Filings / Transferred GSK Contracts / Transferred GSK Promotional Materials]. In the event of any conflict or inconsistency between the terms of the
Termination Agreement and the terms hereof, the terms of the Termination Agreement shall govern. 
 4. Further Actions.
Each of the parties hereto covenants and agrees, at its own expense, to execute and deliver, at the request of the other party hereto, such further instruments of transfer and assignment and to take such other action as such other party may
reasonably request to more effectively consummate the assignments and assumptions contemplated by this Assignment and Assumption. [The Parties will cooperate to send applicable notices to the applicable counterparties to the various Transferred GSK
Contracts regarding assignment of the applicable Transferred GSK Contract hereunder, as required under the terms of the applicable Transferred GSK Contract (or, if such notice is not required, as requested by Assignee).] [If consent of the
counterparty to a given Transferred GSK Contract is required for assignment of such Transferred GSK Contract hereunder, Assignor agrees upon request of Assignee to use commercially reasonable efforts to obtain such consent.]2 

 

	2 	Note to draft: Bracketed text to be reviewed following identification and review of Transferred GSK Contracts. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 29 

 EXECUTION COPY 
  

 5. Miscellaneous. This Assignment and Assumption and all questions regarding its
validity or interpretation, or the breach or performance of this Assignment and Assumption, shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without reference to conflict of law principles. No
amendment or modification of any provision of this Assignment and Assumption shall be effective unless in writing signed by a duly authorized representative of each party hereto. This Assignment and Assumption will bind and inure to the benefit of
Assignor and Assignee and their respective successors and assigns. This Assignment and Assumption may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same
instrument. 
 [The remainder of this page is intentionally left blank; signatures appear on the following page.]

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 30 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the parties have executed this Assignment and Assumption Agreement
as of the date first set forth above. 
  

			
	XENOPORT, INC.
		
	BY:	 	  

		
	NAME:	 	Ronald Barrett, PhD
		
	TITLE:	 	Chief Executive Officer
	
	[GLAXO GROUP LIMITED]
		
	BY:	 	  

		
	NAME:	 	  

		
	TITLE:	 	  

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 31 

 EXECUTION COPY 
  

 EXHIBIT [A – D] 

[Transferred GSK Know-How / Transferred GSK Regulatory Filings / Transferred GSK Contracts / Transferred GSK Promotional Materials]

 [To be completed] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 32 

 EXECUTION COPY 
  

 EXHIBIT 1.14 

Form of Bill of Sale 
 THIS BILL OF SALE (this “Bill of Sale”), is made an entered into as of [            ] 20    
(“Effective Date”) between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410 Central Expressway, Santa Clara, CA 95051 (“XenoPort”) and [Glaxo Group Limited, a company existing
under the laws of England and Wales, having it registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England]3 (“GSK”). 
 BACKGROUND 
 A. GSK and XenoPort are parties to that certain Termination
and Transition Agreement (“Termination Agreement”), dated as of November [    ], 2012, pursuant to which GSK and XenoPort have agreed to settle the Litigation and terminate the Restated Agreement, as set
forth in, and subject to the terms and conditions of, the Termination Agreement and the Stock Purchase Agreement between XenoPort and GSK, dated as of the Termination Effective Date (the “SPA”), to provide for, among other matters,
the reversion to XenoPort of all rights with respect to the Product, and for GSK to purchase certain shares of Common Stock of XenoPort pursuant to the SPA. Capitalized terms used herein and not otherwise defined herein shall have the meanings
respectively ascribed to such capitalized terms in the Termination Agreement; and 
 B. Pursuant to Section [3.4(a)] of the
Termination Agreement, GSK and XenoPort have agreed that GSK will sell, assign, transfer, convey and deliver, and XenoPort will purchase, accept and acquire from GSK, the Transferred GSK Inventory set forth on Schedule 1 attached to this Bill
of Sale. 
 NOW, THEREFORE, for and in consideration of the premises and the mutual covenants contained herein, and for other good and valuable
consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the parties do hereby agree as follows: 
 1. Sale of Inventory. In accordance with, and subject to the terms of, the Termination Agreement, GSK hereby sells, assigns, transfers and conveys and delivers to XenoPort, and XenoPort hereby
purchases, accepts and acquires from GSK, all of GSK’s right, title and interest in, to and under the Transferred GSK Inventory. 
 2. Terms of the Termination Agreement. Nothing herein will, or will be deemed to, modify or otherwise affect any provisions of the Termination Agreement or affect or modify any of the rights or
obligations of the parties under the Termination Agreement, including, but not limited to, Assignor’s representations, warranties, covenants, agreements and indemnities relating to the Transferred GSK Inventory. In the event of any conflict or
inconsistency between the terms of the Termination Agreement and the terms hereof, the terms of the Termination Agreement shall govern. 

 

	3 	Note to draft: Appropriate entity to be confirmed 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 33 

 EXECUTION COPY 
  

 3. Further Actions. Each of the parties hereto covenants and agrees, at its own
expense, to execute and deliver, at the request of the other party hereto, such further instruments of transfer and assignment and to take such other action as such other party may reasonably request to effect the sale of the Transferred GSK
Inventory contemplated by this Bill of Sale. 
 4. Miscellaneous. This Bill of Sale and all questions regarding its
validity or interpretation, or the breach or performance of this Bill of Sale, shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without reference to conflict of law principles. No amendment or
modification of any provision of this Bill of Sale shall be effective unless in writing signed by a duly authorized representative of each party hereto. This Bill of Sale will bind and inure to the benefit of GSK and XenoPort and their respective
successors and assigns. This Bill of Sale may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. 

[The remainder of this page is intentionally left blank; signatures appear on the following page.] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 34 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the parties have executed this Bill of Sale as of the date
first set forth above. 
  

			
	XENOPORT, INC.
		
	BY:	 	  

		
	NAME:	 	Ronald Barrett, PhD
		
	TITLE:	 	Chief Executive Officer
	
	[GLAXO GROUP LIMITED]
		
	BY:	 	  

		
	NAME:	 	  

		
	TITLE:	 	  

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 35 

 EXECUTION COPY 
  

 SCHEDULE 1 

[Insert list of Transferred GSK Inventory] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 36 

 EXECUTION COPY 
  

 EXHIBIT 1.38 

Form of Domain Name Assignment Agreement 
 THIS DOMAIN ASSIGNMENT AGREEMENT (this “Domain Name Assignment”) is made and entered into as of [            
    ,] 2012 (“Effective Date”) between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410 Central Expressway, Santa Clara, CA 95051 (“Assignee” or
“XenoPort”), and [Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England]4 (“Assignor” or “GSK”). 

BACKGROUND 
 A. Assignor and Assignee are parties to that certain Termination and Transition Agreement (“Termination Agreement”), dated as of November [    ], 2012
(“Termination Effective Date”), pursuant to which Assignor and Assignee have agreed to settle the Litigation and terminate the Restated Agreement, as set forth in, and subject to the terms and conditions of, the Termination
Agreement and the Stock Purchase Agreement between XenoPort and GSK, dated as of the Termination Effective Date (the “SPA”), to provide for, among other matters, the reversion to XenoPort of all rights with respect to the Product,
and for GSK to purchase certain shares of Common Stock of XenoPort pursuant to the SPA. Capitalized terms used herein and not otherwise defined herein shall have the meanings respectively ascribed to such capitalized terms in the Termination
Agreement; and 
 B. Pursuant to Section [3.4(a)] of the Termination Agreement, Assignor and Assignee have agreed that Assignor
shall assign to Assignee and Assignee shall acquire all right, title and interest in and to the Transferred GSK Domain Names, as set forth on Schedule 1 attached hereto, including all lower-level internet domain names for which such domain
name is a root or parent, whether in the form of an address for use in electronic mail transfer, a Universal Resource Locator, a file transfer protocol location, or other form suitable for specifying the location of an electronic data file over a
distributed computer network (collectively, the “Domain Names”). 
 NOW, THEREFORE, for and in consideration of
the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the parties do hereby agree as follows: 

1. Assignment. Assignor hereby perpetually, irrevocably and unconditionally assigns, transfers, conveys and sets over to Assignee
and its successors, assigns and other legal representatives all of Assignor’s rights, titles and interests in and to the Domain Names and the goodwill associated therewith, together with any registrations and applications for registration
thereof for such Domain Names, for Assignee’s own use and enjoyment, and for the use and 
  

	4 	Note to draft: Appropriate entity to be confirmed. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 37 

 EXECUTION COPY 
  

 
enjoyment of Assignee’s successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been
made, together with all income, royalties or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement of the Domain Names, with the right
to sue for and collect the same for Assignee’s own use and enjoyment and for the use and enjoyment of its successors, assigns or other legal representatives. 
 2. Terms of the Termination Agreement. Nothing herein will, or will be deemed to, modify or otherwise affect any provisions of the Termination Agreement or affect or modify any of the rights or
obligations of the parties under the Termination Agreement, including, but not limited to, Assignor’s representations, warranties, covenants, agreements and indemnities relating to the Domain Names. In the event of any conflict or inconsistency
between the terms of the Termination Agreement and the terms hereof, the terms of the Termination Agreement shall govern. 
 3.
Further Actions. Assignor agrees to execute such documents, render such assistance, and take such other action as Assignee may request, to apply for, register, perfect, confirm, and protect Assignee’s rights in the Domain Names. Without
limiting the foregoing, within [10] days of the Effective Date, Assignor shall initiate the process of transferring registration for the Domain Names to Assignee with the applicable registrar, including filing a Registrant Name Change Agreement with
the applicable registrar as necessary, in accordance with all registrar policies and requirements for domain transfer to effectuate the transfer of registration for the Domain Names to Assignee. 

4. Miscellaneous. This Domain Name Assignment and all questions regarding its validity or interpretation, or the breach or
performance of this Domain Name Assignment, shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without reference to conflict of law principles. No amendment or modification of any provision of
this Domain Name Assignment shall be effective unless in writing signed by a duly authorized representative of each party hereto. This Domain Name Assignment will bind and inure to the benefit of Assignor and Assignee and their respective successors
and assigns. This Domain Name Assignment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. 

[The remainder of this page is intentionally left blank; signatures appear on the following page.] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 38 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the parties have executed this Domain Name Assignment as of
the date first set forth above. 
  

			
	XENOPORT, INC.
		
	BY:	 	  

		
	NAME:	 	Ronald Barrett, PhD
		
	TITLE:	 	Chief Executive Officer
	
	[GLAXO GROUP LIMITED]
		
	BY:	 	  

		
	NAME:	 	  

		
	TITLE:	 	  

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 39 

 EXECUTION COPY 
  

 SCHEDULE 1 

[Insert list of Transferred GSK Domain Names] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 40 

 EXECUTION COPY 
  

 EXHIBIT 1.94 

Form of Patent Assignment Agreement 
 THIS PATENT ASSIGNMENT AGREEMENT (this “Patent Assignment”) is made and entered into as of [            
    ,] 2012 (“Effective Date”) between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410 Central Expressway, Santa Clara, CA 95051 (“Assignee” or
“XenoPort”), and [Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England]5 (“Assignor” or “GSK”). 

BACKGROUND 
 A. Assignor and Assignee are parties to that certain Termination and Transition Agreement (“Termination Agreement”), dated as of November [    ], 2012
(“Termination Effective Date”), pursuant to which Assignor and Assignee have agreed to settle the Litigation and terminate the Restated Agreement, as set forth in, and subject to the terms and conditions of, the Termination
Agreement and the Stock Purchase Agreement between XenoPort and GSK, dated as of the Termination Effective Date (the “SPA”), to provide for, among other matters, the reversion to XenoPort of all rights with respect to the Product,
and for GSK to purchase certain shares of Common Stock of XenoPort pursuant to the SPA. Capitalized terms used herein and not otherwise defined herein shall have the meanings respectively ascribed to such capitalized terms in the Termination
Agreement; and 
 B. Pursuant to Section [3.4(a)] of the Termination Agreement, Assignor and Assignee have agreed that Assignor
shall assign to Assignee and Assignee shall acquire all right, title and interest in and to the Transferred GSK Patents set forth on Schedule 1 attached hereto. 
 NOW, THEREFORE, for and in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt, adequacy and legal sufficiency of which are
hereby acknowledged, the parties do hereby agree as follows: 
 1. Assignment. Assignor hereby perpetually, irrevocably
and unconditionally assigns, transfers, conveys and sets over to Assignee and its successors, assigns and other legal representatives all of Assignor’s rights, titles and interests in and to the Transferred GSK Patents and the inventions
disclosed therein, together with all additions, divisions, continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions, registrations, patent term extensions, supplemental protection certificates, renewals and foreign
counterparts of any of the foregoing (collectively, the “Transferred Patents”), for Assignee’s own use and enjoyment, and for the use and enjoyment of Assignee’s successors, assigns or other legal representatives, as fully
and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made, 
  

	5 	Note to draft: Appropriate entity to be confirmed. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 41 

 EXECUTION COPY 
  

 
together with all income, royalties or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future
infringement of the Transferred Patents, with the right to sue for and collect the same for Assignee’s own use and enjoyment and for the use and enjoyment of its successors, assigns or other legal representatives. 

2. Terms of the Termination Agreement. Nothing herein will, or will be deemed to, modify or otherwise affect any provisions of the
Termination Agreement or affect or modify any of the rights or obligations of the parties under the Termination Agreement, including, but not limited to, Assignor’s representations, warranties, covenants, agreements and indemnities relating to
the Transferred Patents. In the event of any conflict or inconsistency between the terms of the Termination Agreement and the terms hereof, the terms of the Termination Agreement shall govern. 

3. Further Actions. Each of the parties hereto covenants and agrees, at its own expense, to execute and deliver, at the request of
the other party hereto, such further instruments of transfer and assignment and to take such other action as such other party may reasonably request to effect the assignments contemplated by this Patent Assignment. 

4. Authorization. Assignor authorizes and requests the United States Commissioner of Patents and Trademarks and any other
applicable government authority to record Assignee as the assignee and owner of the Transferred Patents, and issue any and all registrations or patents thereon to Assignee, as assignee of the entire right, title and interest in, to and under the
same, for the sole use and enjoyment of Assignee and its successors, assigns or other legal representatives. 
 5.
Miscellaneous. This Patent Assignment and all questions regarding its validity or interpretation, or the breach or performance of this Patent Assignment, shall be governed by, and construed and enforced in accordance with, the laws of the
State of Delaware, without reference to conflict of law principles. No amendment or modification of any provision of this Patent Assignment shall be effective unless in writing signed by a duly authorized representative of each party hereto. This
Patent Assignment will bind and inure to the benefit of Assignor and Assignee and their respective successors and assigns. This Patent Assignment may be executed in any number of counterparts, each of which shall be deemed an original, and all of
which together shall constitute one and the same instrument. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 42 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the parties have executed this Patent Assignment as of the
date first set forth above. 
  

			
	XENOPORT, INC.
		
	BY:	 	  

		
	NAME:	 	Ronald Barrett, PhD
		
	TITLE:	 	Chief Executive Officer
	
	[GLAXO GROUP LIMITED]
		
	BY:	 	  

		
	NAME:	 	  

		
	TITLE:	 	  

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 43 

 EXECUTION COPY 
  

 SCHEDULE 1 

[Insert list of Transferred GSK Patents] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 44 

 EXECUTION COPY 
  

 EXHIBIT 1.118 

Form of Stock Purchase Agreement 
 See attached. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 45 

 EXECUTION COPY 
  

 EXHIBIT 1.131 

Form of Trademark Assignment Agreement 
 THIS TRADEMARK ASSIGNMENT AGREEMENT (this “Trademark Assignment”) is made and entered into as of [            
    ,] 2012 (“Effective Date”) between XenoPort, Inc., a Delaware corporation having its principal place of business at 3410 Central Expressway, Santa Clara, CA 95051 (“Assignee” or
“XenoPort”), and [Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England]6 (“Assignor” or “GSK”). 

BACKGROUND 
 A. Assignor and Assignee are parties to that certain Termination and Transition Agreement (“Termination Agreement”), dated as of November [    ], 2012
(“Termination Effective Date”), pursuant to which Assignor and Assignee have agreed to settle the Litigation and terminate the Restated Agreement, as set forth in, and subject to the terms and conditions of, the Termination
Agreement and the Stock Purchase Agreement between XenoPort and GSK, dated as of the Termination Effective Date (the “SPA”), to provide for, among other matters, the reversion to XenoPort of all rights with respect to the Product,
and for GSK to purchase certain shares of Common Stock of XenoPort pursuant to the SPA. Capitalized terms used herein and not otherwise defined herein shall have the meanings respectively ascribed to such capitalized terms in the Termination
Agreement; and 
 B. Pursuant to Section [3.4(a)] of the Termination Agreement, Assignor and Assignee have agreed that Assignor
shall assign to Assignee and Assignee shall acquire all right, title and interest in and to the Transferred GSK Trademarks set forth on Schedule 1 attached hereto. 
 NOW, THEREFORE, for and in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt, adequacy and legal sufficiency of which are
hereby acknowledged, the parties do hereby agree as follows: 
 1. Assignment. Assignor hereby perpetually, irrevocably
and unconditionally assigns, transfers, conveys and sets over to Assignee and its successors, assigns and other legal representatives all of Assignor’s rights, titles and interests in and to the Transferred GSK Trademarks and the goodwill
associated therewith, including the rights to apply for and maintain any applications, registrations or renewals therefor, together with any registrations and applications for registration thereof, and intellectual property rights residing in the
foregoing, including copyrights and design rights (collectively, the “Transferred Trademarks”), for Assignee’s own use and enjoyment, and for the use and enjoyment of Assignee’s successors, assigns or other legal
representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if 
  

	6 	 Note to draft: Appropriate entity to be confirmed. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 46 

 EXECUTION COPY 
  

 
this assignment had not been made, together with all income, royalties or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by
reason of past, present or future infringement, dilution or other violation of the Transferred Trademarks by third parties, with the right to sue for and collect the same for Assignee’s own use and enjoyment and for the use and enjoyment of its
successors, assigns or other legal representatives. Assignor hereby waives and agrees not to enforce any rights of attribution and integrity and other moral rights Assignor may have in the Transferred Trademarks. 

2. Terms of the Termination Agreement. Nothing herein will, or will be deemed to, modify or otherwise affect any provisions of the
Termination Agreement or affect or modify any of the rights or obligations of the parties under the Termination Agreement, including, but not limited to, Assignor’s representations, warranties, covenants, agreements and indemnities relating to
the Transferred Trademarks. In the event of any conflict or inconsistency between the terms of the Termination Agreement and the terms hereof, the terms of the Termination Agreement shall govern. 

3. Further Actions. Each of the parties hereto covenants and agrees, at its own expense, to execute and deliver, at the request of
the other party hereto, such further instruments of transfer and assignment and to take such other action as such other party may reasonably request to effect the assignments contemplated by this Trademark Assignment. 

4. Authorization. Assignor authorizes and requests the United States Commissioner of Patents and Trademarks and any other
applicable government authority to record Assignee as the assignee and owner of the Transferred Trademarks, and issue any and all registrations thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for
the sole use and enjoyment of Assignee and its successors, assigns or other legal representatives. 
 5. Miscellaneous.
This Trademark Assignment and all questions regarding its validity or interpretation, or the breach or performance of this Trademark Assignment, shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware,
without reference to conflict of law principles. No amendment or modification of any provision of this Trademark Assignment shall be effective unless in writing signed by a duly authorized representative of each party hereto. This Trademark
Assignment will bind and inure to the benefit of Assignor and Assignee and their respective successors and assigns. This Trademark Assignment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which
together shall constitute one and the same instrument. 
 [The remainder of this page is intentionally left blank; signatures
appear on the following page.] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 47 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the parties have executed this Trademark Assignment as of the
date first set forth above. 
  

			
	XENOPORT, INC.
		
	BY:	 	  

		
	NAME:	 	Ronald Barrett, PhD
		
	TITLE:	 	Chief Executive Officer
	
	[GLAXO GROUP LIMITED]
		
	BY:	 	  

		
	NAME:	 	  

		
	TITLE:	 	  

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 48 

 EXECUTION COPY 
  

 SCHEDULE 1 

[Insert list of Transferred GSK Trademarks] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 49 

 EXECUTION COPY 
  

 EXHIBIT 2.4A 

California Dismissal Letter 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 50 

 EXECUTION COPY 
  

 HAROLD J. MCELHINNY (BAR NO. 66781) 
 HMcElhinny@mofo.com 
 MARK W. DANIS (BAR NO. 147948) 

MDanis@mofo.com 
 MORRISON & FOERSTER
LLP 
 425 Market Street 

San Francisco, California 94105-2482 
 Telephone:
415.268.7000 
 Facsimile: 415.268.7522 

ERIC C. PAI (BAR NO. 247604) 
 EPai@mofo.com

 MORRISON & FOERSTER LLP 
 755 Page Mill Road 
 Palo Alto, California 94304-1018 

Telephone: 650.813.5600 
 Facsimile: 650.494.0792

 Attorneys for Plaintiff 
 XENOPORT,
INC. 
 [Counsel information for Defendants on signature page] 
 UNITED STATES DISTRICT COURT 
 NORTHERN DISTRICT OF CALIFORNIA 

SAN JOSE DIVISION 
  

			
	 XENOPORT, INC., a Delaware corporation,

 
 Plaintiff,

 
 v.

 
 GLAXO GROUP LIMITED, a U.K. corporation, GLAXOSMITHKLINE LLC, a Delaware limited
liability company, and GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC., a Delaware corporation,
  
 Defendants.
	  	 Case No. CV 12-01544 EJD
  

JOINT STIPULATION AND [PROPOSED] ORDER REGARDING DISMISSAL OF ACTION

 
 Judge: Hon. Edward J. Davila

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 51 

 EXECUTION COPY 
  

 Pursuant to Civil Local Rule 7-12, and Rule 41(a)(1)(A) of the Federal Rules of Civil
Procedure, Plaintiff XenoPort, Inc. and Defendants Glaxo Group Limited, GlaxoSmithKline LLC, and GlaxoSmithKline Holdings (Americas) Inc., through their undersigned counsel of record, hereby stipulate to the dismissal with prejudice of the
above-captioned action. All parties shall bear their own costs, expenses and attorneys’ fees. 
 Respectfully submitted,

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 52 

 EXECUTION COPY 
  

							
	Dated: November     , 2012	 		 	MORRISON & FOERSTER LLP
				
		 		 	By:	 	 /s/ Mark W. Danis

		 		 		 	Mark W. Danis
				
		 		 		 	Attorneys for Plaintiff
		 		 		 	XENOPORT, INC.
			
	Dated: November     , 2012	 		 	REED SMITH LLP
				
		 		 	By:	 	 /s/ Lorenzo E. Gasparetti

		 		 		 	Lorenzo E. Gasparetti
				
		 		 		 	 Lorenzo E. Gasparetti (SBN 135976)
 lgasparetti@reedsmith.com
 Michelle Lyu Cheng (SBN 239711)

mcheng@reedsmith.com
 Farah Tabibkhoei (SBN
266312)
 ftabibkhoei@reedsmith.com

REED SMITH LLP
 355 South Grand Avenue, Suite
2900
 Los Angeles, CA 90071-1514

Telephone: +1 213 457 8000
 Facsimile: +1 213 457
8080

				
		 		 		 	 Scott D. Baker (SBN 84923)

sbaker@reedsmith.com
 Raymond Cardozo (SBN
173263)
 rcardozo@reedsmith.com
 REED
SMITH LLP
 101 2nd St. Ste. 1800
 San
Francisco, CA 94105
 Telephone: +1 415 543 8700
 Facsimile: +1 415 391 8269

				
		 		 		 	 Attorneys for Defendants
 GLAXO
GROUP LIMITED,
 GLAXOSMITHKLINE LLC, and

GLAXOSMITHKLINE HOLDINGS
 (AMERICAS)
INC.

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 53 

 EXECUTION COPY 
  

 ORDER 
 PURSUANT TO STIPULATION, IT IS SO ORDERED. 
 Dated: 

 

	
	Honorable Edward J. Davila
	United States District Judge
	Northern District of California

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 54 

 EXECUTION COPY 
  

 EXHIBIT 2.4B 

Delaware Dismissal Letter 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 55 

 EXECUTION COPY 
  

 IN THE UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF DELAWARE 
  

					
	 	 	:	  	
	GLAXO GROUP LIMITED,	 	:	  	
		 	:	  	C.A. No. 12-225-GMS
	 Plaintiff,
	 	:	  	
		 	:	  	
	vs.	 	:	  	
		 	:	  	
	XENOPORT, INC., and DOES 1-10,	 	:	  	
		 	:	  	
	 Defendants.
	 	:	  	
		 	:	  	
	 	 	:	  	

 STIPULATION AND ORDER OF VOLUNTARY DISMISSAL OF ACTION BETWEEN 

PLAINTIFF GLAXO GROUP LIMITED AND DEFENDANT XENOPORT, INC. 

Plaintiff Glaxo Group Limited and Defendant XenoPort, Inc., by their attorneys, hereby stipulate, subject to approval by the Court, that
the above-captioned action shall be dismissed with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii). Each party shall bear its own costs and attorneys’ fees. 
 Dated: November     , 2012 
  

					
	REED SMITH LLP	 		 	YOUNG CONAWAY STARGATT & TAYLOR, LLP
	  
	 		 	  

	 Elizabeth S. Fenton (DE #5563)

1201 Market Street, Suite 1500
 Wilmington, DE
19801
 Telephone: (302) 778-7500

Fax: (302) 778-7575
 E-mail:
efenton@reedsmith.com
	 		 	 Elena C. Norman (No. 4780)

Monté T. Squire (No. 4764)
 Rodney
Square
 1000 North King Street

Wilmington, Delaware 19801

enorman@ycst.com

		 		 	 msquire@ycst.com
 (302)
571-6600

	 Attorneys for Plaintiff

Glaxo Group Limited
	 		 	Attorneys for Defendant XenoPort, Inc.

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 56 

 EXECUTION COPY 
  

 IT IS SO ORDERED this     day of
            , 2012. 
  

	
	  

	Chief, United States District Judge

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 57 

 EXECUTION COPY 
  

 EXHIBIT 4.3A 

Development Plan 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 58 

 EXECUTION COPY 
  

 EXHIBIT 4.3B 

RLS Horizant Approval Letter 
 See Attached. 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 59 

 EXECUTION COPY 
  

 EXHIBIT 4.4 

Commercialization Transition Plan 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 60 

 EXECUTION COPY 
  

 EXHIBIT 4.6 

Manufacturing Technology Transfer Plan 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 61 

 EXECUTION COPY 
  

 EXHIBIT 4.9 

Safety Data Exchange Transfer Plan 
 [... * ...] 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 62 

 EXECUTION COPY 
  

 EXHIBIT 8.3 

Press Releases 
 (See attached.) 

  
  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 63EX-10.32

 Exhibit 10.32 
 EXECUTION VERSION 
 STOCK PURCHASE AGREEMENT 

This STOCK PURCHASE AGREEMENT (the “Agreement”), is made as of November 8, 2012, by and between XenoPort, Inc., a
Delaware corporation (the “Company”), and Glaxo Group Limited, a company existing under the laws of England and Wales (the “Purchaser”). 
 WHEREAS, the parties have entered into the Termination and Transition Agreement, dated as of the date hereof, by and between the Company and the Purchaser (the “Termination and Transition
Agreement”); 
 WHEREAS, in connection with the Termination and Transition Agreement, the Purchaser wishes to purchase
at the Initial Closing (as defined below), upon the terms and conditions stated in this Agreement, US$20,000,000 of common stock of the Company, par value US$0.001 per share (the “Common Stock”), in cash as set forth herein;

 WHEREAS, the Purchaser wishes to grant to the Company the one-time option exercisable pursuant to the conditions specified
herein (the “Put Option”), to require the Purchaser to purchase for cash up to an additional US$20,000,000 of Common Stock; 
 WHEREAS, the sale of the shares of Common Stock as set forth herein is being undertaken in reliance upon a valid exemption from the registration requirements of the Securities Act of 1933, as amended (the
“Securities Act”); and 
 WHEREAS, the Company and the Purchaser wish to agree to certain other rights and
obligations in connection with the purchase, ownership, transfer and sale of the shares of Common Stock as set forth herein. 

NOW THEREFORE, in consideration of the covenants and promises set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
 ARTICLE I 

PURCHASE AND SALE OF SHARES; PUT OPTION 
 1.1 Purchase of the Initial Shares. Subject to the terms and conditions of this Agreement, the Purchaser agrees to purchase at the Initial Closing, and the Company agrees to sell and issue to the
Purchaser, 1,841,112 shares of Common Stock, free and clear of any liens and encumbrances (the “Initial Shares”), at a price per share equal to US$10.863 (which equals 112.5% of the average of the closing prices of the Common Stock,
as reported by The NASDAQ Stock Market (“Nasdaq”), for the 10 Trading Days (as defined below) ending on the last Trading Day immediately preceding October 31, 2012) (the “Initial Issue Price”), for an aggregate
purchase price of US$20,000,000 (the “Aggregate Purchase Price”). 

 1.2 Initial Closing Date. The purchase and sale of the Initial Shares shall take
place at the offices of Wilson Sonsini Goodrich & Rosati, Professional Corporation, 650 Page Mill Road, Palo Alto, California, on the date that is the second Trading Day after the date of this Agreement, or such other date as the
Company and the Purchaser mutually agree (the “Initial Closing”). The date and time of the Initial Closing is hereafter referred to as the “Initial Closing Date.” 

1.3 Form of Payment; Delivery of Shares. On the Initial Closing Date, (i) the Purchaser shall pay the Aggregate Purchase
Price to the Company by wire transfer of immediately available funds denominated in U.S. dollars to the account of the Company previously designated in writing to the Purchaser, and (ii) the Company shall have executed and delivered a copy of
irrevocable instructions to the transfer agent for the Company (the “Transfer Agent”) to deliver to the Purchaser the Initial Shares, represented in a restricted, electronic book-entry account (the “Restricted Electronic
Shares”) maintained by the Transfer Agent on behalf of the Purchaser, with such evidence of such Restricted Electronic Shares delivered to the Purchaser within three Trading Days of the Initial Closing. The Initial Shares (and, if any stock
certificates are subsequently issued representing the Initial Shares, such stock certificates (any such stock certificates, together with any Restricted Electronic Shares or unrestricted book entry electronic shares, the “Stock
Certificates”)) shall be subject to the legends required pursuant to Section 2.12 hereof. 
 1.4 Put
Option. Beginning on the Initial Closing Date and ending on the date that is six months after the Initial Closing Date (the “Put Exercise Period”), the Company shall have a one-time right, but not an obligation, to exercise the
Put Option by electing on any Trading Day during the Put Exercise Period (the date of the notice of such election in the United States, the “Put Exercise Date”) to sell to the Purchaser, and if such right is exercised, the Purchaser
shall have the obligation to purchase from the Company, up to US$20,000,000 (the “Maximum Put Amount;” such elected Put Option amount, the “Aggregate Put Price”) worth of additional shares of Common Stock (the
“Put Shares,” and, together with the Initial Shares, the “Shares”) at a price per share equal to 112.5% of the average of the closing prices of the Common Stock, as reported by Nasdaq, during the 10 Trading Days
ending on the Trading Day immediately preceding the Put Exercise Date) pursuant to the terms and conditions set forth in this Section 1.4. Notwithstanding the foregoing, the Company may only deliver a Put Notice (as defined below) exercising
the Put Option if, following the Initial Closing Date, there has not occurred any of the following events: (i) a Change in Control (as defined below), (ii) a Bankruptcy Event (as defined below) or (iii) a Third Party (as defined
below) acquiring or exclusively licensing rights from the Company to the Compound (as defined in the Termination and Transition Agreement) and/or Product (as defined in the Termination and Transition Agreement) in the Territory (as defined in the
Termination and Transition Agreement) under an arrangement in which the Company has no right to record on its own behalf the gross invoice amounts charged to third parties for sales of the Product in the Territory. On the Put Exercise Date, the
Company shall provide electronic notice to the Purchaser (the “Put Notice”), at the electronic mail address of the Purchaser specified in Section 9.6, of its election to exercise the Put Option and the number of shares of
Common Stock that the Company is electing to be subject to the Put Option. The Purchaser shall purchase and pay for the Put Shares (the “Put Closing”) on the twentieth Trading Day following the date of the Put Notice, unless

  
 2 

 
another Trading Day is otherwise agreed to by the Company and the Purchaser (the “Put Closing Date”). On the Put Closing Date, (i) the Company shall sell to the Purchaser
the Put Shares, free and clear of any liens and encumbrances, (ii) the Purchaser shall pay the Aggregate Put Price to the Company by wire transfer of immediately available funds denominated in U.S. dollars to the account of the Company
previously designated in writing to the Purchaser, and (iii) the Company shall deliver to the Purchaser the Put Shares, represented by Restricted Electronic Shares, which Restricted Electronic Shares shall be subject to the legends required
pursuant to Section 2.12 hereof. Notwithstanding the foregoing, the maximum number of Shares that may be subject to the Put Option shall not exceed an amount that, when aggregated solely with the Initial Shares held by the Purchaser on the Put
Exercise Date, would cause the Purchaser’s beneficial ownership (measured as of the Put Exercise Date after giving pro forma effect to the issuance of the Put Shares) to exceed 9.99% of the total number of shares of Common Stock then
outstanding (as calculated in accordance with the rules and regulations promulgated under the Exchange Act (as defined below)) and the number of Put Shares shall be automatically reduced on the Put Exercise Date to the extent otherwise in excess of
such maximum number. 
 ARTICLE II 
 REPRESENTATIONS AND WARRANTIES OF THE PURCHASER 
 The Purchaser represents
and warrants to the Company that, as of the date hereof: 
 2.1 Due Organization. The Purchaser is duly organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or ownership of its
properties requires such qualification and failure to have such would prevent such party from performing its obligations under this Agreement, with the requisite corporate authority to own and use its properties and assets and to carry on its
business as currently conducted. The Purchaser is not in violation of any of the provisions of its certificate of incorporation, bylaws or other organizational or charter documents. 

2.2 Due Authorization; Enforceability. The Purchaser has the requisite corporate power and authority to enter into and to
consummate the transactions contemplated by this Agreement, and otherwise to carry out its obligations hereunder. The execution, delivery and performance of this Agreement by the Purchaser has been duly authorized by all necessary action of the
Purchaser, and no other act or proceeding on the part of or on behalf of the Purchaser or its stockholders is necessary to approve the execution and delivery of this Agreement, the performance by the Purchaser of its obligations hereunder and the
consummation of the transactions contemplated hereby. This Agreement has been duly executed and delivered by the Purchaser and constitutes a legal, valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with
its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally, by general equity principles or by limitations on indemnification pursuant
to public policy. 
 2.3 No Conflicts; No Consents. The execution, delivery and performance of this Agreement by the
Purchaser will not infringe any law, regulation, judgment or order applicable to 

  
 3 

 
the Purchaser and is not and will not be contrary to the provisions of the constitutional documents of the Purchaser and will not (with or without notice, lapse of time or both) result in any
breach of the terms of, or constitute a default under, any instrument or agreement to which the Purchaser is a party or by which it or its property is bound. There are no restrictions (contractual or otherwise) prohibiting or otherwise affecting the
purchase of the Shares by the Purchaser, other than any necessary to ensure compliance with the registration requirements of the Securities Act, or an exemption therefrom, and no consents or approvals are required to be obtained by the Purchaser in
connection with the purchase of the Shares by the Purchaser. All consents and approvals of any court, government agencies or other regulatory body required by the Purchaser for the purchase of the Shares and the execution, delivery and performance
of the terms of this Agreement have been obtained and are in full force and effect. 
 2.4 Investment Purpose. The
Purchaser is acquiring the Shares for its own account for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under or exempt from the
registration requirements of the Securities Act. The Purchaser has no present intention of changing or influencing the control of the Company. 
 2.5 Common Stock. As of the date hereof, the Purchaser does not own any Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock. 

2.6 Investor Status. The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of
Regulation D under the Securities Act. 
 2.7 Reliance on Exemptions. The Purchaser understands that the Shares are
being offered and sold to it in reliance on a specific exemption from the registration requirements of United States federal and state securities laws, including the Securities Act, and that the Company is relying upon the truth and accuracy of the
Purchaser’s representations and warranties set forth herein in order to determine the availability of such exemption and the eligibility of the Purchaser to acquire the Shares. 

2.8 Information. The Purchaser has been afforded the opportunity to ask questions of the Company related to the Company and its
business. Neither such inquiries nor any other due diligence investigation conducted by the Purchaser or its advisors and representatives shall modify, amend or affect the Purchaser’s right to rely on the representations and warranties of the
Company contained in this Agreement. The Purchaser understands that its investment in the Shares involves a high degree of risk. The Purchaser has sought such accounting, legal and tax advice as it has considered necessary to make an informed
investment decision with respect to its acquisition of the Shares. 
 2.9 No Governmental Review. The Purchaser
understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Shares or the fairness or suitability of the investment in the Shares nor have
such authorities passed upon or endorsed the merits of the offering of the Shares. 

  
 4 

 2.10 Transfer or Resale. The Purchaser understands that: (i) the Shares have not
been registered under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred in the absence of registration or an applicable exemption from registration requirements; and (ii) the Company
is not under any obligation to register the Shares with the Securities and Exchange Commission (the “SEC”) for resale under the Securities Act or any state securities laws. 

2.11 Financing. At the Initial Closing and the Put Closing, the Purchaser will have sufficient cash or other immediately available
funds to enable the Purchaser to pay the Aggregate Purchase Price and the Aggregate Put Price, as the case may be, and to perform its obligations with respect to the transactions contemplated by this Agreement. 

2.12 Legends. 
 (a) The Purchaser understands that the Stock Certificates or other instruments representing the Shares shall be subject to or bear a restrictive legend in substantially the following form (and a
stop-transfer order may be placed against transfer of such Stock Certificates in contravention of such legend): 
 THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER SAID ACT. 
 (b) The Purchaser
understands that the Stock Certificates or other instruments representing the Shares will also contain a legend reading substantially as follows while the terms of this Agreement are applicable (and the Company agrees that such legend shall not be
included on, and shall be removed from, certificates for Shares as to which the terms of this Agreement no longer are applicable): 
 THE SHARES EVIDENCED HEREBY ARE SUBJECT TO A STOCK PURCHASE AGREEMENT (A COPY OF WHICH MAY BE OBTAINED FROM THE COMPANY) WHICH IMPOSES CERTAIN TRANSFER RESTRICTIONS, VOTING AGREEMENTS AND OTHER
OBLIGATIONS ON THE HOLDER OF SUCH SHARES, AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON HOLDING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID STOCK PURCHASE AGREEMENT. 

  
 5 

 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF THE COMPANY 
 The Company represents and
warrants to the Purchaser that, as of the date hereof, except as set forth in the SEC Reports (as defined below), which exceptions shall be deemed to be representations and warranties as if made hereunder: 

3.1 Due Organization. The Company is duly organized, validly existing and in good standing under the laws of the jurisdiction of
its incorporation, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or ownership of its properties requires such qualification and failure to have such would
prevent such party from performing its obligations under this Agreement, with the requisite corporate authority to own and use its properties and assets and to carry on its business as currently conducted. The Company is not in violation of any of
the provisions of its certificate of incorporation, bylaws or other organizational or charter documents. 
 3.2
Capitalization. As of September 30, 2012, the authorized capital stock of the Company consisted of (i) 100,000,000 shares of Common Stock, of which 42,954,802 shares were outstanding and (ii) 5,000,000 shares of preferred
stock, of which no shares were outstanding. As of September 30, 2012, the Company had 6,474,265 shares of Common Stock issuable upon the exercise of outstanding stock options and vesting of other outstanding equity awards and 1,857,013 shares
of Common Stock reserved for future issuance under its outstanding equity plans. Since September 30, 2012, the authorized capital stock of the Company has not changed and the number of shares of Common Stock outstanding has not decreased. Other
than set forth in this Section 3.2, the SEC Reports, or pursuant to this Agreement, there are no other securities convertible into or exchangeable for, or options, warrants, calls, subscriptions, rights, contracts, commitments, arrangements or
understandings of any kind to which the Company is a party or by which it is bound obligating the Company to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other voting securities of the
Company. 
 3.3 Due Authorization; Enforceability. The Company has the requisite corporate power and authority to enter
into and to consummate the transactions contemplated by this Agreement, and otherwise to carry out its obligations hereunder. The execution, delivery and performance of this Agreement by the Company has been duly authorized by all necessary action
of the Company, and no other act or proceeding on the part of or on behalf of the Company or its stockholders is necessary to approve the execution and delivery of this Agreement, the performance by the Company of its obligations hereunder and the
consummation of the transactions contemplated hereby. This Agreement has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its
terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally, by general equity principles or by limitations on indemnification pursuant to
public policy. 
 3.4 No Conflicts; No Consents. The execution, delivery and performance of this Agreement by the Company
will not infringe any law, regulation, judgment or order applicable to 

  
 6 

 
the Company and is not and will not be contrary to the provisions of the constitutional documents of the Company and will not (with or without notice, lapse of time or both) result in any breach
of the terms of, or constitute a default under, any instrument or agreement to which the Company is a party or by which it or its property is bound. There are no restrictions (contractual or otherwise) prohibiting or otherwise affecting the issuance
and sale of the Shares by the Company, other than any necessary to ensure compliance with the registration requirements of the Securities Act, or an exemption therefrom, and no consents or approvals are required to be obtained by the Company in
connection with the issuance and sale of the Shares by the Company. All consents and approvals of any court, government agencies or other regulatory body required by the Company for the issuance and sale of the Shares and the execution, delivery and
performance of the terms of this Agreement have been obtained and are in full force and effect. 
 3.5 SEC Filings; Financial
Statements. 
 (a) Since January 1, 2012, the Company has filed all reports required to be filed by it under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or 15(d) thereof. Such reports required to be filed by the Company under the Exchange Act, including pursuant to
Section 13(a) or 15(d) thereof, together with any materials filed by the Company under the Exchange Act, whether or not any such reports were required to be filed (but not including any materials furnished), being collectively referred to
herein as the “SEC Reports.” As of their respective dates, the SEC Reports filed by the Company complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated
thereunder, and none of the SEC Reports, when filed by the Company, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. 
 (b) The financial statements included in the SEC
Reports present fairly, in all material respects, the consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown, and such financial statements have been
prepared in conformity with U.S. GAAP applied on a consistent basis (except as may be disclosed therein or in the notes thereto, and, in the case of quarterly financial statements, as permitted by Form 10-Q under the Exchange Act). 

3.6 Issuance of Securities. The Shares are duly authorized and, upon payment for the Shares and issuance at the Initial Closing or
Put Closing, as applicable, pursuant to the terms of this Agreement, will be duly and validly issued, fully paid and non-assessable, and shall be free and clear of all liabilities, debts, obligations, encumbrances, leases, indebtedness, liens,
charges, security interests, and pledges, of whatever nature, whether fixed or contingent, disclosed or undisclosed, foreseen or unforeseen, except for restrictions on transfer set forth in this Agreement or imposed by applicable securities laws.
The Company has not sold, issued or distributed any shares of Common Stock during the six-month period preceding the date of this Agreement, including any sales pursuant to Rule 144A under, or Regulation D or S of, the Securities Act, other than
shares issued pursuant to (i) employee benefit plans, qualified stock option plans or other employee compensation plans or arrangements, or pursuant to outstanding options, restricted stock units, rights or warrants and (ii) the
Company’s underwritten public offering on July 30, 2012. 

  
 7 

 3.7 The NASDAQ Stock Market. The Company’s Common Stock is listed on Nasdaq. The
Company is in compliance with applicable Nasdaq continued listing requirements, and to the Company’s knowledge there are no proceedings pending or threatened against the Company to revoke or suspend such listing. The Company has not received
any notice of, nor to the Company’s knowledge is there any basis for, the delisting of the Common Stock from Nasdaq. 
 3.8
Private Offering. Assuming the correctness of the representations and warranties of the Purchaser set forth in Article II hereof, the offer and sale of the Shares hereunder is exempt from registration under the Securities Act. 

3.9 Absence of Existing Defaults and Conflicts. The Company is not in violation of its certificate of incorporation or bylaws or
in default (or with the giving of notice or lapse of time would be in default) under any existing obligation, agreement, covenant or condition contained in any indenture, loan agreement, mortgage, lease or other agreement or instrument to which the
Company is a party or by which the Company is bound or to which any of its properties is subject, except such defaults that would not have a Material Adverse Effect. 
 3.10 Legal and Governmental Proceedings. 
 (a) There are no legal or
governmental proceedings pending or, to the Company’s knowledge, threatened to which the Company is a party or to which any of the properties of the Company is subject other than proceedings that would not (i) have a Material Adverse
Effect or (ii) effect the power or ability of the Company to perform its obligations under this Agreement in any material manner (other than, for the avoidance of doubt, the proceedings between the parties and the transactions contemplated
under the Termination and Transition Agreement and this Agreement). 
 (b) The Company is not subject to any material judgment,
order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator. 

3.11 No Material Adverse Change in Business. Since September 30, 2012, (i) there has been no Material Adverse Effect;
(ii) the Company has not incurred any liability or obligation, direct or contingent, nor entered into any material transaction, except those liabilities or obligations incurred or transactions entered into in the ordinary course of business,
consistent (as to amount and nature) with past practices since the date of the financial statements of the Company included in the SEC Reports, none of which, individually or in the aggregate, would have a Material Adverse Effect; (iii) the
Company has not purchased any of its outstanding capital stock other than ordinary and customary repurchases of restricted stock from employees upon termination of service pursuant to the terms of the Company’s equity incentive plans, nor
declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends; and (iv) there has not been any material change in the capital stock, short-term debt or long-term debt
of the Company. 
 3.12 No Unlawful Payments. Neither the Company nor, to the Company’s knowledge, any director,
officer, employee, agent, or representative of the Company, has taken or, with respect to the 

  
 8 

 
Company, will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or giving of money, property, gifts or anything else of value,
directly or indirectly, to any “government official” (including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or
on behalf of any of the foregoing, or any political party or party official or candidate for political office) to influence official action or secure an improper advantage; and the Company acknowledges that it has and enforces a policy concerning
compliance with applicable anti-corruption laws. 
 ARTICLE IV 

COVENANTS 

4.1 Form D and “Blue Sky;” Listing. The Company may elect to file a Form D with respect to the Shares in
compliance with Regulation D under the Securities Act. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Shares for sale to the Purchaser pursuant to
this Agreement under applicable securities or “Blue Sky” laws of the states of the United States and any applicable foreign jurisdictions. The Company shall make all filings and reports relating to the offer and sale of the Shares required
under applicable securities or “Blue Sky” laws of the states of the United States and any applicable foreign jurisdictions following the Initial Closing Date. The Company shall use its commercially reasonable efforts to take any required
action to cause the Shares to be listed on Nasdaq as soon as practicable. 
 4.2 Rule 144. The Company shall file the
reports required to be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted by the SEC thereunder (or, if the Company is not required to file such reports, it will, after the end of the Transfer Restriction
Period upon the request of the Purchaser, make publicly available such information as necessary to permit sales of the Shares by Purchaser pursuant to Rule 144 under the Securities Act), and it will take such further action as the Purchaser may
reasonably request, all to the extent required from time to time to enable the Purchaser to sell such Shares without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 under the Securities Act, as such
rule may be amended from time to time; provided, however, that all sales of the Shares by Purchaser will be subject to compliance with the transfer restrictions of Article V. 
 4.3 Termination of Covenants. The provisions of Sections 4.1 and 4.2 shall terminate and be of no further force and effect on the date on which the Purchaser no longer holds any Shares. 

4.4 Expenses; Fees. The Company and the Purchaser shall each pay their own expenses in connection with the transactions
contemplated by this Agreement. 
 4.5 Further Assurances. The Company and the Purchaser agree to cooperate with each
other and their respective officers, employees, attorneys, accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate the intents and purposes of this Agreement, subject to
the terms and conditions hereof and compliance with applicable law, including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other party hereto in complying with the terms hereof.

 4.6 Additional Stock Acquisition. The Purchaser agrees not to acquire any beneficial ownership in any shares of Common
Stock or any securities convertible into or exchangeable or exercisable for Common Stock (other than the Shares) from the date hereof until the earlier of (i) the date that is six months and 10 Trading Days after the Initial Closing Date
and (ii) the Put Closing Date, without the prior written consent of the Company. 

  
 9 

 ARTICLE V 
 TRANSFER RESTRICTIONS 
 5.1 Restrictions on Transfer of Shares within
Transfer Restriction Period. The Purchaser agrees not to sell, assign, transfer, pledge, hypothecate, or otherwise encumber or dispose of in any way (each, a “Transfer”), all or any part of or any interest in (i) the
Initial Shares for a period ending on the date that is six months after the Initial Closing Date and (ii) the Put Shares for a period ending on the date that is six months after the Put Closing Date (each, a “Transfer Restriction
Period”). Any Transfer of the Initial Shares or the Put Shares made within the applicable Transfer Restriction Period shall be null and void, shall not be recorded on the books of the Company and shall not be recognized by the Company. The
restrictions on Transfer set forth in this Section 5.1 shall not apply to Transfers to an Affiliate of the Purchaser, provided that each transferee agrees in writing as a condition precedent to such Transfer to be bound by the terms of this
Article V. 
 5.2 Restrictions on Transfer of Shares after Transfer Restriction Period. After the applicable
Transfer Restriction Period has expired, the Purchaser agrees that, until such time that is 90 days after the Shares owned by the Purchaser represent less than 2.00% of the issued and outstanding Common Stock, any Transfer or Transfers of
(i) the Shares within any one-week period shall not exceed 1.00% of the number of shares of Common Stock outstanding, (ii) the Shares within any three-month period shall not exceed 5.00% of the number of shares of Common Stock outstanding,
(iii) the Initial Shares within any three-month period shall not exceed the number of Initial Shares and (iv) the Put Shares within any three-month period shall not exceed the number of Put Shares (the “Transfer Volume
Limitation”). 
 5.3 Lapse of Transfer Restrictions. Notwithstanding anything else under this Article V
(but subject to the requirements of Section 2.12), all restrictions on Transfers under this Article V shall lapse and no longer be under effect if there has been a Change in Control or a Bankruptcy Event. 

5.4 Removal of Legends. The legends set forth in Section 2.12 shall be removed and the Company (or the Transfer Agent) shall,
upon request, promptly issue a Stock Certificate without such legends to the holder of the Shares upon which it is stamped, if, unless otherwise required by state securities laws, (i) such Shares are sold or transferred pursuant to an effective
registration statement under the Securities Act and in compliance with this Agreement, (ii) in connection with a sale, assignment or other transfer, such holder provides the Company and the Transfer Agent with reasonable and customary assurance
(including, to the extent required by the Transfer Agent, an 

  
 10 

 
opinion of counsel), in a reasonably acceptable form to the Company and the Transfer Agent, to the effect that such sale, assignment or transfer of the Shares may be made without registration
under the Securities Act, and such transfer is in compliance with this Agreement, or (iii) such holder provides the Company and the Transfer Agent with reasonable and customary assurance (including, to the extent required by the Transfer Agent,
an opinion of counsel), in a reasonably acceptable form to the Company and the Transfer Agent, that the Shares can be sold, assigned or transferred pursuant to Rule 144 of the Securities Act without any restriction as to the number of
securities that can then be immediately sold and in compliance with this Agreement. The Company and the Purchaser agree to cooperate with each other, and with the Transfer Agent, in order to facilitate the orderly and efficient removal of any
legends upon Transfers of the Shares in compliance with this Agreement. 
 ARTICLE VI 

VOTING OF SHARES 
 6.1 Voting Agreement. At any meeting of the stockholders of the Company, however called, or at any adjournment thereof, (i) the Purchaser will appear or otherwise cause all Shares to be
counted as present thereat for purposes of calculating a quorum, through granting a proxy or otherwise, (ii) the Purchaser shall vote (or cause to be voted), covering all of the Shares, in the same proportion (e.g. for, against, withheld,
abstain, and/or electing any other choice (such as frequency for any stockholder vote on executive compensation)) as the votes that are collectively cast by all other holders of the Company’s Common Stock who are present and voting with respect
to such matter and (iii) if such meeting involves a vote regarding a Change in Control or similar transaction that would give rise to any appraisal rights or dissenter’s rights in respect of the Shares, the Purchaser agrees to waive and
not to exercise any such appraisal rights or dissenter’s rights. 
 6.2 Termination of Voting Agreement. The
provisions of this Article VI will terminate (i) with respect to any Shares that are transferred in compliance with this Agreement, upon such transfer, and (ii) with respect to all other Shares, upon the earliest of any of the following
events: (A) the Shares owned by the Purchaser representing less than 2.00% of the issued and outstanding Common Stock, (B) a Change in Control being consummated with respect to the Company and (C) a Bankruptcy Event; provided,
however, that notwithstanding this Section 6.2, if applicable, clause (iii) of Section 6.1 will survive until the expiration of any period in which to perfect or exercise such appraisal rights or dissenter’s rights. 

  
 11 

 ARTICLE VII 
 CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL 
 The obligation of the
Company hereunder to issue and sell the Initial Shares and the Put Shares to the Purchaser at the Initial Closing and Put Closing, respectively, is subject to the satisfaction, at or before the applicable closing date as specified below, of each of
the following conditions, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time by providing the Purchaser with prior written notice thereof: 

7.1 With respect to the Initial Shares, the Purchaser shall have executed and delivered to the Company the Termination and Transition
Agreement, and such agreement shall be in full force and effect consistent with its terms. 
 7.2 With respect to the Initial
Shares, the Purchaser shall have delivered to the Company the Aggregate Purchase Price for the Initial Shares being purchased by the Purchaser at the Initial Closing by wire transfer of immediately available funds pursuant to the wire instructions
provided by the Company. 
 7.3 With respect to the Put Shares, the Purchaser shall have delivered to the Company at or before
the Put Closing Date the Aggregate Put Price for the Put Shares being purchased by the Purchaser at the Put Closing by wire transfer of immediately available funds pursuant to the wire instructions provided by the Company. 

7.4 With respect to the Initial Shares and the Put Shares, the representations and warranties of the Purchaser shall be true and correct
in all material respects as of the date hereof, and the Purchaser shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by
the Purchaser at or prior to the Initial Closing Date or the Put Closing Date, as applicable. 
 7.5 With respect to the Initial
Shares and the Put Shares, no provision of any applicable law or regulation and no judgment, injunction, order or decree shall prohibit the Initial Closing or the Put Closing, as applicable, or shall prohibit the Purchaser from acquiring the Shares
being sold hereunder. 
 ARTICLE VIII 
 CONDITIONS TO PURCHASER’S OBLIGATION TO PURCHASE 
 The obligation of
the Purchaser hereunder to purchase the Initial Shares and the Put Shares at the Initial Closing and Put Closing, respectively, is subject to the satisfaction, at or before the applicable closing date as specified below, of each of the following
conditions, provided that these conditions are for the Purchaser’s sole benefit and may be waived by the Purchaser at any time by providing the Company with prior written notice thereof: 

8.1 With respect to the Initial Shares, the Company shall have executed and delivered to the Purchaser the Termination and Transition
Agreement, and such agreement shall be in full force and effect consistent with its terms. 

  
 12 

 8.2 With respect to the Initial Shares and the Put Shares, the representations and
warranties of the Company shall be true and correct in all material respects as of the date hereof; with respect to the Initial Shares, the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Initial Closing Date; with respect to the Put Shares, the Company shall have performed, satisfied and complied in all material
respects with the covenants, agreements and conditions required by Sections 4.1 and 4.2 of this Agreement to be performed, satisfied or complied with by the Company at or prior to the Put Closing Date; and the Company shall have delivered to the
Purchaser a certificate, dated as of the Initial Closing Date or the Put Closing Date, as applicable, of an executive officer of the Company to such effect with respect to such closing date. 

8.3 With respect to the Initial Shares and the Put Shares, no provision of any applicable law or regulation and no judgment, injunction,
order or decree shall prohibit the Initial Closing or the Put Closing, as applicable, or shall prohibit the Purchaser from acquiring the Shares being sold hereunder. 
 8.4 With respect to the Initial Shares and the Put Shares, the Company shall have delivered to the Purchaser an opinion from Cooley LLP providing opinions solely related to the due authorization, valid
issuance, fully paid and nonassessable status of the Initial Shares or the Put Shares, as applicable, and dated as of the date hereof with respect to the Initial Shares or the Put Closing Date with respect to the Put Shares, in the form attached as
Exhibit A. 
 ARTICLE IX 
 MISCELLANEOUS 
 9.1 Governing Law. This Agreement and all questions
regarding its validity or interpretation, or the breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without reference to conflict of law principles.

 9.2 Waiver of Breach. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be
waived only by a written instrument executed by a duly authorized representative of the party waiving compliance. The delay or failure of either party at any time to require performance of any provision of this Agreement shall in no manner affect
such party’s rights at a later time to enforce the same. No waiver by either party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or
term. 
 9.3 Modification. No amendment or modification of any provision of this Agreement shall be effective unless in
writing signed by a duly authorized representative of each party. No 

  
 13 

 
provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and
signed by a duly authorized representative of each party. 
 9.4 Severability. In the event any provision of this
Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the parties and all other
provisions of this Agreement shall remain in full force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.

 9.5 Entire Agreement. This Agreement, together with the Termination and Transition Agreement, constitutes the entire
agreement between the parties relating to its subject matter and supersedes all prior or contemporaneous agreements, understandings or representations, either written or oral, between the Company and the Purchaser with respect to such subject
matter. 
 9.6 Notices. Unless otherwise agreed by the parties or specified in this Agreement, all communications between
the parties relating to, and all written documentation to be prepared and provided under, this Agreement shall be in the English language. Any notice required or permitted under this Agreement, unless otherwise specified herein, shall be:
(a) delivered personally; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing evidence of receipt, postage pre-paid where applicable; or (d) sent
by facsimile (receipt verified and a copy promptly sent by another permissible method of providing notice described in paragraphs (a), (b) or (c)), to the following addresses of the parties or such other address for a party as may be specified
by like notice: 
 If to the Company: 
 XenoPort, Inc. 
 3410 Central Expressway 

Santa Clara, CA 95051 
 Telephone: (408) 616-7200 
 Facsimile: (408) 616-7211 

Attention: Secretary 
 With a copy, which shall not constitute notice, to: 
 Wilson Sonsini
Goodrich & Rosati, Professional Corporation 
 650 Page Mill Road 

Palo Alto, CA 94304 

			
	Telephone:	 	(650) 493-9300
	Facsimile:	 	(650) 493-6811
	Attention:	 	Kenneth A. Clark
		 	Tony Jeffries

  
 14 

 If to the Purchaser: 

Glaxo Group Limited 
 Glaxo Wellcome House, Berkeley Avenue 
 Greenford, Middlesex, UB6 0NN, England

 Telephone: 
 Facsimile: 
 Attention: Company Secretary 

Email: 
 With a
copy, which shall not constitute notice, to: 
 GlaxoSmithKline 

709 Swedeland Road 
 P.O. Box 1539 
 King of Prussia, PA 19406-0939 USA 

Telephone: 

Facsimile: 

Attention: Senior Vice President, Worldwide Business Development 
 Email: 
 and 

GlaxoSmithKline 

2301 Renaissance Boulevard 
 Mailcode RN0220 
 King of Prussia, PA 19406-2772 

Telephone: 

Facsimile: 

Attention: Vice President and Associate General Counsel, Business Development Transactions 

Email: 
 Unless
otherwise specified herein, any notice required or permitted to be given concerning this Agreement shall be effective upon receipt by the party to whom it is addressed or within seven days of dispatch whichever is earlier. 

9.7 Assignment. This Agreement shall not be assignable by either party to any Affiliate (as defined below) or Third Party hereto
without the written consent of the other party hereto. Subject to the foregoing, this Agreement shall inure to the benefit of each party, its successors and permitted assigns. Any assignment of this Agreement in contravention of this
Section 9.7 shall be null and void. 
 9.8 Headings; Interpretation. The captions to the several Articles and
Sections of this Agreement are not a part of this Agreement, but are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall be deemed

  
 15 

 
to be followed by the phrase “without limitation” or like expression; (b) the singular shall include the plural and vice versa; (c) masculine, feminine and neuter pronouns and
expressions shall be interchangeable; and (d) references to Nasdaq shall include any successor or other national securities exchange or market on which the Common Stock is then listed. 

9.9 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all
of which together shall constitute one and the same instrument. 
 9.10 Interpretation. For purposes of this Agreement,
the number of shares of Common Stock, including the Shares, and related prices, including the Initial Issue Price and the Aggregate Put Price, shall be appropriately adjusted for stock splits, stock dividends, recapitalizations, consolidations,
combinations, exchanges of shares or similar events that are applicable to the shares of Common Stock. 
 9.11 No Third Party
Beneficiaries. Unless otherwise expressly stated herein, nothing in this Agreement, express or implied, is intended to confer upon any Person (as defined below) other than the parties hereto or their respective permitted assignees and successors
in interest any rights or remedies under or by reason of this Agreement. 
 9.12 Public Disclosures and Statements. The
Company and the Purchaser agree that neither party nor any of their Affiliates will make any public disclosure regarding this Agreement except as contemplated by the Termination and Transition Agreement; provided, however, that this provision will
not limit either party’s right to effect any public disclosure that it is or may be required to make under applicable law, or the rules of applicable securities exchanges, in each case upon advice of legal counsel, including that the Company
will be entitled to file a copy of this Agreement as an exhibit to the Company’s reports filed with the SEC. 
 9.13
Specific Performance and Injunctive Relief. The Company and the Purchaser agree that if any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, irreparable damage would
occur, no adequate remedy at law would exist and damages would be difficult to determine, and that the parties shall be entitled to specific performance of the terms hereof and injunctive relief, in addition to any other remedy at law or equity.

 9.14 Certain Definitions. 
 (a) “Affiliate” of a party shall mean any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such party, as
the case may be, for as long as such control exists. As used herein, “control” shall mean: (a) to possess, directly or indirectly, the power to direct the management and policies of such Person, whether through ownership of voting
securities or by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial ownership of at least 50% (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) of the voting share capital in such Person. 

  
 16 

 (b) “Bankruptcy Event” shall mean the Company making an assignment for the
benefit of creditors or commencing any proceeding under any bankruptcy, reorganization, insolvency, dissolution or liquidation law of any jurisdiction or any such petition being filed or any such proceeding being commenced against the Company and
either (1) the Company by any act indicating its approval thereof, consents thereto or acquiesces therein or (2) such petition, application or proceeding not being dismissed within 90 days. 

(c) “Change in Control” shall mean the occurrence, in a single transaction or in a series of related transactions, of
any one or more of the following events: (a) there is consummated a sale of all or substantially all of the assets of the Company and its subsidiaries in one or a series of integrated transactions not in the ordinary course of business to a
Third Party; (b) any person or group of persons within the meaning of Section 13(d)(3) of the Exchange Act becomes the beneficial owner, directly or indirectly, of 50% or more of the then outstanding Common Stock of the Company; or
(c) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company
immediately prior thereto do not own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar
transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their ownership of the
outstanding Common Stock of the Company immediately prior to such transaction; or (d) individuals who, on the date of this Agreement, are members of the board of directors of the Company (the “Incumbent Board”) cease for any
reason to constitute at least a majority of the members of the board of directors; provided, however, that if the appointment or election (or nomination for election) of any new member of the board of directors was approved or recommended by a
majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Agreement, be considered as a member of the Incumbent Board. 

(d) “Material Adverse Effect” means any change, effect, event or circumstance that is materially adverse to the
business, financial condition, results of operations, or assets and liabilities, taken as a whole, of the Company. 
 (e)
“Person” means any individual, corporation, partnership, firm, association, joint venture, joint stock company, trust or other entity, or any government or regulatory administrative or political subdivision or agency, department or
instrumentality thereof. 
 (f) “Third Party” shall mean any Person other than the Company, the Purchaser and
their respective Affiliates. 
 (g) “Trading Day” shall mean a day on which the Common Stock is traded for a
regular trading session on Nasdaq. 

  
 17 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

					
	XENOPORT, INC.
		
	By:	 	 /s/ Ronald W. Barrett

		 	Ronald W. Barrett, PhD
		 	Chief Executive Officer
	
	GLAXO GROUP LIMITED
		
	By:	 	 /s/ Paul Williamson

		 	Name:	 	Paul Williamson
		 	Title:	 	 Authorized Signatory
 For and
on behalf of
 Edinburgh Pharmaceutical Industries Limited Corporate Director

 [Signature Page to Stock Purchase Agreement] 

 Exhibit A 
 Form of Legal Opinion 

            , 2012 
 Glaxo Group Limited 
 Glaxo Wellcome House, Berkeley Avenue 

Greenford, Middlesex, UB6 0NN, England 
 Ladies
and Gentlemen: 
 We have acted as counsel for XenoPort Inc., a Delaware corporation (the “Company”), in
connection with issuance and sale of shares of Common Stock of the Company, par value $0.001 (the “[Initial][Put] Shares”), to Glaxo Group Limited (the “Purchaser”) pursuant to that certain Stock
Purchase Agreement, dated as of             , 2012 by and between the Company and the Purchaser (the “Purchase Agreement”). We are rendering this opinion pursuant to
Section 8.4 of the Purchase Agreement. Except as otherwise defined herein, capitalized terms used but not defined herein have the respective meanings given to them in the Purchase Agreement. 

In connection with this opinion, we have examined and relied upon representations and warranties as to factual matters contained in, and
made pursuant to, the Purchase Agreement, the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as currently in effect, and originals or copies certified to our satisfaction of such other documents,
records, certificates, memoranda and other instruments as we deem necessary or appropriate to enable us to render the opinion expressed below. As to certain factual matters, we have relied upon a certificate of officers of the Company and have not
sought to independently verify such matters. 
 In rendering this opinion, we have assumed: the genuineness and authenticity of
all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; the due authorization, execution and delivery of all
documents (except the due authorization, execution and delivery by the Company of the Purchase Agreement), where authorization, execution and delivery are prerequisites to the effectiveness of such documents; and the genuineness and authenticity of
all signatures on original documents (except the signatures on behalf of the Company to the Purchase Agreement). We have also assumed: that all individuals executing and delivering documents had the legal capacity to so execute and deliver; that the
Purchaser has received all documents that it was to receive under the Purchase Agreement; that the Purchase Agreement is an obligation binding upon the Purchaser; and that there are no extrinsic agreements or understandings among the parties to the
Purchase Agreement that would modify or interpret the terms thereof or the respective rights or obligations of the parties thereunder. 
 Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion herein is expressed solely with respect to the General
Corporation Law of the State of Delaware. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, 

 
events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. We are not rendering any opinion as to compliance with
any federal or state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof. 
 Based upon
and subject to the foregoing, and subject to the qualifications and exceptions contained herein, we are of the opinion that the [Initial][Put] Shares, when issued and paid for by the Purchaser pursuant to the Purchase Agreement, will be validly
issued, fully paid and nonassessable. 
 This opinion is intended solely for your benefit and is not to be made available to or
to be relied upon by any other person, firm or entity without our prior written consent. 
 Sincerely, 

 

			
	Cooley LLP
		
	By:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]